DISCLAIMER
These codes are currently under development by the LOINC team, and are subject to change prior to inclusion in a public release. It is possible that they may not be published in the next, or any, public release. They are provided here for informational purposes only.
SPECIAL USE
Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release.
Guidance for mapping to SARS-CoV-2 LOINC terms
Full list of LOINCs related to SARS-CoV-2/COVID-19
The page linked above includes an option to export terms in CSV format.
Receive email notices of new Special Use LOINC terms
scroll/swipe to view more columns
| Created On | LOINC | Long Common Name | Special Use | Component | Prop | Time | System | Scale | Method | Shortname |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-05-21 | 95354-7 | Transfuse convalescent plasma [Volume] | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Transfuse convalescent plasma | Vol | Pt | ^Patient | Qn | Trans Convl Plasma Vol | |
| 2020-05-21 | 95355-4 | Convalescent plasma given [Volume] | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Convalescent plasma given | Vol | Pt | ^Patient | Qn | Convl plasma Gvn Vol | |
| 2020-05-20 | 95209-3 | SARS coronavirus+SARS coronavirus 2 Ag [Presence] in Respiratory specimen by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus+SARS coronavirus 2 Ag | PrThr | Pt | Respiratory | Ord | IA.rapid | SARS-CoV+SARS-CoV-2 Ag Resp Ql IA.rapid |
| 2020-05-14 | 95125-1 | SARS coronavirus 2 IgA+IgM [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgA+IgM | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 IgA+IgM SerPl Ql IA |
| 2020-05-07 | 94845-5 | SARS coronavirus 2 RNA [Presence] in Saliva (oral fluid) by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Saliva | Ord | Probe.amp.tar | SARS-CoV-2 RNA Sal Ql NAA+probe |
| 2020-05-06 | 94822-4 | SARS coronavirus 2 RNA [Presence] in Saliva (oral fluid) by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Saliva | Ord | Sequencing | SARS-CoV-2 RNA Sal Ql Seq |
| 2020-05-05 | 94821-6 | COVID-19 Intubation advance directives Document | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation advance directives | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intubation Adv Dir Doc |
| 2020-05-04 | 94819-0 | SARS coronavirus 2 RNA [Log #/volume] (viral load) in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | LnCnc | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 RNA XXX NAA+probe-Log# |
| 2020-05-01 | 94762-2 | SARS coronavirus 2 Ab [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 Ab SerPl Ql IA |
| 2020-05-01 | 94763-0 | SARS coronavirus 2 [Presence] in Unspecified specimen by Organism specific culture | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 | PrThr | Pt | XXX | Ord | Organism specific culture | SARS-CoV-2 XXX Ql Cult |
| 2020-05-01 | 94764-8 | SARS coronavirus 2 whole genome [Nucleotide sequence] in Isolate by Sequencing | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 whole genome | Seq | Pt | Isolate | Nom | Sequencing | SARS-CoV-2 genome Islt-Seq |
| 2020-05-01 | 94767-1 | SARS coronavirus 2 S gene [Presence] in Serum or Plasma by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | SARS-CoV-2 S gene SerPl Ql NAA+probe |
| 2020-05-01 | 94765-5 | SARS coronavirus 2 E gene [Presence] in Serum or Plasma by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | SARS-CoV-2 E gene SerPl Ql NAA+probe |
| 2020-05-01 | 94766-3 | SARS coronavirus 2 N gene [Presence] in Serum or Plasma by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | SARS-CoV-2 N gene SerPl Ql NAA+probe |
| 2020-05-01 | 94768-9 | SARS coronavirus 2 IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgA | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | SARS-CoV-2 IgA SerPlBld Ql IA.rapid |
| 2020-05-01 | 94769-7 | SARS coronavirus 2 Ab [Units/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab | ACnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 Ab SerPl IA-aCnc |
| 2020-05-01 | 94806-7 | COVID-19 Intubation Consultation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Consultation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intub+Consult |
| 2020-05-01 | 94808-3 | COVID-19 Intubation Consultation note Resident | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Consultation note | Find | Pt | {Setting} | Doc | Resident | COVID19 Intub+Consult Res |
| 2020-05-01 | 94807-5 | COVID-19 Intubation Consultation note Attending | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Consultation note | Find | Pt | {Setting} | Doc | Attending | COVID19 Intub+Consult Attend |
| 2020-05-01 | 94811-7 | COVID-19 Intubation Evaluation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Evaluation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intub Eval note |
| 2020-05-01 | 94809-1 | COVID-19 Intubation Progress note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Progress note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intub+Progress |
| 2020-05-01 | 94810-9 | COVID-19 Intubation Procedure note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Procedure note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intub Proced |
| 2020-05-01 | 94812-5 | COVID-19 Intubation and Cardiopulmonary resuscitation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Cardiopulmonary resuscitation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Intub+CPR |
| 2020-05-01 | 94813-3 | COVID-19 Intubation Conference note Team | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Intubation+Conference note | Find | Pt | {Setting} | Doc | Team | COVID19 Intub Conference Team |
| 2020-05-01 | 94814-1 | Critical care medicine COVID-19 Consultation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Consultation note | Find | Pt | {Setting} | Doc | Critical Care Medicine | CCM COVID19 Consult note |
| 2020-04-30 | 94758-0 | SARS coronavirus 2 E gene [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 E gene Resp Ql NAA+probe |
| 2020-04-30 | 94756-4 | SARS coronavirus 2 N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar.CDC primer-probe set N1 | SARS-CoV-2 N gene Resp Ql NAA N1 |
| 2020-04-30 | 94757-2 | SARS coronavirus 2 N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N2 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar.CDC primer-probe set N2 | SARS-CoV-2 N gene Resp Ql NAA N2 |
| 2020-04-30 | 94761-4 | SARS coronavirus 2 IgG Ab [Presence] in DBS by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Bld.dot | Ord | IA | SARS-CoV-2 IgG DBS Ql IA |
| 2020-04-30 | 94760-6 | SARS coronavirus 2 N gene [Presence] in Nasopharynx by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Nph | Ord | Probe.amp.tar | SARS-CoV-2 N gene Nph Ql NAA+probe |
| 2020-04-30 | 94759-8 | SARS coronavirus 2 RNA [Presence] in Nasopharynx by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Nph | Ord | Probe.amp.tar | SARS-CoV-2 RNA Nph Ql NAA+probe |
| 2020-04-29 | 94745-7 | SARS coronavirus 2 RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | ThreshNum | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 RNA Ct Resp Qn NAA+probe |
| 2020-04-29 | 94746-5 | SARS coronavirus 2 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 RNA Ct XXX Qn NAA+probe |
| 2020-04-15 | 94720-0 | SARS coronavirus 2 IgA Ab [Units/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgA | ACnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 IgA SerPl IA-aCnc |
| 2020-04-15 | 94721-8 | COVID-19 Evaluation note | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Evaluation note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Eval note |
| 2020-04-15 | 94722-6 | COVID-19 Initial Evaluation form | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Initial evaluation form | Find | Pt | {Setting} | Doc | {Role} | COVID19 Initial Eval form |
| 2020-04-15 | 94723-4 | Emergency department COVID-19 Initial Evaluation form | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | COVID19+Initial evaluation form | Find | Pt | Emergency department | Doc | {Role} | ED COVID19 Initial Eval form |
| 2020-04-04 | 94660-8 | SARS coronavirus 2 RNA [Presence] in Serum or Plasma by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | SARS-CoV-2 RNA SerPl Ql NAA+probe |
| 2020-04-04 | 94661-6 | SARS coronavirus 2 Ab [Interpretation] in Serum or Plasma | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab | Imp | Pt | Ser/Plas | Nom | SARS-CoV-2 Ab SerPl-Imp | |
| 2020-04-03 | 94648-3 | Date contact confirmed as a case | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Date of case confirmation | Date | Pt | ^Contact | Qn | Date contact confirmed as case | |
| 2020-04-03 | 94651-7 | Country of travel [Location] | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Country of travel | Loc | Pt | ^Patient | Nom | Country of trav | |
| 2020-04-03 | 94649-1 | Health department identifier | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Health department | ID | Pt | Organization | Nom | Health dept ID | |
| 2020-04-03 | 94650-9 | Contact identifier Contact | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Contact identifier | ID | Pt | ^Contact | Nom | ||
| 2020-04-03 | 94653-3 | City of travel [Location] | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | City of travel | Loc | Pt | ^Patient | Nom | City of trav | |
| 2020-04-03 | 94652-5 | Known exposure date | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Known exposure date | Date | Pt | ^Patient | Qn | ||
| 2020-04-03 | 94654-1 | Known exposure panel | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Known exposure panel | - | Pt | ^Patient | - | Exposure pnl | |
| 2020-04-03 | 94657-4 | Contact case identifier | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Case identifier | ID | Pt | ^Contact | Nom | Case ID Contact | |
| 2020-04-03 | 94656-6 | State of known exposure | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | State of known exposure | Loc | Pt | ^Patient | Nom | ||
| 2020-04-03 | 94659-0 | Case identifier | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Case identifier | ID | Pt | ^Patient | Nom | Case ID | |
| 2020-04-03 | 94658-2 | City of known exposure | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | City of known exposure | Loc | Pt | ^Patient | Nom | ||
| 2020-04-02 | 94639-2 | SARS coronavirus 2 ORF1ab region [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 ORF1ab XXX Ql NAA+probe |
| 2020-04-02 | 94640-0 | SARS coronavirus 2 S gene [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 S gene Resp Ql NAA+probe |
| 2020-04-02 | 94641-8 | SARS coronavirus 2 S gene [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 S gene XXX Ql NAA+probe |
| 2020-04-02 | 94642-6 | SARS coronavirus 2 S gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | ThreshNum | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 S gene Ct Resp Qn NAA+probe |
| 2020-04-02 | 94643-4 | SARS coronavirus 2 S gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 S gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 S gene Ct XXX Qn NAA+probe |
| 2020-04-02 | 94644-2 | SARS coronavirus 2 ORF1ab region [Cycle Threshold #] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 ORF1ab Ct Resp Qn NAA+probe |
| 2020-04-02 | 94645-9 | SARS coronavirus 2 RdRp gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RdRp gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 RdRp Ct XXX Qn NAA+probe |
| 2020-04-02 | 94646-7 | SARS coronavirus 2 RdRp gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RdRp gene | ThreshNum | Pt | Respiratory | Qn | Probe.amp.tar | SARS-CoV-2 RdRp Ct Resp Qn NAA+probe |
| 2020-04-02 | 94647-5 | SARS-related coronavirus RNA [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-related coronavirus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARSr-CoV RNA XXX Ql NAA+probe |
| 2020-03-27 | 94562-6 | SARS coronavirus 2 IgA Ab [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgA | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 IgA SerPl Ql IA |
| 2020-03-27 | 94564-2 | SARS coronavirus 2 IgM Ab [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgM | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 IgM SerPl Ql IA |
| 2020-03-27 | 94563-4 | SARS coronavirus 2 IgG Ab [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 IgG SerPl Ql IA |
| 2020-03-27 | 94565-9 | SARS coronavirus 2 RNA [Presence] in Nasopharynx by NAA with non-probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Nph | Ord | Non-probe.amp.tar | SARS-CoV-2 RNA Nph Ql NAA+non-probe |
| 2020-03-24 | 94558-4 | SARS coronavirus 2 Ag [Presence] in Respiratory specimen by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ag | PrThr | Pt | Respiratory | Ord | IA.rapid | SARS-CoV-2 Ag Resp Ql IA.rapid |
| 2020-03-24 | 94559-2 | SARS coronavirus 2 ORF1ab region [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 ORF1ab Resp Ql NAA+probe |
| 2020-03-12 | 94547-7 | SARS coronavirus 2 IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG+IgM | PrThr | Pt | Ser/Plas | Ord | IA | SARS-CoV-2 IgG+IgM SerPl Ql IA |
| 2020-03-10 | 94531-1 | SARS coronavirus 2 RNA panel - Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA panel | - | Pt | Respiratory | - | Probe.amp.tar | SARS-CoV-2 RNA Pnl Resp NAA+probe |
| 2020-03-10 | 94532-9 | SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-related coronavirus+MERS coronavirus RNA | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-rel CoV+MERS RNA Resp Ql NAA+probe |
| 2020-03-10 | 94533-7 | SARS coronavirus 2 N gene [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 N gene Resp Ql NAA+probe |
| 2020-03-10 | 94534-5 | SARS coronavirus 2 RdRp gene [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RdRp gene | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 RdRp Resp Ql NAA+probe |
| 2020-03-09 | 94499-1 | Respiratory viral pathogens DNA and RNA panel - Respiratory specimen Qualitative by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Respiratory viral pathogens DNA & RNA panel | - | Pt | Respiratory | Ord | Probe.amp.tar | Resp viral path DNA+RNA Pnl Resp NAA+prb |
| 2020-03-09 | 94500-6 | SARS coronavirus 2 RNA [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-CoV-2 RNA Resp Ql NAA+probe |
| 2020-03-09 | 94501-4 | Middle East respiratory syndrome coronavirus (MERS-CoV) RNA [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | Middle east respiratory syndrome coronavirus RNA | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | MERS-CoV RNA Resp Ql NAA+probe |
| 2020-03-09 | 94502-2 | SARS-related coronavirus RNA [Presence] in Respiratory specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-related coronavirus RNA | PrThr | Pt | Respiratory | Ord | Probe.amp.tar | SARS-rel CoV RNA Resp Ql NAA+probe |
| 2020-03-09 | 94503-0 | SARS coronavirus 2 IgG and IgM panel - Serum, Plasma or Blood by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG & IgM panel | - | Pt | Ser/Plas/Bld | - | IA.rapid | SARS-CoV-2 IgG+IgM Pnl SerPlBld IA.rapid |
| 2020-03-09 | 94505-5 | SARS coronavirus 2 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 IgG SerPl IA-aCnc |
| 2020-03-09 | 94506-3 | SARS coronavirus 2 IgM Ab [Units/volume] in Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgM | ACnc | Pt | Ser/Plas | Qn | IA | SARS-CoV-2 IgM SerPl IA-aCnc |
| 2020-03-09 | 94504-8 | SARS coronavirus 2 Ab panel - Serum or Plasma by Immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab panel | - | Pt | Ser/Plas | - | IA | SARS-CoV-2 Ab Pnl SerPl IA |
| 2020-03-09 | 94507-1 | SARS coronavirus 2 IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | SARS-CoV-2 IgG SerPlBld Ql IA.rapid |
| 2020-03-09 | 94508-9 | SARS coronavirus 2 IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 Ab.IgM | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | SARS-CoV-2 IgM SerPlBld Ql IA.rapid |
| 2020-03-09 | 94509-7 | SARS coronavirus 2 E gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 E gene Ct XXX Qn NAA+probe |
| 2020-03-09 | 94510-5 | SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 N gene Ct XXX Qn NAA+probe |
| 2020-03-09 | 94511-3 | SARS coronavirus 2 ORF1ab region [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-CoV-2 ORF1ab Ct XXX Qn NAA+probe |
| 2020-01-31 | 94306-8 | SARS coronavirus 2 RNA panel - Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA panel | - | Pt | XXX | - | Probe.amp.tar | SARS-CoV-2 RNA Pnl XXX NAA+probe |
| 2020-01-31 | 94307-6 | SARS coronavirus 2 N gene [Presence] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N1 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar.CDC primer-probe set N1 | SARS-CoV-2 N gene XXX Ql NAA N1 |
| 2020-01-31 | 94309-2 | SARS coronavirus 2 RNA [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 RNA XXX Ql NAA+probe |
| 2020-01-31 | 94308-4 | SARS coronavirus 2 N gene [Presence] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N2 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar.CDC primer-probe set N2 | SARS-CoV-2 N gene XXX Ql NAA N2 |
| 2020-01-31 | 94310-0 | SARS-like coronavirus N gene [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-like coronavirus N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-like CoV N XXX Ql NAA+probe |
| 2020-01-31 | 94311-8 | SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N1 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar.CDC primer-probe set N1 | SARS-CoV-2 N gene Ct XXX Qn NAA N1 |
| 2020-01-31 | 94312-6 | SARS coronavirus 2 N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N2 | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar.CDC primer-probe set N2 | SARS-CoV-2 N gene Ct XXX Qn NAA N2 |
| 2020-01-31 | 94313-4 | SARS-like coronavirus N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS-like coronavirus N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | SARS-like CoV N Ct XXX Qn NAA+probe |
| 2020-01-31 | 94314-2 | SARS coronavirus 2 RdRp gene [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 RdRp gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 RdRp XXX Ql NAA+probe |
| 2020-01-31 | 94315-9 | SARS coronavirus 2 E gene [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 E gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 E gene XXX Ql NAA+probe |
| 2020-01-31 | 94316-7 | SARS coronavirus 2 N gene [Presence] in Unspecified specimen by NAA with probe detection | Special Use codes are developed in response to an urgent or emergent situation. These codes are based on the most up to date information available at the time of their creation. They have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation. However, be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release. | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | SARS-CoV-2 N gene XXX Ql NAA+probe |
| 2020-05-22 | 95358-8 | Rabbit hemorrhagic disease virus RNA panel - Unspecified specimen by NAA with probe detection | Rabbit hemorrhagic disease virus RNA panel | - | Pt | XXX | - | Probe.amp.tar | RHDV RNA Pnl XXX NAA+probe | |
| 2020-05-22 | 95360-4 | Rabbit hemorrhagic disease virus type 2 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Rabbit hemorrhagic disease virus type 2 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | RHDV2 RNA Ct XXX Qn NAA+probe | |
| 2020-05-22 | 95359-6 | Rabbit hemorrhagic disease virus type 1 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Rabbit hemorrhagic disease virus type 1 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | RHDV1 RNA Ct XXX Qn NAA+probe | |
| 2020-05-20 | 95286-1 | SBF2 gene full mutation analysis in Blood or Tissue by Sequencing | SBF2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | SBF2 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95288-7 | YARS gene full mutation analysis in Blood or Tissue by Sequencing | YARS gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | YARS gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95210-1 | Anaplasma marginale Ab/Negative control in Serum by Immunoassay | Anaplasma marginale Ab/Negative control | RelRto | Pt | Ser | Qn | IA | A marginale Ab Ser IA | |
| 2020-05-20 | 95212-7 | Neospora caninum Ab/Negative control in Serum by Immunoassay | Neospora caninum Ab/Negative control | RelRto | Pt | Ser | Qn | IA | N caninum Ab Ser IA | |
| 2020-05-20 | 95211-9 | Bluetongue virus Ag/Negative control in Serum by Immunoassay | Bluetongue virus Ag/Negative control | RelRto | Pt | Ser | Qn | IA | BTV Ag Ser IA | |
| 2020-05-20 | 95213-5 | Basophils/100 leukocytes in Stem cell product by Manual count | Basophils/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Basophils/leuk NFr Stem cell prod Manual | |
| 2020-05-20 | 95214-3 | Blasts/100 leukocytes in Stem cell product by Manual count | Blasts/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Blasts/leuk NFr Stem cell prod Manual | |
| 2020-05-20 | 95217-6 | Nucleated erythrocytes/100 leukocytes in Stem cell product by Manual count | Erythrocytes.nucleated/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | nRBC/100 WBC NFr Stem cell prod Manual | |
| 2020-05-20 | 95216-8 | Eosinophils/100 leukocytes in Stem cell product by Manual count | Eosinophils/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Eosinophil/leuk NFr Stem cell prod Manua | |
| 2020-05-20 | 95215-0 | CBC W Differential panel - Stem cell product | Complete blood count W Differential panel | - | Pt | ^Stem cell product | Qn | CBC W Diff Pnl Stem cell prod | ||
| 2020-05-20 | 95220-0 | Lymphocytes/100 leukocytes in Stem cell product by Manual count | Lymphocytes/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Lymphocytes/leuk NFr Stem cell prod Manu | |
| 2020-05-20 | 95219-2 | Variant lymphocytes/100 leukocytes in Stem cell product by Manual count | Lymphocytes.variant/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Variant Lymphs/leuk NFr Stem cell prod M | |
| 2020-05-20 | 95218-4 | Leukocytes [Mass/volume] in Stem cell product | Leukocytes | MCnc | Pt | ^Stem cell product | Qn | WBC Stem cell prod-mCnc | ||
| 2020-05-20 | 95221-8 | Metamyelocytes/100 leukocytes in Stem cell product by Manual count | Metamyelocytes/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Metamyelocytes/leuk NFr Stem cell prod M | |
| 2020-05-20 | 95222-6 | Monocytes/100 leukocytes in Stem cell product by Manual count | Monocytes/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Monocytes/leuk NFr Stem cell prod Manual | |
| 2020-05-20 | 95223-4 | Mononuclear cells/100 leukocytes in Stem cell product by Manual count | Mononuclear cells/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Mononuc Cells/leuk NFr Stem cell prod Ma | |
| 2020-05-20 | 95226-7 | Segmented neutrophils/100 leukocytes in Stem cell product by Manual count | Neutrophils.segmented/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Neuts Seg/leuk NFr Stem cell prod Manual | |
| 2020-05-20 | 95224-2 | Myelocytes/100 leukocytes in Stem cell product by Manual count | Myelocytes/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Myelocytes/leuk NFr Stem cell prod Manua | |
| 2020-05-20 | 95225-9 | Band form neutrophils/100 leukocytes in Stem cell product by Manual count | Neutrophils.band form/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Neuts Band/leuk NFr Stem cell prod Manua | |
| 2020-05-20 | 95227-5 | Other cells/100 leukocytes in Stem cell product by Manual count | Other cells/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Other cells/leuk NFr Stem cell prod Manu | |
| 2020-05-20 | 95228-3 | Promyelocytes/100 leukocytes in Stem cell product by Manual count | Promyelocytes/100 leukocytes | NFr | Pt | ^Stem cell product | Qn | Manual count | Promyelocytes/leuk NFr Stem cell prod Ma | |
| 2020-05-20 | 95229-1 | Biliary tract neoplasm chromosome analysis in Tissue | Biliary tract neoplasm chromosome analysis | Find | Pt | Tiss | Doc | Biliary Neo Chrom Analysis Tiss | ||
| 2020-05-20 | 95230-9 | Biliary tract neoplasm chromosome aneuploidy and cytology analysis in Tissue | Biliary tract neoplasm chromosome aneuploidy & cytology analysis | Find | Pt | Tiss | Doc | Biliary Neo Chrom-Cyt Analysis Tiss | ||
| 2020-05-20 | 95231-7 | Chromosome aneuploidy details in Blood or Tissue by Molecular genetics method Narrative | Chromosome aneuploidy details | Find | Pt | Bld/Tiss | Nar | Molgen | Chromosome aneup Bld/T | |
| 2020-05-20 | 95232-5 | Microalbumin [Presence] in Urine by Test strip | Albumin | PrThr | Pt | Urine | Ord | Detection limit <= 20 mg/L test strip | Microalbumin Ur Ql Test Str | |
| 2020-05-20 | 95233-3 | Microalbumin/Creatinine [Presence] in Urine by Test strip | Albumin/Creatinine | PrThr | Pt | Urine | Ord | Detection limit <= 20 mg/L test strip | Microalbumin/Creat Ur Ql Test Str | |
| 2020-05-20 | 95234-1 | Hepatitis B virus surface Ag [Interpretation] in Serum or Plasma | Hepatitis B virus surface Ag | Imp | Pt | Ser/Plas | Nom | HBV surface Ag SerPl-Imp | ||
| 2020-05-20 | 95236-6 | Hepatitis B virus DNA [Interpretation] in Serum or Plasma | Hepatitis B virus DNA | Imp | Pt | Ser/Plas | Nom | HBV DNA SerPl-Imp | ||
| 2020-05-20 | 95235-8 | Hepatitis B virus Ab [Interpretation] in Serum or Plasma | Hepatitis B virus Ab | Imp | Pt | Ser/Plas | Nom | HBV Ab SerPl-Imp | ||
| 2020-05-20 | 95237-4 | Hepatitis C virus Ab [Interpretation] in Serum or Plasma | Hepatitis C virus Ab | Imp | Pt | Ser/Plas | Nom | HCV Ab SerPl-Imp | ||
| 2020-05-20 | 95238-2 | Hepatitis D virus Ab [Interpretation] in Serum or Plasma | Hepatitis D virus Ab | Imp | Pt | Ser/Plas | Nom | HDV Ab SerPl-Imp | ||
| 2020-05-20 | 95239-0 | Hepatitis D virus IgM panel - Serum | Hepatitis D virus Ab.IgM panel | - | Pt | Ser | - | HDV IgM Pnl Ser | ||
| 2020-05-20 | 95240-8 | Hepatitis E virus Ab [Interpretation] in Serum or Plasma | Hepatitis E virus Ab | Imp | Pt | Ser/Plas | Nom | HEV Ab SerPl-Imp | ||
| 2020-05-20 | 95266-3 | Vitamin B6 and metabolite panel - Serum or Plasma | Vitamin B6 & metabolite panel | - | Pt | Ser/Plas | Qn | Vit B6 + metabolite Pnl SerPl | ||
| 2020-05-20 | 95267-1 | Autoimmune connective tissue IgG panel - Serum or Plasma | Autoimmune connective tissue Ab.IgG panel | - | Pt | Ser/Plas | - | Autoimm conn tiss IgG pnl SerPl | ||
| 2020-05-20 | 95268-9 | Clinical factors affecting result interpretation [Identifier] | Clinical factors affecting result interpretation | Prid | Pt | ^Patient | Nom | Factors affect result imp | ||
| 2020-05-20 | 95269-7 | HLA-A+B+C (class I) Ab [Presence] in Serum or Plasma by Immunoassay | HLA-A+B+C Ab | PrThr | Pt | Ser/Plas | Ord | IA | HLA-A+B+C Ab SerPl Ql IA | |
| 2020-05-20 | 95270-5 | Platelet and HLA glycoprotein antibody panel - Blood | Platelet & HLA glycoprotein antibody panel | - | Pt | Bld | - | Platelet + HLA glycoprotein Ab Pnl Bld | ||
| 2020-05-20 | 95271-3 | Bicarbonate [Moles/volume] in Body fluid --post secretin | Bicarbonate^post secretin | SCnc | Pt | Body fld | Qn | HCO3 p SCT Fld-sCnc | ||
| 2020-05-20 | 95272-1 | Aquaporin 4 water channel IgG Ab [Presence] in Serum by Cell binding assay immunofluorescent assay | Aquaporin 4 water channel Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | AQP4 H2O channel IgG Ser Ql CBA IFA | |
| 2020-05-20 | 95273-9 | Aquaporin 4 water channel IgG Ab [Titer] in Serum by Cell binding assay immunofluorescent assay | Aquaporin 4 water channel Ab.IgG | Titr | Pt | Ser | Qn | CBA IFA | AQP4 H2O channel IgG Titr Ser CBA IFA | |
| 2020-05-20 | 95274-7 | DNM2 gene full mutation analysis in Blood or Tissue by Sequencing | DNM2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | DNM2 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95276-2 | GARS gene full mutation analysis in Blood or Tissue by Sequencing | GARS gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GARS gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95275-4 | FGD4 gene full mutation analysis in Blood or Tissue by Sequencing | FGD4 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | FGD4 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95278-8 | HSPB1 gene full mutation analysis in Blood or Tissue by Sequencing | HSPB1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | HSPB1 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95277-0 | GJB1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | GJB1 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | GJB1 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-05-20 | 95279-6 | HSPB8 gene full mutation analysis in Blood or Tissue by Sequencing | HSPB8 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | HSPB8 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95280-4 | MTMR2 gene full mutation analysis in Blood or Tissue by Sequencing | MTMR2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | MTMR2 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95282-0 | PARK2 gene deletion and duplication mutation analysis in Blood or Tissue by Molecular genetics method | PARK2 gene deletion+duplication | Find | Pt | Bld/Tiss | Doc | Molgen | PARK2 gene Del+Dup Bld/T | |
| 2020-05-20 | 95281-2 | NDRG1 gene full mutation analysis in Blood or Tissue by Sequencing | NDRG1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | NDRG1 gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95284-6 | PINK1 gene deletion in Blood or Tissue by Molecular genetics method | PINK1 gene deletion | Find | Pt | Bld/Tiss | Doc | Molgen | PINK1 gene Del Bld/T | |
| 2020-05-20 | 95283-8 | PARK7 gene deletion in Blood or Tissue by Molecular genetics method | PARK7 gene deletion | Find | Pt | Bld/Tiss | Doc | Molgen | PARK7 gene Del Bld/T | |
| 2020-05-20 | 95285-3 | RAB7A gene full mutation analysis in Blood or Tissue by Sequencing | RAB7A gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | RAB7A gene Full Mut Anl Bld/T Seq | |
| 2020-05-20 | 95287-9 | TRPV4 gene full mutation analysis in Blood or Tissue by Sequencing | TRPV4 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | TRPV4 gene Full Mut Anl Bld/T Seq | |
| 2020-05-19 | 95132-7 | Dialysis and Therapeutic apheresis Consult note | Consultation note | Find | Pt | {Setting} | Doc | Dialysis+Therapeutic apheresis | Dialy+Ther Apher Consult note | |
| 2020-05-19 | 95133-5 | Dialysis and Therapeutic apheresis Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Dialysis+Therapeutic apheresis | Dialy+Ther Apher Discharge sum | |
| 2020-05-19 | 95134-3 | Dialysis and Therapeutic apheresis Progress note | Progress note | Find | Pt | {Setting} | Doc | Dialysis+Therapeutic apheresis | Dialy+Ther Apher Progress note | |
| 2020-05-19 | 95135-0 | Noroxycodone [Mass/volume] in Urine | Noroxycodone | MCnc | Pt | Urine | Qn | Noroxycodone Ur-mCnc | ||
| 2020-05-19 | 95136-8 | Cytomegalovirus DNA panel - Amniotic fluid by NAA with probe detection | Cytomegalovirus DNA panel | - | Pt | Amnio fld | - | Probe.amp.tar | CMV DNA Pnl Amn NAA+probe | |
| 2020-05-19 | 95137-6 | Parvovirus B19 DNA panel - Amniotic fluid by NAA with probe detection | Parvovirus B19 DNA panel | - | Pt | Amnio fld | - | Probe.amp.tar | B19V DNA Pnl Amn NAA+probe | |
| 2020-05-19 | 95140-0 | Herpes simplex virus 1 and 2 DNA panel - Amniotic fluid by NAA with probe detection | Herpes simplex virus 1 & 2 DNA panel | - | Pt | Amnio fld | - | Probe.amp.tar | HSV 1+2 DNA Pnl Amn NAA+probe | |
| 2020-05-19 | 95138-4 | Epstein Barr virus DNA panel - Amniotic fluid by NAA with probe detection | Epstein Barr virus DNA panel | - | Pt | Amnio fld | - | Probe.amp.tar | EBV DNA Pnl Amn NAA+probe | |
| 2020-05-19 | 95139-2 | Varicella zoster virus DNA panel - Amniotic fluid by NAA with probe detection | Varicella zoster virus DNA panel | - | Pt | Amnio fld | - | Probe.amp.tar | VZV DNA Pnl Amn NAA+probe | |
| 2020-05-19 | 95141-8 | Hepatitis D virus Ab panel - Serum | Hepatitis D virus Ab panel | - | Pt | Ser | - | HDV Ab Pnl Ser | ||
| 2020-05-19 | 95142-6 | Hepatitis A virus IgM panel - Serum | Hepatitis A virus Ab.IgM panel | - | Pt | Ser | - | HAV IgM Pnl Ser | ||
| 2020-05-19 | 95143-4 | UGT1A1 gene TA repeats [Genotype] in Blood or Tissue by Molecular genetics method Nominal | UGT1A1 gene.TA repeats | Geno | Pt | Bld/Tiss | Nom | Molgen | UGT1A1 TA Geno Bld/T | |
| 2020-05-19 | 95144-2 | Hepatitis D virus RNA panel - Serum | Hepatitis D virus RNA panel | - | Pt | Ser | - | HDV RNA Pnl Ser | ||
| 2020-05-19 | 95145-9 | Hepatitis B virus core Ab panel - Serum or Plasma | Hepatitis B virus core Ab panel | - | Pt | Ser/Plas | - | HBV core Ab Pnl SerPl | ||
| 2020-05-19 | 95146-7 | Hepatitis B virus core IgM panel - Serum or Plasma | Hepatitis B virus core Ab.IgM panel | - | Pt | Ser/Plas | - | HBV core IgM Pnl SerPl | ||
| 2020-05-19 | 95147-5 | Hepatitis B virus DNA panel - Serum or Plasma | Hepatitis B virus DNA panel | - | Pt | Ser/Plas | - | HBV DNA Pnl SerPl | ||
| 2020-05-19 | 95148-3 | Hepatitis B virus surface Ag and Hepatitis B virus e Ab and Ag panel - Serum or Plasma | Hepatitis B virus surface Ag & little e Ab & Ag panel | - | Pt | Ser/Plas | - | HBV surf Ag + HBV e Ab + Ag Pnl SerPl | ||
| 2020-05-19 | 95149-1 | Hepatitis B virus surface Ag panel - Serum or Plasma | Hepatitis B virus surface Ag panel | - | Pt | Ser/Plas | - | HBV surface Ag Pnl SerPl | ||
| 2020-05-19 | 95150-9 | Avian infectious laryngotracheitis virus RNA [#/volume] (viral load) in Unspecified specimen by NAA with probe detection | Avian infectious laryngotracheitis virus RNA | NCnc | Pt | XXX | Qn | Probe.amp.tar | ILT RNA # XXX NAA+probe | |
| 2020-05-19 | 95151-7 | Infectious bronchitis virus RNA [#/volume] (viral load) in Unspecified specimen by NAA with probe detection | Infectious bronchitis virus RNA | NCnc | Pt | XXX | Qn | Probe.amp.tar | IBV RNA # XXX NAA+probe | |
| 2020-05-19 | 95152-5 | Mycoplasma synoviae DNA [#/volume] in Unspecified specimen by NAA with probe detection | Mycoplasma synoviae DNA | NCnc | Pt | XXX | Qn | Probe.amp.tar | M synoviae DNA # XXX NAA+probe | |
| 2020-05-19 | 95153-3 | Ornithobacterium rhinotracheale RNA [#/volume] in Unspecified specimen by NAA with probe detection | Ornithobacterium rhinotracheale RNA | NCnc | Pt | XXX | Qn | Probe.amp.tar | ORT RNA # XXX NAA+probe | |
| 2020-05-19 | 95154-1 | PRRSV ORF5 gene sequence homology to Prime Pac in Isolate by Sequencing | Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Prime Pac | NFr | Pt | Isolate | Qn | Sequencing | PRRSV Prime Pac Hmlgy Islt Seq-NFr | |
| 2020-05-19 | 95157-4 | Salmonella gallinarum+Salmonella pullorum Ab [Presence] in Serum, Plasma or Blood by Agglutination | Salmonella gallinarum+Salmonella pullorum Ab | PrThr | Pt | Ser/Plas/Bld | Ord | Aggl | S gallinarum+pullorum Ab SerPlBld Ql Agg | |
| 2020-05-19 | 95155-8 | PRRSV ORF5 gene sequence homology to Prevacent in Isolate by Sequencing | Porcine reproductive and respiratory syndrome virus ORF5 gene sequence homology to Prevacent | NFr | Pt | Isolate | Qn | Sequencing | PRRSV Prevacent Hmlgy Islt Seq-NFr | |
| 2020-05-19 | 95156-6 | Hepatitis E virus RNA [Presence] in Unspecified specimen by NAA with probe detection | Hepatitis E virus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | HEV RNA XXX Ql NAA+probe | |
| 2020-05-19 | 95158-2 | Avian encephalomyelitis virus Ab/Positive control in Serum by Immunoassay | Avian encephalomyelitis virus Ab/Positive control | RelRto | Pt | Ser | Qn | IA | AEV Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95159-0 | Avian metapneumovirus Ab/Positive control in Serum by Immunoassay | Avian metapneumovirus Ab/Positive control | RelRto | Pt | Ser | Qn | IA | aMPV Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95160-8 | Avian paramyxovirus 1 Ab/Positive control in Serum by Immunoassay | Avian paramyxovirus 1 Ab/Positive control | RelRto | Pt | Ser | Qn | IA | APMV1 Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95161-6 | Avian reovirus Ab/Positive control in Serum by Immunoassay | Avian reovirus Ab/Positive control | RelRto | Pt | Ser | Qn | IA | AVREOV Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95162-4 | Bordetella avium Ab/Positive control in Serum by Immunoassay | Bordetella avium Ab/Positive control | RelRto | Pt | Ser | Qn | IA | B avium Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95163-2 | Infectious bronchitis virus Ab/Positive control in Serum by Immunoassay | Infectious bronchitis virus Ab/Positive control | RelRto | Pt | Ser | Qn | IA | IBV Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95164-0 | Infectious bursal disease virus Ab/Positive control in Serum by Immunoassay | Infectious bursal disease virus Ab/positive control | RelRto | Pt | Ser | Qn | IA | IBDV Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95165-7 | Mycoplasma gallisepticum Ab/Positive control in Serum by Immunoassay | Mycoplasma gallisepticum Ab/Positive control | RelRto | Pt | Ser | Qn | IA | M gallisep Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95166-5 | Mycoplasma synoviae Ab/Positive control in Serum by Immunoassay | Mycoplasma synoviae Ab/Positive control | RelRto | Pt | Ser | Qn | IA | M synoviae Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95168-1 | Avian infectious laryngotracheitis virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Avian infectious laryngotracheitis virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | ILT RNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95167-3 | Ornithobacterium rhinotracheale Ab/Positive control in Serum by Immunoassay | Ornithobacterium rhinotracheale Ab/Positive control | RelRto | Pt | Ser | Qn | IA | ORT Ab/Pos cntrl Ser IA | |
| 2020-05-19 | 95169-9 | Infectious bronchitis virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Infectious bronchitis virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | IBV RNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95170-7 | Mycoplasma gallisepticum DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycoplasma gallisepticum DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M gallisep DNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95171-5 | Mycoplasma synoviae DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycoplasma synoviae DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M synoviae DNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95172-3 | Mycoplasma iowae DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycoplasma iowae DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M iowae DNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95173-1 | Mycoplasma meleagridis DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycoplasma meleagridis DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M meleagridis DNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95174-9 | Ornithobacterium rhinotracheale RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Ornithobacterium rhinotracheale RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | ORT RNA Ct XXX Qn NAA+probe | |
| 2020-05-19 | 95175-6 | Avian encephalomyelitis virus Ab [Titer] in Serum by Immunoassay | Avian encephalomyelitis virus Ab | Titr | Pt | Ser | Qn | IA | AEV Ab Titr Ser IA | |
| 2020-05-19 | 95176-4 | Avian metapneumovirus Ab [Titer] in Serum by Immunoassay | Avian metapneumovirus Ab | Titr | Pt | Ser | Qn | IA | aMPV Ab Titr Ser IA | |
| 2020-05-19 | 95177-2 | Avian reovirus Ab [Titer] in Serum by Immunoassay | Avian reovirus Ab | Titr | Pt | Ser | Qn | IA | AVREOV Ab Titr Ser IA | |
| 2020-05-19 | 95178-0 | Bordetella avium Ab [Titer] in Serum by Immunoassay | Bordetella avium Ab | Titr | Pt | Ser | Qn | IA | B avium Ab Titr Ser IA | |
| 2020-05-19 | 95179-8 | Infectious bursal disease virus Ab [Titer] in Serum by Immunoassay | Infectious bursal disease virus Ab | Titr | Pt | Ser | Qn | IA | IBDV Ab Titr Ser IA | |
| 2020-05-19 | 95180-6 | Mycoplasma gallisepticum Ab [Titer] in Serum by Immunoassay | Mycoplasma gallisepticum Ab | Titr | Pt | Ser | Qn | IA | M gallisep Ab Titr Ser IA | |
| 2020-05-19 | 95181-4 | Mycoplasma synoviae Ab [Titer] in Serum by Immunoassay | Mycoplasma synoviae Ab | Titr | Pt | Ser | Qn | IA | M synoviae Ab Titr Ser IA | |
| 2020-05-19 | 95182-2 | Ornithobacterium rhinotracheale Ab [Titer] in Serum by Immunoassay | Ornithobacterium rhinotracheale Ab | Titr | Pt | Ser | Qn | IA | ORT Ab Titr Ser IA | |
| 2020-05-19 | 95183-0 | Clostridioides difficile toxin and BI-NAP1-027 strain DNA panel - Stool by NAA with probe detection | Clostridioides difficile toxin & BI-NAP1-027 strain DNA panel | - | Pt | Stool | - | Probe.amp.tar | C diff tox+BI-NAP1-027 DNA Pnl Stl NAA+p | |
| 2020-05-19 | 95184-8 | Cytomegalovirus T-cell immunodeficiency panel - Blood by Flow cytometry (FC) | Cytomegalovirus T-cell immunodeficiency panel | - | Pt | Bld | Qn | Flow cytometry | CMV T-cell panel Bld FC | |
| 2020-05-19 | 95185-5 | HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A1 CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | HLA-A1 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95186-3 | CD107a+b expressing CMV-specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95187-1 | CD107a+b expressing HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B35 CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab HLA-B35 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95188-9 | CD107a+b expressing HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B8 CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab HLA-B8 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95191-3 | CD107a+b expressing HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A1 CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab HLA-A1 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95189-7 | CD107a+b expressing HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B7 CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab HLA-B7 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95190-5 | CD107a+b expressing HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A2 CMV specific.CMV antigen stimulated CD107a+b expressing | NCnc | Pt | Bld | Qn | Flow cytometry | CD107ab HLA-A2 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95192-1 | Interferon-gamma producing CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95193-9 | Interferon-gamma producing HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B35 CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g HLA-B35 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95194-7 | Interferon-gamma producing HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B8 CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g HLA-B8 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95195-4 | Interferon-gamma producing HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B7 CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g HLA-B7 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95196-2 | Interferon-gamma producing HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A2 CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g HLA-A2 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95199-6 | HLA-B35 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B35 CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | HLA-B35 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95197-0 | Interferon-gamma producing HLA-A1 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A1 CMV specific.CMV antigen stimulated gamma interferon producing | NCnc | Pt | Bld | Qn | Flow cytometry | IFN-g HLA-A1 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95198-8 | CMV-specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95202-8 | HLA-A2 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-A2 CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | HLA-A2 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95201-0 | HLA-B7 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B7 CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | HLA-B7 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95200-2 | HLA-B8 CMV specific CD8 cells [#/volume] in Blood by Flow cytometry (FC) | Cells.CD8.HLA-B8 CMV specific | NCnc | Pt | Bld | Qn | Flow cytometry | HLA-B8 CMV CD8 Cells # Bld FC | |
| 2020-05-19 | 95203-6 | PMA+ionomycin stimulated CD107a+b expressing CD8 cells/100 CD3+CD8+ cells in Blood by Flow cytometry (FC) | Cells.CD8.PMA+ionomycin stimulated CD107a+b expressing/100 cells.CD3+CD8+ | NFr | Pt | Bld | Qn | Flow cytometry | CD107ab CD8 Cells/100 CD3+CD8+ NFr Bld F | |
| 2020-05-19 | 95204-4 | PMA+ionomycin stimulated gamma interferon producing CD8 Cells/100 CD3+CD8+ cells in Blood by Flow cytometry (FC) | Cells.CD8.PMA+ionomycin stimulated gamma interferon producing/100 cells.CD3+CD8+ | NFr | Pt | Bld | Qn | Flow cytometry | IFN-g CD8 Cells/100 CD3+CD8+ NFr Bld FC | |
| 2020-05-19 | 95205-1 | Hepatitis B virus surface Ab panel - Serum or Plasma | Hepatitis B virus surface Ab panel | - | Pt | Ser/Plas | - | HBV surface Ab Pnl SerPl | ||
| 2020-05-19 | 95206-9 | Hepatitis C virus Ab panel - Serum or Plasma | Hepatitis C virus Ab panel | - | Pt | Ser/Plas | - | HCV Ab Pnl SerPl | ||
| 2020-05-19 | 95207-7 | Hepatitis E virus RNA panel - Serum | Hepatitis E virus RNA panel | - | Pt | Ser | - | HEV RNA Pnl Ser | ||
| 2020-05-18 | 95127-7 | Mycobacterium tuberculosis lipoarabinomannan Ag [Presence] in Urine by Rapid immunoassay | Mycobacterium tuberculosis lipoarabinomannan Ag | PrThr | Pt | Urine | Ord | IA.rapid | LAM Ag Ur Ql IA.rapid | |
| 2020-05-18 | 95128-5 | Edoxaban [Mass/volume] in Platelet poor plasma | Edoxaban | MCnc | Pt | PPP | Qn | Edoxaban PPP-mCnc | ||
| 2020-05-18 | 95129-3 | Dense fine speckled 70 protein IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | Dense fine speckled 70 protein Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | DFS70 IgG SerPl IA-aCnc | |
| 2020-05-18 | 95130-1 | Aggressive prostate cancer risk [Score] by Calculated by ExoDx | Aggressive prostate cancer risk | Score | Pt | ^Patient | Qn | Calculated.ExoDx | Aggr PC risk Score Patient Calc.ExoDx | |
| 2020-05-18 | 95131-9 | FASI v1.0 - Mobility (Wheelchair) [CMS Assessment] | FASI v1.0 - Mobility (Wheelchair) | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-14 | 95121-0 | Coagulation factor VIII activity and inhibitor panel - Platelet poor plasma by Chromogenic method | Coagulation factor VIII activity & inhibitor panel | - | Pt | PPP | - | Chromo | Fact VIII Act+Inhib Pnl PPP Chro | |
| 2020-05-14 | 95122-8 | Coagulation factor VIII inhibitor [Interpretation] in Platelet poor plasma by Chromogenic method | Coagulation factor VIII inhibitor | Imp | Pt | PPP | Nom | Chromo | Fact VIII Inhib PPP Chro-Imp | |
| 2020-05-14 | 95123-6 | Gene fusion transcript details in Blood or Tissue by Molecular genetics method Narrative | Gene fusion transcript details | Find | Pt | Bld/Tiss | Nar | Molgen | Gene fusion details Bld/T | |
| 2020-05-14 | 95124-4 | Sarcoma targeted gene fusion transcript analysis in Tissue by Sequencing | Sarcoma targeted gene fusion transcript analysis | Find | Pt | Tiss | Doc | Sequencing | Sarcoma gene fusion analysis Tiss Seq | |
| 2020-05-14 | 95126-9 | Lipid and glucose panel - Serum or Plasma | Lipid & glucose panel | - | Pt | Ser/Plas | Qn | Lipid & glucose Pnl SerPl | ||
| 2020-05-13 | 95053-5 | DOPamine [Mass/volume] in Plasma --supine | DOPamine^supine | MCnc | Pt | Plas | Qn | DOPamine sup Plas-mCnc | ||
| 2020-05-13 | 95054-3 | EPINEPHrine [Mass/volume] in Plasma --standing | EPINEPHrine^standing | MCnc | Pt | Plas | Qn | Epineph stand Plas-mCnc | ||
| 2020-05-13 | 95055-0 | DOPamine [Mass/volume] in Plasma --standing | DOPamine^standing | MCnc | Pt | Plas | Qn | DOPamine stand Plas-mCnc | ||
| 2020-05-13 | 95056-8 | Catecholamines supine and standing panel - Plasma | Catecholamines supine and standing panel | - | Pt | Plas | Qn | Catechols Sup Stand Pnl Plas | ||
| 2020-05-13 | 95068-3 | ADRB2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | ADRB2 gene targeted mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | ADRB2 Mut Anl Bld/T | |
| 2020-05-13 | 95070-9 | Chromosome 9 and 11 and 15 aneuploidy in Bone marrow by FISH | Chromosome 9 & 11 & 15 aneuploidy | Find | Pt | Bone mar | Doc | FISH | Chr 9+11+15 aneu Mar FISH | |
| 2020-05-13 | 95069-1 | Chromosome 1q and 9 and 11 and 15 aneuploidy and 13q deletion in Bone marrow by FISH | Chromosome 1q & 9 & 11 & 15 aneuploidy & chromosome region 13q deletion | Find | Pt | Bone mar | Doc | FISH | Chr 1q+9+11+15 aneu 13q Del Mar FISH | |
| 2020-05-13 | 95071-7 | Chromosome region 14q32 rearrangements in Bone marrow by FISH | Chromosome region 14q32 rearrangements | Find | Pt | Bone mar | Doc | FISH | Chr 14q32 Rearr Mar FISH | |
| 2020-05-13 | 95072-5 | 1,3 beta glucan [Mass/volume] in Cerebral spinal fluid | 1,3 beta glucan | MCnc | Pt | CSF | Qn | 1,3 beta glucan CSF-mCnc | ||
| 2020-05-13 | 95073-3 | Histoplasma capsulatum Ag [Mass/volume] in Bronchoalveolar lavage by Immunoassay | Histoplasma capsulatum Ag | MCnc | Pt | BAL | Qn | IA | H capsul Ag BAL IA-mCnc | |
| 2020-05-13 | 95074-1 | Bacteria [Presence] in Bronchoalveolar lavage by Light microscopy | Bacteria | PrThr | Pt | BAL | Ord | Microscopy.light | Bacteria BAL Ql Micro | |
| 2020-05-13 | 95075-8 | Cannabidiol/Tetrahydrocannabinol [Ratio] in Urine by Confirmatory method | Cannabidiol/Tetrahydrocannabinol | Ratio | Pt | Urine | Qn | Confirm | Cannabidiol/THC Ur Cfm-Rto | |
| 2020-05-13 | 95076-6 | C peptide [Mass/volume] in Serum or Plasma --15 min post meal | C peptide^15M post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 15M p meal SerPl-mCnc | ||
| 2020-05-13 | 95077-4 | Glucagon [Mass/volume] in Serum or Plasma --5 hours post meal | Glucagon^5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95078-2 | Glucose [Mass/volume] in Serum or Plasma --15 min post meal | Glucose^15M post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 15M p meal SerPl-mCnc | ||
| 2020-05-13 | 95079-0 | Insulin [Units/volume] in Serum or Plasma --15 min post meal | Insulin^15M post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 15M p meal SerPl-aCnc | ||
| 2020-05-13 | 95081-6 | C peptide [Mass/volume] in Serum or Plasma --1.5 hours post meal | C peptide^1.5H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 1.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95080-8 | C peptide post fasting and meal stimulation panel - Serum or Plasma | C peptide post fasting and meal stimulation panel | - | Pt | Ser/Plas | - | C peptide p Cfst + meal Pnl SerPl | ||
| 2020-05-13 | 95084-0 | C peptide [Mass/volume] in Serum or Plasma --2 hours post meal | C peptide^2H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 2h p meal SerPl-mCnc | ||
| 2020-05-13 | 95082-4 | C peptide [Mass/volume] in Serum or Plasma --1 hour post meal | C peptide^1H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 1h p meal SerPl-mCnc | ||
| 2020-05-13 | 95083-2 | C peptide [Mass/volume] in Serum or Plasma --2.5 hours post meal | C peptide^2.5H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 2.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95085-7 | C peptide [Mass/volume] in Serum or Plasma --3.5 hours post meal | C peptide^3.5H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 3.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95086-5 | C peptide [Mass/volume] in Serum or Plasma --30 min post meal | C peptide^30M post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 30M p meal SerPl-mCnc | ||
| 2020-05-13 | 95087-3 | C peptide [Mass/volume] in Serum or Plasma --3 hours post meal | C peptide^3H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 3h p meal SerPl-mCnc | ||
| 2020-05-13 | 95090-7 | C peptide [Mass/volume] in Serum or Plasma --5 hours post meal | C peptide^5H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95088-1 | C peptide [Mass/volume] in Serum or Plasma --4.5 hours post meal | C peptide^4.5H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 4.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95089-9 | C peptide [Mass/volume] in Serum or Plasma --4 hours post meal | C peptide^4H post meal | MCnc | Pt | Ser/Plas | Qn | C peptide 4h p meal SerPl-mCnc | ||
| 2020-05-13 | 95093-1 | Glucagon [Mass/volume] in Serum or Plasma --1 hour post meal | Glucagon^1H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 1h p meal SerPl-mCnc | ||
| 2020-05-13 | 95092-3 | Glucagon [Mass/volume] in Serum or Plasma --1.5 hours post meal | Glucagon^1.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 1.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95091-5 | Glucagon post fasting and meal stimulation panel - Serum or Plasma | Glucagon post fasting and meal stimulation panel | - | Pt | Ser/Plas | - | Glucagon p Cfst + meal Pnl SerPl | ||
| 2020-05-13 | 95094-9 | Glucagon [Mass/volume] in Serum or Plasma --2.5 hours post meal | Glucagon^2.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 2.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95095-6 | Glucagon [Mass/volume] in Serum or Plasma --2 hours post meal | Glucagon^2H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 2h p meal SerPl-mCnc | ||
| 2020-05-13 | 95096-4 | Glucagon [Mass/volume] in Serum or Plasma --3.5 hours post meal | Glucagon^3.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 3.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95098-0 | Glucagon [Mass/volume] in Serum or Plasma --3 hours post meal | Glucagon^3H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 3h p meal SerPl-mCnc | ||
| 2020-05-13 | 95099-8 | Glucagon [Mass/volume] in Serum or Plasma --4.5 hours post meal | Glucagon^4.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 4.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95097-2 | Glucagon [Mass/volume] in Serum or Plasma --30 min post meal | Glucagon^30M post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 30M p meal SerPl-mCnc | ||
| 2020-05-13 | 95100-4 | Glucagon [Mass/volume] in Serum or Plasma --4 hours post meal | Glucagon^4H post meal | MCnc | Pt | Ser/Plas | Qn | Glucagon 4h p meal SerPl-mCnc | ||
| 2020-05-13 | 95101-2 | Glucagon [Mass/volume] in Serum or Plasma --fasting | Glucagon^post Cfst | MCnc | Pt | Ser/Plas | Qn | Glucagon p fast SerPl-mCnc | ||
| 2020-05-13 | 95102-0 | Glucose post fasting and meal stimulation panel - Serum or Plasma | Glucose post fasting and meal stimulation panel | - | Pt | Ser/Plas | - | Glucose p Cfst + meal Pnl SerPl | ||
| 2020-05-13 | 95103-8 | Glucose [Mass/volume] in Serum or Plasma --2.5 hours post meal | Glucose^2.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 2.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95104-6 | Glucose [Mass/volume] in Serum or Plasma --3.5 hours post meal | Glucose^3.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 3.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95105-3 | Glucose [Mass/volume] in Serum or Plasma --30 min post meal | Glucose^30M post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 30M p meal SerPl-mCnc | ||
| 2020-05-13 | 95106-1 | Glucose [Mass/volume] in Serum or Plasma --3 hours post meal | Glucose^3H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 3h p meal SerPl-mCnc | ||
| 2020-05-13 | 95107-9 | Glucose [Mass/volume] in Serum or Plasma --4.5 hours post meal | Glucose^4.5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 4.5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95108-7 | Glucose [Mass/volume] in Serum or Plasma --4 hours post meal | Glucose^4H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 4h p meal SerPl-mCnc | ||
| 2020-05-13 | 95109-5 | Glucose [Mass/volume] in Serum or Plasma --5 hours post meal | Glucose^5H post meal | MCnc | Pt | Ser/Plas | Qn | Glucose 5h p meal SerPl-mCnc | ||
| 2020-05-13 | 95111-1 | Insulin [Units/volume] in Serum or Plasma --1.5 hours post meal | Insulin^1.5H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 1.5h p meal SerPl-aCnc | ||
| 2020-05-13 | 95110-3 | Insulin post fasting and meal stimulation panel - Serum or Plasma | Insulin post fasting and meal stimulation panel | - | Pt | Ser/Plas | - | Insulin p Cfst + meal Pnl SerPl | ||
| 2020-05-13 | 95112-9 | Insulin [Units/volume] in Serum or Plasma --1 hour post meal | Insulin^1H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 1h p meal SerPl-aCnc | ||
| 2020-05-13 | 95113-7 | Insulin [Units/volume] in Serum or Plasma --2.5 hours post meal | Insulin^2.5H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 2.5h p meal SerPl-aCnc | ||
| 2020-05-13 | 95114-5 | Insulin [Units/volume] in Serum or Plasma --2 hours post meal | Insulin^2H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 2h p meal SerPl-aCnc | ||
| 2020-05-13 | 95115-2 | Insulin [Units/volume] in Serum or Plasma --3.5 hours post meal | Insulin^3.5H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 3.5h p meal SerPl-aCnc | ||
| 2020-05-13 | 95117-8 | Insulin [Units/volume] in Serum or Plasma --3 hours post meal | Insulin^3H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 3h p meal SerPl-aCnc | ||
| 2020-05-13 | 95116-0 | Insulin [Units/volume] in Serum or Plasma --30 min post meal | Insulin^30M post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 30M p meal SerPl-aCnc | ||
| 2020-05-13 | 95118-6 | Insulin [Units/volume] in Serum or Plasma --4.5 hours post meal | Insulin^4.5H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 4.5h p meal SerPl-aCnc | ||
| 2020-05-13 | 95119-4 | Insulin [Units/volume] in Serum or Plasma --4 hours post meal | Insulin^4H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 4h p meal SerPl-aCnc | ||
| 2020-05-13 | 95120-2 | Insulin [Units/volume] in Serum or Plasma --5 hours post meal | Insulin^5H post meal | ACnc | Pt | Ser/Plas | Qn | Insulin 5h p meal SerPl-aCnc | ||
| 2020-05-12 | 95042-8 | Used or needed assistive devices in the past month [CMS Assessment] | Used or needed assistive devices in the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-12 | 95043-6 | Toileting hygiene - most dependent performance during the past month [CMS Assessment] | Toileting hygiene - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-12 | 95044-4 | Patient refused specimen collection | Refused specimen collection | Find | Pt | ^Patient | Ord | Patient refused spec collection | ||
| 2020-05-11 | 95020-4 | FASI v1.0 - Self-care [CMS Assessment] | FASI v1.0 - Self-care | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95021-2 | Manual wheelchair use [CMS Assessment] | Manual wheelchair use | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-11 | 95022-0 | Motorized wheelchair/scooter use [CMS Assessment] | Motorized wheelchair &or scooter use | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-11 | 95023-8 | FASI v1.0 - Mobility [CMS Assessment] | FASI v1.0 - Mobility | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95024-6 | FASI v1.0 - Manual wheelchair - usual performance [CMS Assessment] | FASI v1.0 - Manual wheelchair - usual performance | - | RptPeriod | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95025-3 | FASI v1.0 - Manual wheelchair - most dependent performance [CMS Assessment] | FASI v1.0 - Manual wheelchair - most dependent performance | - | 1Mo | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95026-1 | FASI v1.0 - Motorized wheelchair/scooter - most dependent performance [CMS Assessment] | FASI v1.0 - Motorized wheelchair &or scooter - most dependent performance | - | 1Mo | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95027-9 | FASI v1.0 - Motorized wheelchair &or scooter - usual performance [CMS Assessment] | FASI v1.0 - Motorized wheelchair &or scooter - usual performance | - | RptPeriod | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95028-7 | FASI v1.0 - Instrumental Activities of Daily Living [CMS Assessment] | FASI v1.0 - Instrumental Activities of Daily Living | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95029-5 | FASI v1.0 - Instrumental Activities of Daily Living - usual performance [CMS Assessment] | FASI v1.0 - Instrumental Activities of Daily Living - usual performance | - | RptPeriod | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95030-3 | FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance [CMS Assessment] | FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance | - | 1Mo | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95031-1 | FASI v1.0 - Assistive Devices for Everyday Activities [CMS Assessment] | FASI v1.0 - Assistive Devices for Everyday Activities | - | Pt | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95032-9 | FASI v1.0 - Functional Abilities and Goals [CMS Assessment] | FASI v1.0 - Functional Abilities and Goals | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95034-5 | FASI v1.0 - Availability of Assistance [CMS Assessment] | FASI v1.0 - Availability of Assistance | - | Pt | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95035-2 | FASI v1.0 - Availability of Paid and Unpaid Assistance [CMS Assessment] | FASI v1.0 - Availability of Paid and Unpaid Assistance | - | Pt | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95033-7 | FASI v1.0 - Preferences for Customary Routine and Activities [CMS Assessment] | FASI v1.0 - Preferences for Customary Routine and Activities | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95037-8 | FASI v1.0 - Availability of Unpaid Assistance [CMS Assessment] | FASI v1.0 - Availability of Unpaid Assistance | - | Pt | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95036-0 | FASI v1.0 - Availability of Paid Assistance [CMS Assessment] | FASI v1.0 - Availability of Paid Assistance | - | Pt | ^Patient | - | CMS Assessment | ||
| 2020-05-11 | 95041-0 | COVID-19 Progress note | COVID19+progress note | Find | Pt | {Setting} | Doc | {Role} | COVID19 Progress note | |
| 2020-05-10 | 94853-9 | West Nile virus IgG and IgM panel - Cerebral spinal fluid Qualitative | West Nile virus Ab.IgG & IgM panel | - | Pt | CSF | Ord | WNV IgG+IgM Pnl CSF | ||
| 2020-05-10 | 94854-7 | West Nile virus IgG and IgM panel - Serum Qualitative | West Nile virus Ab.IgG & IgM panel | - | Pt | Ser | Ord | WNV IgG+IgM Pnl Ser | ||
| 2020-05-10 | 94855-4 | carBAMazepine hypersensitivity genotype panel - Blood or Tissue | Carbamazepine hypersensitivity genotype panel | - | Pt | Bld/Tiss | - | carBAMazepine hypersens geno Pnl Bld/T | ||
| 2020-05-10 | 94856-2 | Microscopic observation [Presence] in Sputum by Acid fast stain --2nd specimen | Microscopic observation^2nd specimen | PrThr | Pt | Sputum | Ord | Acid fast stain | Acid fast Stn sp2 Spt Ql | |
| 2020-05-10 | 94857-0 | Microscopic observation [Presence] in Sputum by Acid fast stain --3rd specimen | Microscopic observation^3rd specimen | PrThr | Pt | Sputum | Ord | Acid fast stain | Acid fast Stn sp3 Spt Ql | |
| 2020-05-10 | 94858-8 | Glycerol [Moles/volume] in Serum by calculation | Glycerol | SCnc | Pt | Ser | Qn | Calculated | Glycerol Ser Calc-sCnc | |
| 2020-05-10 | 94861-2 | Transthyretin - transthyretin peak 2 [Mass difference] in Blood | Transthyretin - transthyretin peak 2 | MDiff | Pt | Bld | Qn | TTR - TTR 2 MDiff Bld | ||
| 2020-05-10 | 94860-4 | Transthyretin [Mass] in Blood | Transthyretin | Mass | Pt | Bld | Qn | TTR Bld Qn | ||
| 2020-05-10 | 94859-6 | Glycerol and glycerol-corrected triglyceride panel - Serum or Plasma | Glycerol & Glycerol-corrected triglyceride panel | - | Pt | Ser/Plas | - | Glycerol + glycerol corr TG Pnl SerPl | ||
| 2020-05-10 | 94862-0 | Transthyretin peak 2 [Mass] in Blood | Transthyretin peak 2 | Mass | Pt | Bld | Qn | TTR 2 Bld Qn | ||
| 2020-05-10 | 94863-8 | Transthyretin width at half peak height [Mass] in Blood | Transthyretin width at half peak height | Mass | Pt | Bld | Qn | TTR width at half height Bld Qn | ||
| 2020-05-10 | 94864-6 | Transthyretin-associated familial amyloidosis panel - Blood | Transthyretin-associated familial amyloidosis panel | - | Pt | Bld | - | TTR-assoc familial amyloidosis Pnl Bld | ||
| 2020-05-10 | 94865-3 | Triglyceride [Mass/volume] corrected for glycerol in Serum | Triglyceride^^corrected for glycerol | MCnc | Pt | Ser | Qn | Trigl Glycer cor Ser-mCnc | ||
| 2020-05-10 | 94866-1 | 7-Alpha hydroxy-4-cholesten-3-one [Mass/volume] in Serum or Plasma | 7-Alpha hydroxy-4-cholesten-3-one | MCnc | Pt | Ser/Plas | Qn | 7a-OH-4-chol-3-one SerPl-mCnc | ||
| 2020-05-10 | 94867-9 | Ganglioside GD1b IgG Ab [Titer] in Serum by Immunoassay | Ganglioside GD1b Ab.IgG | Titr | Pt | Ser | Qn | IA | GD1b Gangl IgG Titr Ser IA | |
| 2020-05-10 | 94870-3 | Ganglioside GD1b IgM Ab [Presence] in Serum by Immunoassay | Ganglioside GD1b Ab.IgM | PrThr | Pt | Ser | Ord | IA | GD1b Gangl IgM Ser Ql IA | |
| 2020-05-10 | 94868-7 | Ganglioside GD1b IgG Ab [Presence] in Serum by Immunoassay | Ganglioside GD1b Ab.IgG | PrThr | Pt | Ser | Ord | IA | GD1b Gangl IgG Ser Ql IA | |
| 2020-05-10 | 94869-5 | Ganglioside GD1b IgM Ab [Titer] in Serum by Immunoassay | Ganglioside GD1b Ab.IgM | Titr | Pt | Ser | Qn | IA | GD1b Gangl IgM Titr Ser IA | |
| 2020-05-10 | 94871-1 | Aldosterone and sodium panel - 24 hour Urine | Aldosterone & sodium panel | - | 24H | Urine | Qn | Aldosterone + Na Pnl 24h Ur | ||
| 2020-05-10 | 94873-7 | Cortisol.free post corticotropin stimulation panel - Serum or Plasma | Cortisol.free post corticotropin stimulation panel | - | Pt | Ser/Plas | Qn | Cortis F p corticotropin stim Pnl SerPl | ||
| 2020-05-10 | 94872-9 | Cholesterol and triglyceride panel - Body fluid | Cholesterol & triglyceride panel | - | Pt | Body fld | Qn | Chol + Trigl Pnl Fld | ||
| 2020-05-10 | 94875-2 | Nuclear IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | Nuclear Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | Nuclear IgG SerPl IA-aCnc | |
| 2020-05-10 | 94874-5 | Cyclic citrullinated peptide IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | Cyclic citrullinated peptide Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | cCP IgG SerPl IA-aCnc | |
| 2020-05-10 | 94876-0 | Self-care priorities for the next 6 months [CMS Assessment] | Self-care priorities for the next 6Mo | Find | Pt | ^Patient | Nar | CMS Assessment | ||
| 2020-05-10 | 94877-8 | Mobility priorities for the next 6 months [CMS Assessment] | Mobility priorities for the next 6Mo | Find | Pt | ^Patient | Nar | CMS Assessment | ||
| 2020-05-10 | 94878-6 | Instrumental activities of daily living priorities for the next 6 months [CMS Assessment] | Instrumental activities of daily living priorities for the next 6Mo | Find | Pt | ^Patient | Nar | CMS Assessment | ||
| 2020-05-10 | 94879-4 | Need for and availability of a cane/crutch [CMS Assessment] | Need for and availability of a cane &or crutch | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94880-2 | Need for and availability of a walker [CMS Assessment] | Need for and availability of a walker | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94881-0 | Need for and availability of a standard folding walker [CMS Assessment] | Need for and availability of a standard folding walker | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94882-8 | Need for and availability of a walker with seat [CMS Assessment] | Need for and availability of a walker with seat | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94883-6 | Need for and availability of a walker with wheels [CMS Assessment] | Need for and availability of a walker with wheels | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94884-4 | Need for and availability of a wheelchair [CMS Assessment] | Need for and availability of a wheelchair | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94885-1 | Need for and availability of a manual wheelchair [CMS Assessment] | Need for and availability of a manual wheelchair | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94886-9 | Need for and availability of a motorized wheelchair/scooter [CMS Assessment] | Need for and availability of a motorized wheelchair &or scooter | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94887-7 | Need for and availability of a limb prosthesis [CMS Assessment] | Need for and availability of a limb prosthesis | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94888-5 | Need for and availability of a specialized seating pad [CMS Assessment] | Need for and availability of a specialized seating pad | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94889-3 | Need for and availability of a mechanical lift [CMS Assessment] | Need for and availability of a mechanical lift | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94890-1 | Need for and availability of a reacher/grabber [CMS Assessment] | Need for and availability of a reacher &or grabber | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94891-9 | Need for and availability of a sock aid [CMS Assessment] | Need for and availability of a sock aid | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94892-7 | Need for and availability of a orthotic/brace [CMS Assessment] | Need for and availability of a orthotic &or brace | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94894-3 | Need for and availability of a electronic bed [CMS Assessment] | Need for and availability of a electronic bed | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94893-5 | Need for and availability of a bed rail [CMS Assessment] | Need for and availability of a bed rail | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94895-0 | Need for and availability of a grab bars [CMS Assessment] | Need for and availability of a grab bars | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94896-8 | Need for and availability of a transfer board [CMS Assessment] | Need for and availability of a transfer board | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94897-6 | Need for and availability of a shower/commode chair [CMS Assessment] | Need for and availability of a shower &or commode chair | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94898-4 | Need for and availability of a walk or wheel-in shower [CMS Assessment] | Need for and availability of a walk or wheel-in shower | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94899-2 | Need for and availability of glasses or contact lenses [CMS Assessment] | Need for and availability of glasses or contact lenses | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94900-8 | Need for and availability of a hearing aid [CMS Assessment] | Need for and availability of a hearing aid | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94901-6 | Need for and availability of a communication device [CMS Assessment] | Need for and availability of a communication device | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94902-4 | Need for and availability of stair rails [CMS Assessment] | Need for and availability of stair rails | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94903-2 | Need for and availability of a lift chair [CMS Assessment] | Need for and availability of a lift chair | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94904-0 | Need for and availability of ramps [CMS Assessment] | Need for and availability of ramps | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94905-7 | Need for and availability of a raised toilet seat [CMS Assessment] | Need for and availability of a raised toilet seat | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94906-5 | Need for and availability of a glucometer [CMS Assessment] | Need for and availability of a glucometer | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94907-3 | Need for and availability of Continuous Positive Airway Pressure device [CMS Assessment] | Need for and availability of Continuous Positive Airway Pressure device | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94908-1 | Need for and availability of a oxygen concentrator [CMS Assessment] | Need for and availability of a oxygen concentrator | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94909-9 | Assistive devices needed [CMS Assessment] | Assistive devices needed | Find | Pt | ^Patient | Nom | CMS Assessment | ||
| 2020-05-10 | 94910-7 | Need for and availability of other assistive devices [CMS Assessment] | Need for and availability of other assistive devices | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94911-5 | Living arrangement priorities for the next 6 months [CMS Assessment] | Living arrangement priorities for the next 6Mo | Find | Pt | ^Patient | Nar | CMS Assessment | ||
| 2020-05-10 | 94912-3 | Availability of caregiver assistance [CMS Assessment] | Availability of caregiver assistance | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94913-1 | Level of paid caregiver assistance in the past month [CMS Assessment] | Level of paid caregiver assistance in the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94914-9 | Level of unpaid caregiver assistance in the past month [CMS Assessment] | Level of unpaid caregiver assistance in the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94915-6 | Paid caregiver's ability and willingness to provide self-care assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide self-care assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94916-4 | Unpaid caregiver's ability and willingness to provide self-care assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide self-care assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94917-2 | Paid caregiver's ability and willingness to provide mobility assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide mobility assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94918-0 | Unpaid caregiver's ability and willingness to provide mobility assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide mobility assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94919-8 | Paid caregiver's ability and willingness to provide instrumental activities of daily living assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide instrumental activities of daily living assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94920-6 | Unpaid caregiver's ability and willingness to provide instrumental activities of daily living assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide instrumental activities of daily living assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94921-4 | Paid caregiver's ability and willingness to provide medication administration assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide medication administration assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94922-2 | Unpaid caregiver's ability and willingness to provide medication administration assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide medication administration assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94923-0 | Paid caregiver's ability and willingness to provide medical procedure/treatment assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide medical procedure &or treatment assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94926-3 | Unpaid caregiver's ability and willingness to provide management of equipment assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide management of equipment assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94924-8 | Unpaid caregiver's ability and willingness to provide medical procedure/treatment assistance [CMS Assessment] | Unpaid caregiver's ability and willingness to provide medical procedure &or treatment assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94925-5 | Paid caregiver's ability and willingness to provide management of equipment assistance [CMS Assessment] | Paid caregiver's ability and willingness to provide management of equipment assistance | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94929-7 | Paid caregiver's ability and willingness to provide advocacy or facilitation of person's participation [CMS Assessment] | Paid caregiver's ability and willingness to provide advocacy or facilitation of person's participation | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94928-9 | Unpaid caregiver's ability and willingness to provide supervision [CMS Assessment] | Unpaid caregiver's ability and willingness to provide supervision | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94927-1 | Paid caregiver's ability and willingness to provide supervision [CMS Assessment] | Paid caregiver's ability and willingness to provide supervision | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94930-5 | Unpaid caregiver's ability and willingness to provide advocacy or facilitation of person's participation [CMS Assessment] | Unpaid caregiver's ability and willingness to provide advocacy or facilitation of person's participation | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94931-3 | Caregiving priorities for the next 6 months [CMS Assessment] | Caregiving priorities for the next 6Mo | Find | Pt | ^Patient | Nar | CMS Assessment | ||
| 2020-05-10 | 94932-1 | Does the patient walk [CMS Assessment] | Does the patient walk | Find | Pt | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94933-9 | Eating - most dependent performance during the past month [CMS Assessment] | Eating - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94935-4 | Wash upper body - most dependent performance during the past month [CMS Assessment] | Wash upper body - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94936-2 | Shower &or bathe self - most dependent performance during the past month [CMS Assessment] | Shower &or bathe self - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94934-7 | Oral hygiene - most dependent performance during the past month [CMS Assessment] | Oral hygiene - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94938-8 | Lower body dressing - most dependent performance during the past month [CMS Assessment] | Lower body dressing - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94939-6 | Putting on and taking off footwear - most dependent performance during the past month [CMS Assessment] | Putting on and taking off footwear - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94937-0 | Upper body dressing - most dependent performance during the past month [CMS Assessment] | Upper body dressing - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94942-0 | Lying to sitting on side of bed - most dependent performance during the past month [CMS Assessment] | Lying to sitting on side of bed - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94940-4 | Roll left and right - most dependent performance during the past month [CMS Assessment] | Roll left and right - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94941-2 | Sit to lying - most dependent performance during the past month [CMS Assessment] | Sit to lying - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94945-3 | Toilet transfer - most dependent performance during the past month [CMS Assessment] | Toilet transfer - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94944-6 | Bed-to-chair transfer - most dependent performance during the past month [CMS Assessment] | Bed-to-chair transfer - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94943-8 | Sit to stand - most dependent performance during the past month [CMS Assessment] | Sit to stand - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94946-1 | Car transfer - most dependent performance during the past month [CMS Assessment] | Car transfer - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94947-9 | Walks 10 feet - most dependent performance during the past month [CMS Assessment] | Walks 10 feet - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94948-7 | Walks 50 feet with two turns - most dependent performance during the past month [CMS Assessment] | Walks 50 feet with two turns - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94951-1 | Go up and down a curb/step - most dependent performance during the past month [CMS Assessment] | Go up and down a curb &or step - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94949-5 | Walks 150 feet - most dependent performance during the past month [CMS Assessment] | Walks 150 feet - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94950-3 | Walks 10 feet on uneven surfaces - most dependent performance during the past month [CMS Assessment] | Walks 10 feet on uneven surfaces - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94954-5 | Picking up object - most dependent performance during the past month [CMS Assessment] | Picking up object - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94952-9 | Go up and down 4 steps - most dependent performance during the past month [CMS Assessment] | Go up and down 4 steps - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94953-7 | Go up and down 12 steps - most dependent performance during the past month [CMS Assessment] | Go up and down 12 steps - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94955-2 | Walks indoors - most dependent performance during the past month [CMS Assessment] | Walks indoors - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94956-0 | Carries something in both hands - most dependent performance during the past month [CMS Assessment] | Carries something in both hands - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94957-8 | Walks for 15 minutes - most dependent performance during the past month [CMS Assessment] | Walks for 15M - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94959-4 | Wheels 50 feet with two turns - most dependent performance during the past month [CMS Assessment] | Wheels 50 feet with two turns - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94960-2 | Wheels 150 feet - most dependent performance during the past month [CMS Assessment] | Wheels 150 feet - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94958-6 | Walks across a street - most dependent performance during the past month [CMS Assessment] | Walks across a street - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94961-0 | Wheels for 15 minutes - most dependent performance during the past month [CMS Assessment] | Wheels for 15M - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94962-8 | Wheels across a street - most dependent performance during the past month [CMS Assessment] | Wheels across a street - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94963-6 | Makes a light cold meal - most dependent performance during the past month [CMS Assessment] | Makes a light cold meal - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94964-4 | Makes a light hot meal - most dependent performance during the past month [CMS Assessment] | Makes a light hot meal - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94965-1 | Light daily housework - most dependent performance during the past month [CMS Assessment] | Light daily housework - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94966-9 | Heavier periodic housework - most dependent performance during the past month [CMS Assessment] | Heavier periodic housework - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94967-7 | Light shopping- most dependent performance during the past month [CMS Assessment] | Light shopping- most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94968-5 | Answering telephone call- most dependent performance during the past month [CMS Assessment] | Answering telephone call- most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94969-3 | Placing telephone call - most dependent performance during the past month [CMS Assessment] | Placing telephone call - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94970-1 | Medication management.oral medications - most dependent performance during the past month [CMS Assessment] | Medication management.oral medications - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94971-9 | Medication management.inhalant &or mist medications - most dependent performance during the past month [CMS Assessment] | Medication management.inhalant &or mist medications - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94972-7 | Medication management.injectable medications - most dependent performance during the past month [CMS Assessment] | Medication management.injectable medications - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94973-5 | Simple financial management - most dependent performance during the past month [CMS Assessment] | Simple financial management - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94974-3 | Complex financial management - most dependent performance during the past month [CMS Assessment] | Complex financial management - most dependent performance during the past Mo | Find | 1Mo | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94975-0 | Living arrangement during the past month [CMS Assessment] | Living arrangement during the past 1Mo | Find | 1Mo | ^Patient | Nom | CMS Assessment | ||
| 2020-05-10 | 94976-8 | Makes a light cold meal - usual functional ability [CMS Assessment] | Makes a light cold meal - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94977-6 | Makes a light hot meal - usual functional ability [CMS Assessment] | Makes a light hot meal - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94978-4 | Light daily housework - usual functional ability [CMS Assessment] | Light daily housework - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94979-2 | Heavier periodic housework - usual functional ability [CMS Assessment] | Heavier periodic housework - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94980-0 | Light shopping - usual functional ability [CMS Assessment] | Light shopping - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94981-8 | Answering telephone call - usual functional ability [CMS Assessment] | Answering telephone call - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94982-6 | Placing telephone call - usual functional ability [CMS Assessment] | Placing telephone call - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94983-4 | Medication management.oral medications - usual functional ability [CMS Assessment] | Medication management.oral medications - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94984-2 | Medication management.inhalant/mist medications - usual functional ability [CMS Assessment] | Medication management.inhalant &or mist medications - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94985-9 | Medication management.injectable medications - usual functional ability [CMS Assessment] | Medication management.injectable medications - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94986-7 | Simple financial management - usual functional ability [CMS Assessment] | Simple financial management - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94987-5 | Complex financial management - usual functional ability [CMS Assessment] | Complex financial management - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94988-3 | Living arrangement [CMS Assessment] | Living arrangement | Find | RptPeriod | ^Patient | Nom | CMS Assessment | ||
| 2020-05-10 | 94989-1 | Wheels across a street - usual functional ability [CMS Assessment] | Wheels across a street - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94990-9 | Wheels for 15 minutes - usual functional ability [CMS Assessment] | Wheels for 15 minutes - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94991-7 | Wheels 150 feet - usual functional ability [CMS Assessment] | Wheels 150 feet - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94992-5 | Wheels 50 feet with two turns - usual functional ability [CMS Assessment] | Wheels 50 feet with two turns - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94993-3 | Walks across a street - usual functional ability [CMS Assessment] | Walks across a street - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94994-1 | Walks for 15 minutes - usual functional ability [CMS Assessment] | Walks for 15 minutes - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94995-8 | Carries something in both hands - usual functional ability [CMS Assessment] | Carries something in both hands - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94996-6 | Walks indoors - usual functional ability [CMS Assessment] | Walks indoors - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94997-4 | Picking up object - usual functional ability [CMS Assessment] | Picking up object - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95000-6 | Go up and down a curb/step - usual functional ability [CMS Assessment] | Go up and down a curb &or step - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94998-2 | Go up and down 12 steps - usual functional ability [CMS Assessment] | Go up and down 12 steps - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 94999-0 | Go up and down 4 steps - usual functional ability [CMS Assessment] | Go up and down 4 steps - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95004-8 | Walks 10 feet - usual functional ability [CMS Assessment] | Walks 10 feet - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95003-0 | Walks 50 feet with two turns - usual functional ability [CMS Assessment] | Walks 50 feet with two turns - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95001-4 | Walks 10 feet on uneven surfaces - usual functional ability [CMS Assessment] | Walks 10 feet on uneven surfaces - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95002-2 | Walks 150 feet - usual functional ability [CMS Assessment] | Walks 150 feet - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95005-5 | Car transfer - usual functional ability [CMS Assessment] | Car transfer - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95006-3 | Toilet transfer - usual functional ability [CMS Assessment] | Toilet transfer - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95007-1 | Chair/bed-to-chair transfer - usual functional ability [CMS Assessment] | Chair &or bed-to-chair transfer - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95010-5 | Sit to lying - usual functional ability [CMS Assessment] | Sit to lying - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95009-7 | Lying to sitting on side of bed - usual functional ability [CMS Assessment] | Lying to sitting on side of bed - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95008-9 | Sit to stand - usual functional ability [CMS Assessment] | Sit to stand - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95012-1 | Putting on/taking off footwear - usual functional ability [CMS Assessment] | Putting on &or taking off footwear - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95013-9 | Lower body dressing - usual functional ability [CMS Assessment] | Lower body dressing - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95014-7 | Upper body dressing - usual functional ability [CMS Assessment] | Upper body dressing - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95011-3 | Roll left and right - usual functional ability [CMS Assessment] | Roll left and right - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95017-0 | Toileting hygiene - usual functional ability [CMS Assessment] | Toileting hygiene - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95015-4 | Shower/bathe self - usual functional ability [CMS Assessment] | Shower &or bathe self - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95016-2 | Wash upper body - usual functional ability [CMS Assessment] | Wash upper body - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95018-8 | Oral hygiene - usual functional ability [CMS Assessment] | Oral hygiene - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-10 | 95019-6 | Eating - usual functional ability [CMS Assessment] | Eating - usual functional ability | Find | RptPeriod | ^Patient | Ord | CMS Assessment | ||
| 2020-05-08 | 94846-3 | History of Specimen collection problem | Specimen collection problem | Hx | Pt | ^Patient | Nom | Hx of Spec collection problem | ||
| 2020-05-08 | 94847-1 | Reason specimen not collected | Reason specimen not collected | Find | Pt | Specimen | Nom | Reason spec not collected | ||
| 2020-05-08 | 94848-9 | Functional assessment standardized items (FASI) - version 1.0 [CMS Assessment] | Functional assessment standardized items (FASI) - version 1.0 | - | - | ^Patient | - | CMS Assessment | ||
| 2020-05-08 | 94850-5 | FASI v1.0 - Self-care - most dependent performance [CMS Assessment] | FASI v1.0 - Self-care - most dependent performance | - | 1Mo | ^Patient | - | CMS Assessment | ||
| 2020-05-08 | 94851-3 | FASI v1.0 - Mobility - usual performance [CMS Assessment] | FASI v1.0 - Mobility - usual performance | - | RptPeriod | ^Patient | - | CMS Assessment | ||
| 2020-05-08 | 94849-7 | FASI v1.0 - Self-care - usual performance [CMS Assessment] | FASI v1.0 - Self-care - usual performance | - | RptPeriod | ^Patient | - | CMS Assessment | ||
| 2020-05-08 | 94852-1 | FASI v1.0 - Mobility - most dependent performance [CMS Assessment] | FASI v1.0 - Mobility - most dependent performance | - | 1Mo | ^Patient | - | CMS Assessment | ||
| 2020-05-06 | 94823-2 | Cytomegalovirus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Cytomegalovirus DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | CMV DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94825-7 | Parvovirus B19 DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Parvovirus B19 DNA | LaCnc | Pt | Amnio fld | Qn | Probe.amp.tar | B19V DNA Amn NAA+probe-Log IU | |
| 2020-05-06 | 94824-0 | Parvovirus B19 DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Parvovirus B19 DNA | ACnc | Pt | Amnio fld | Qn | Probe.amp.tar | B19V DNA Amn NAA+probe-aCnc | |
| 2020-05-06 | 94828-1 | Epstein Barr virus DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Epstein Barr virus DNA | ACnc | Pt | Amnio fld | Qn | Probe.amp.tar | EBV DNA Amn NAA+probe-aCnc | |
| 2020-05-06 | 94826-5 | Parvovirus B19 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Parvovirus B19 DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | B19V DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94827-3 | Epstein Barr virus DNA [Presence] in Amniotic fluid by NAA with probe detection | Epstein Barr virus DNA | PrThr | Pt | Amnio fld | Ord | Probe.amp.tar | EBV DNA Amn Ql NAA+probe | |
| 2020-05-06 | 94829-9 | Epstein Barr virus DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Epstein Barr virus DNA | LaCnc | Pt | Amnio fld | Qn | Probe.amp.tar | EBV DNA Amn NAA+probe-Log IU | |
| 2020-05-06 | 94830-7 | Epstein Barr virus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Epstein Barr virus DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | EBV DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94831-5 | Varicella zoster virus DNA [Units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Varicella zoster virus DNA | ACnc | Pt | Amnio fld | Qn | Probe.amp.tar | VZV DNA Amn NAA+probe-aCnc | |
| 2020-05-06 | 94834-9 | Herpes simplex virus 1+2 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Herpes simplex virus 1+2 DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | HSV1+2 DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94832-3 | Varicella zoster virus DNA [log units/volume] (viral load) in Amniotic fluid by NAA with probe detection | Varicella zoster virus DNA | LaCnc | Pt | Amnio fld | Qn | Probe.amp.tar | VZV DNA Amn NAA+probe-Log IU | |
| 2020-05-06 | 94833-1 | Varicella zoster virus DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Varicella zoster virus DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | VZV DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94838-0 | Enterovirus RNA [Presence] in Amniotic fluid by NAA with probe detection | Enterovirus RNA | PrThr | Pt | Amnio fld | Ord | Probe.amp.tar | EV RNA Amn Ql NAA+probe | |
| 2020-05-06 | 94837-2 | Dengue virus 1+2+3+4 RNA [Presence] in Amniotic fluid by NAA with probe detection | Dengue virus 1+2+3+4 RNA | PrThr | Pt | Amnio fld | Ord | Probe.amp.tar | DENV1+2+3+4 RNA Amn Ql NAA+probe | |
| 2020-05-06 | 94835-6 | Herpes simplex virus 1 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Herpes simplex virus 1 DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | HSV1 DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94836-4 | Herpes simplex virus 2 DNA [Log #/volume] (viral load) in Amniotic fluid by NAA with probe detection | Herpes simplex virus 2 DNA | LnCnc | Pt | Amnio fld | Qn | Probe.amp.tar | HSV2 DNA Amn NAA+probe-Log# | |
| 2020-05-06 | 94839-8 | Calcium [Mass/volume] in Urine from Fetus | Calcium | MCnc | Pt | Urine^Fetus | Qn | Calcium Ur Fetus-mCnc | ||
| 2020-05-06 | 94840-6 | Chloride [Moles/volume] in Urine from Fetus | Chloride | SCnc | Pt | Urine^Fetus | Qn | Chloride Ur Fetus-sCnc | ||
| 2020-05-06 | 94843-0 | Osmolality of Urine from Fetus | Osmolality | Osmol | Pt | Urine^Fetus | Qn | Osmolality Ur Fetus | ||
| 2020-05-06 | 94842-2 | Sodium [Moles/volume] in Urine from Fetus | Sodium | SCnc | Pt | Urine^Fetus | Qn | Sodium Ur Fetus-sCnc | ||
| 2020-05-06 | 94841-4 | Potassium [Moles/volume] in Urine from Fetus | Potassium | SCnc | Pt | Urine^Fetus | Qn | Potassium Ur Fetus-sCnc | ||
| 2020-05-06 | 94844-8 | Creatinine [Mass/volume] in Urine from Fetus | Creatinine | MCnc | Pt | Urine^Fetus | Qn | Creat Ur Fetus-mCnc | ||
| 2020-05-04 | 94815-8 | CV2 IgG Ab [Titer] in Serum by Immunofluorescence | CV2 Ab.IgG | Titr | Pt | Ser | Qn | IF | CV2 IgG Titr Ser IF | |
| 2020-05-04 | 94817-4 | Striated muscle Ab [Titer] in Serum by Immunoassay | Striated muscle Ab | Titr | Pt | Ser | Qn | IA | Stria Mus Ab Titr Ser IA | |
| 2020-05-04 | 94816-6 | Voltage-gated potassium channel Ab [Moles/volume] in Serum by Immunoassay | Voltage-gated potassium channel Ab | SCnc | Pt | Ser | Qn | IA | VGKC Ab Ser IA-sCnc | |
| 2020-05-04 | 94818-2 | Paraneoplastic Ab panel - Cerebral spinal fluid by Immunofluorescence | Paraneoplastic Ab panel | - | Pt | CSF | - | IF | Paraneoplastic Ab Pnl CSF IF | |
| 2020-05-04 | 94820-8 | Whole mRNA transcriptome sequence analysis in Blood or Tissue by Sequencing | Whole mRNA transcriptome sequence analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | Whole mRNA Seq Analysis Bld/T Seq | |
| 2020-05-01 | 94770-5 | Wound, Ostomy, and Continence Care Telehealth Note | Note | Find | Pt | Telehealth | Doc | Wound, ostomy, and continence care | WOC Telehealth Note | |
| 2020-05-01 | 94771-3 | Anesthesiology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Anesthesiology | Anesthesiology Telehealth Note | |
| 2020-05-01 | 94772-1 | Blood banking and transfusion medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Blood banking and transfusion medicine | Bld Bnk+Trans Med Telehealth Note | |
| 2020-05-01 | 94773-9 | Burn management Telehealth Note | Note | Find | Pt | Telehealth | Doc | Burn management | Burn Telehealth Note | |
| 2020-05-01 | 94774-7 | Cardiac surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cardiac surgery | Cardiac surgery Telehealth Note | |
| 2020-05-01 | 94775-4 | Critical care medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Critical Care Medicine | CCM Telehealth Note | |
| 2020-05-01 | 94776-2 | Dentistry Telehealth Note | Note | Find | Pt | Telehealth | Doc | Dentistry | Dentistry Telehealth Note | |
| 2020-05-01 | 94777-0 | Dermatology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Dermatology | Dermatology Telehealth Note | |
| 2020-05-01 | 94778-8 | Ethics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Ethics | Ethics Telehealth Note | |
| 2020-05-01 | 94779-6 | Family medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Family medicine | Fam Med Telehealth Note | |
| 2020-05-01 | 94780-4 | Gastroenterology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Gastroenterology | Gastroenterology Telehealth Note | |
| 2020-05-01 | 94781-2 | General medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | General medicine | General medicine Telehealth Note | |
| 2020-05-01 | 94782-0 | Surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Surgery | Surgery Telehealth Note | |
| 2020-05-01 | 94783-8 | Geriatric medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Geriatric medicine | Geri med Telehealth Note | |
| 2020-05-01 | 94784-6 | Gynecologic oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Gynecologic oncology | Gyn Onc Telehealth Note | |
| 2020-05-01 | 94785-3 | Healthcare navigator Telehealth Note | Note | Find | Pt | Telehealth | Doc | Healthcare navigator | Navigator Telehealth Note | |
| 2020-05-01 | 94786-1 | Hematology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Hematology | Hematology Telehealth Note | |
| 2020-05-01 | 94787-9 | Interventional radiology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Interventional radiology | IR Telehealth Note | |
| 2020-05-01 | 94788-7 | Clinical pathology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Clinical pathology | Clin Path Telehealth Note | |
| 2020-05-01 | 94789-5 | Maternal and fetal medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Maternal and fetal medicine | Maternal fetal med Telehealth Note | |
| 2020-05-01 | 94790-3 | Nutrition and dietetics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Nutrition and dietetics | Nutr+diet Telehealth Note | |
| 2020-05-01 | 94791-1 | Occupational therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Occupational therapy | OT Telehealth Note | |
| 2020-05-01 | 94792-9 | Oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Oncology | Oncology Telehealth Note | |
| 2020-05-01 | 94793-7 | Wound care management Telehealth Note | Note | Find | Pt | Telehealth | Doc | Wound care management | Wound care management Telehealth Note | |
| 2020-05-01 | 94794-5 | Ophthalmology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Ophthalmology | Ophthalmol Telehealth Note | |
| 2020-05-01 | 94795-2 | Pastoral care Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pastoral care | Pastoral Care Telehealth Note | |
| 2020-05-01 | 94796-0 | Pharmacology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pharmacology | Pharmacology Telehealth Note | |
| 2020-05-01 | 94797-8 | Plastic surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Plastic surgery | Plastic surgery Telehealth Note | |
| 2020-05-01 | 94798-6 | Psychology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Psychology | Psych Telehealth Note | |
| 2020-05-01 | 94799-4 | Radiation oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Radiation oncology | Radiation Onc Telehealth Note | |
| 2020-05-01 | 94800-0 | Rapid response team Telehealth Note | Note | Find | Pt | Telehealth | Doc | Rapid response team | Rapid response team Telehealth Note | |
| 2020-05-01 | 94801-8 | Recreational therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Recreational therapy | Rec therapy Telehealth Note | |
| 2020-05-01 | 94802-6 | Respiratory therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Respiratory therapy | Resp therapy Telehealth Note | |
| 2020-05-01 | 94803-4 | Speech-language pathology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Speech-language pathology | Speech-lang path Telehealth Note | |
| 2020-05-01 | 94804-2 | Trauma Telehealth Note | Note | Find | Pt | Telehealth | Doc | Trauma | Trauma Telehealth Note | |
| 2020-05-01 | 94805-9 | Vascular surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Vascular surgery | Vascular surgery Telehealth Note | |
| 2020-04-30 | 94753-1 | Psychotropic medication pharmacogenomic analysis in Blood or Tissue by Molecular genetics method | Psychotropic medication pharmacogenomic analysis | Find | Pt | Bld/Tiss | Doc | Molgen | Psychotropic Pharmg Analy Bld/T | |
| 2020-04-30 | 94754-9 | CD21lowCD38- cells/100 CD19 cells in Blood | Cells.CD21lowCD38-/100 Cells.CD19 | NFr | Pt | Bld | Qn | CD21lowCD38- cells/100 CD19 cells NFr Bl | ||
| 2020-04-30 | 94755-6 | CD21lowCD38- cells [#/volume] in Blood | Cells.CD21lowCD38- | NCnc | Pt | Bld | Qn | CD21lowCD38- cells # Bld | ||
| 2020-04-29 | 94743-2 | Gynecologic oncology Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Gynecologic oncology | Gyn Onc Eval note | |
| 2020-04-29 | 94744-0 | Healthcare navigator Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Healthcare navigator | Navigator Eval note | |
| 2020-04-29 | 94747-3 | Medical Aid in Dying Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Medical aid in dying | MAiD Eval note | |
| 2020-04-29 | 94748-1 | Medical Aid in Dying Patient Consent Document | Consent | Find | Pt | {Setting} | Doc | Medical aid in dying.patient | MAiD Patient Consent | |
| 2020-04-29 | 94750-7 | Wound, Ostomy, and Continence Care Evaluation note | Evaluation note | Find | Pt | {Setting} | Doc | Wound, ostomy, and continence care | WOC Eval note | |
| 2020-04-29 | 94749-9 | Medical Aid in Dying Progress note | Progress note | Find | Pt | {Setting} | Doc | Medical aid in dying | MAiD Progress note | |
| 2020-04-29 | 94751-5 | RHCE gene allele Ee [Genotype] in Blood or Tissue by Molecular genetics method Nominal | RHCE gene allele Ee | Geno | Pt | Bld/Tiss | Nom | Molgen | RHCE allele Ee Geno Bld/T | |
| 2020-04-29 | 94752-3 | RHCE gene allele Cc [Genotype] in Blood or Tissue by Molecular genetics method Nominal | RHCE gene allele Cc | Geno | Pt | Bld/Tiss | Nom | Molgen | RHCE allele Cc Geno Bld/T | |
| 2020-04-28 | 94742-4 | Disease stage classification method | Disease stage classification method | Type | Pt | ^Patient | Nom | * | Disease stg class method | |
| 2020-04-26 | 94741-6 | Cancer chemotherapy received in the past 4W | Cancer chemotherapy received in the past 4W | Find | 4W | ^Patient | Ord | Chemotherapy rcvd past 4W | ||
| 2020-04-21 | 94727-5 | Gabapentin [Mass/volume] in Saliva (oral fluid) by Confirmatory method | Gabapentin | MCnc | Pt | Saliva | Qn | Confirm | Gabapentin Sal Cfm-mCnc | |
| 2020-04-21 | 94728-3 | DULoxetine [Mass/volume] in Saliva (oral fluid) by Confirmatory method | DULoxetine | MCnc | Pt | Saliva | Qn | Confirm | DULoxetine Sal Cfm-mCnc | |
| 2020-04-21 | 94729-1 | Cyclobenzaprine [Mass/volume] in Saliva (oral fluid) by Confirmatory method | Cyclobenzaprine | MCnc | Pt | Saliva | Qn | Confirm | Cyclobenzaprine Sal Cfm-mCnc | |
| 2020-04-21 | 94730-9 | Hypnotics [Presence] in Saliva (oral fluid) by Confirmatory method | Hypnotics | PrThr | Pt | Saliva | Ord | Confirm | Hypnotics Sal Ql Cfm | |
| 2020-04-21 | 94731-7 | Narcotics and opioids [Presence] in Saliva (oral fluid) by Confirmatory method | Narcotics | PrThr | Pt | Saliva | Ord | Confirm | Narcotics Sal Ql Cfm | |
| 2020-04-21 | 94732-5 | DULoxetine [Presence] in Saliva (oral fluid) by Confirmatory method | DULoxetine | PrThr | Pt | Saliva | Ord | Confirm | DULoxetine Sal Ql Cfm | |
| 2020-04-21 | 94733-3 | Anticonvulsants [Presence] in Saliva (oral fluid) by Confirmatory method | Anticonvulsants | PrThr | Pt | Saliva | Ord | Confirm | Anticonvulsants Sal Ql Cfm | |
| 2020-04-21 | 94734-1 | Prostate cancer grade group [Score] in Prostate tumor Qualitative | Prostate cancer grade group | Score | Pt | Prostate tumor | Ord | Prostate CA grade grp PrT Ql | ||
| 2020-04-21 | 94735-8 | Prostate tumor area with Gleason pattern 4+5/Total tumor area [Area Fraction] in Prostate tumor by Microscopy | Prostate tumor area with Gleason pattern 4+5/Total tumor area | AreaFr | Pt | Prostate tumor | Qn | Microscopy | Gleason 4+5/Total AreaFr PrT Micro | |
| 2020-04-21 | 94736-6 | Tissue block identifier [Identifier] in Specimen | Tissue block identifier | ID | Pt | Specimen | Nom | Tissue block ID Spec | ||
| 2020-04-21 | 94737-4 | Intraductal carcinoma of prostate [Presence] in Specimen by Microscopy | Intraductal carcinoma of prostate | PrThr | Pt | Specimen | Ord | Microscopy | Intraductal CA Prostate Spec Ql Micro | |
| 2020-04-21 | 94738-2 | Biopsy site [Anatomy] | Biopsy site | Anat | Pt | ^Patient | Nom | Biopsy site Patient | ||
| 2020-04-21 | 94739-0 | Prostate cancer grade group basis [Type] in Prostate tumor | Prostate cancer grade group basis | Type | Pt | Prostate tumor | Nom | Grade grp basis PrT | ||
| 2020-04-21 | 94740-8 | Gleason scoring basis [Type] in Prostate tumor | Gleason scoring basis | Type | Pt | Prostate tumor | Nom | Gleason Basis PrT | ||
| 2020-04-17 | 94725-9 | Aerodigestive medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Aerodigestive medicine | Aerodigestive med Telehealth Note | |
| 2020-04-17 | 94726-7 | Cleft and Craniofacial Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cleft and Craniofacial | Cleft+Craniofacial Telehealth Note | |
| 2020-04-15 | 94724-2 | Pulmonary Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pulmonary disease | Pulmonary disease Telehealth Note | |
| 2020-04-14 | 94690-5 | Chondroitin-6-sulfate/Creatinine [Ratio] in Urine | Chondroitin-6-sulfate/Creatinine | Ratio | Pt | Urine | Qn | C6S/Creat Ur-Rto | ||
| 2020-04-14 | 94691-3 | Dermatan sulfate, heparan sulfate, chondroitin-6-sulfate, keratan sulfate panel - Urine | Dermatan sulfate & heparan sulfate & chondroitin-6-sulfate & keratan sulfate panel | - | Pt | Urine | Qn | MPS panel Ur | ||
| 2020-04-14 | 94693-9 | Heparan sulfate/Creatinine [Ratio] in Urine | Heparan sulfate/Creatinine | Ratio | Pt | Urine | Qn | Heparan sulfate/Creat Ur-Rto | ||
| 2020-04-14 | 94692-1 | Dermatan sulfate/Creatinine [Ratio] in Urine | Dermatan sulfate/Creatinine | Ratio | Pt | Urine | Qn | Dermatan Sulfate/Creat Ur-Rto | ||
| 2020-04-14 | 94694-7 | Acetylcholine receptor ganglionic neuronal Ab [Moles/volume] in Serum by Immunoassay | Acetylcholine receptor ganglionic neuronal Ab | SCnc | Pt | Ser | Qn | IA | nAChR Ab Ser IA-sCnc | |
| 2020-04-14 | 94695-4 | Axonal autoimmune Ab panel - Serum or Plasma | Axonal autoimmune Ab panel | - | Pt | Ser/Plas | - | Axonal autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94696-2 | Dementia autoimmune Ab panel - Serum or Plasma | Dementia autoimmune Ab panel | - | Pt | Ser/Plas | - | Dementia autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94697-0 | Encephalopathy autoimmune Ab panel - Serum or Plasma | Encephalopathy autoimmune Ab panel | - | Pt | Ser/Plas | - | Encephalopathy autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94698-8 | Epilepsy autoimmune Ab panel - Serum or Plasma | Epilepsy autoimmune Ab panel | - | Pt | Ser/Plas | - | Epilepsy autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94701-0 | Movement disorder autoimmune Ab panel - Serum or Plasma | Movement disorder autoimmune Ab panel | - | Pt | Ser/Plas | - | Movement autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94700-2 | Liver diseases autoimmune Ab panel - Serum or Plasma | Liver diseases autoimmune Ab panel | - | Pt | Ser/Plas | - | Liver diseases autoimmune Ab pnl SerPl | ||
| 2020-04-14 | 94699-6 | Glutamate decarboxylase 65 Ab [Moles/volume] in Serum by Immunoassay | Glutamate decarboxylase 65 Ab | SCnc | Pt | Ser | Qn | IA | GAD65 Ab Ser IA-sCnc | |
| 2020-04-14 | 94702-8 | PCA-1 Ab [Titer] in Serum by Immunofluorescence | Purkinje cell cytoplasmic type 1 Ab | Titr | Pt | Ser | Qn | IF | PCA-1 Ab Titr Ser IF | |
| 2020-04-14 | 94703-6 | PCA-2 Ab [Titer] in Serum by Immunofluorescence | Purkinje cell cytoplasmic type 2 Ab | Titr | Pt | Ser | Qn | IF | PCA-2 Ab Titr Ser IF | |
| 2020-04-14 | 94704-4 | Voltage-gated calcium channel N type binding Ab [Moles/volume] in Serum by Immunoassay | Voltage-gated calcium channel N type binding Ab | SCnc | Pt | Ser | Qn | IA | VGCC-N Bind Ab Ser IA-sCnc | |
| 2020-04-14 | 94705-1 | Voltage-gated calcium channel P/Q type binding Ab [Moles/volume] in Serum by Immunoassay | Voltage-gated calcium channel PQ type binding Ab | SCnc | Pt | Ser | Qn | IA | VGCC-P/Q Bind Ab Ser IA-sCnc | |
| 2020-04-14 | 94707-7 | Dementia autoimmune Ab panel - Cerebral spinal fluid | Dementia autoimmune Ab panel | - | Pt | CSF | - | Dementia autoimmune Ab pnl CSF | ||
| 2020-04-14 | 94706-9 | CV2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | CV2 Ab.IgG | Titr | Pt | CSF | Qn | IF | CV2 IgG Titr CSF IF | |
| 2020-04-14 | 94708-5 | Encephalopathy autoimmune Ab panel - Cerebral spinal fluid | Encephalopathy autoimmune Ab panel | - | Pt | CSF | - | Encephalopathy autoimmune Ab pnl CSF | ||
| 2020-04-14 | 94709-3 | Epilepsy autoimmune Ab panel - Cerebral spinal fluid | Epilepsy autoimmune Ab panel | - | Pt | CSF | - | Epilepsy autoimmune Ab pnl CSF | ||
| 2020-04-14 | 94712-7 | Movement disorder autoimmune Ab panel - Cerebral spinal fluid | Movement disorder autoimmune Ab panel | - | Pt | CSF | - | Movement autoimmune Ab pnl CSF | ||
| 2020-04-14 | 94711-9 | Glutamate decarboxylase 65 Ab [Moles/volume] in Cerebral spinal fluid by Immunoassay | Glutamate decarboxylase 65 Ab | SCnc | Pt | CSF | Qn | IA | GAD65 Ab CSF IA-sCnc | |
| 2020-04-14 | 94713-5 | Aspartylglycosamine [Moles/volume] in Cerebral spinal fluid | Aspartylglycosamine | SCnc | Pt | CSF | Qn | Aspartylglycosamine CSF-sCnc | ||
| 2020-04-14 | 94714-3 | Beta globulin [Mass/time] in 24 hour Urine by Electrophoresis | Beta globulin | MRat | 24H | Urine | Qn | Electrophoresis | B-Globulin 24h Ur Elph-mRate | |
| 2020-04-14 | 94715-0 | Gamma globulin [Mass/time] in 24 hour Urine by Electrophoresis | Gamma globulin | MRat | 24H | Urine | Qn | Electrophoresis | Gamma glob 24h Ur Elph-mRate | |
| 2020-04-14 | 94716-8 | AGTR1 gene c.1166A>C [Genotype] in Blood by Molecular genetics method Nominal | AGTR1 gene.c.1166A>C | Geno | Pt | Bld | Nom | Molgen | AGTR1 c.1166A>C Geno Bld | |
| 2020-04-14 | 94717-6 | SLC25A15 gene c.562_564delTTC [Genotype] in Blood or Tissue by Molecular genetics method Nominal | SLC25A15 gene.c.562_564delTTC | Geno | Pt | Bld/Tiss | Nom | Molgen | SLC25A15 c.562_564delTTC Geno Bld/T | |
| 2020-04-14 | 94718-4 | Alpha defensins 1+2+3 [Presence] in Synovial fluid by Immunoassay | Alpha defensins 1+2+3 | PrThr | Pt | Synv fld | Ord | IA | Alpha defensins 1+2+3 Snv Ql IA | |
| 2020-04-14 | 94719-2 | Plazomicin [Susceptibility] by Gradient strip | Plazomicin | Susc | Pt | Isolate | OrdQn | Gradient strip | Plazomicin Islt Grad strip | |
| 2020-04-13 | 94678-0 | NM Liver and Biliary ducts and Gallbladder Views for patency | Views for patency^W radionuclide IV | Find | Pt | Abdomen>Liver+Biliary ducts+Gallbladder | Doc | NM | NM Liver+BDs+GB Views for pat W RNC IV | |
| 2020-04-13 | 94679-8 | XR Chest Single View and Abdomen Supine and Upright and Lateral-decubitus | View && Views supine + upright + lateral-decubitus | Find | Pt | Chest && Abdomen | Doc | XR | XR Chest 1V + Abd Sup+Upr+Lat-Decub | |
| 2020-04-13 | 94681-4 | US.doppler Thoracic and Abdominal Aorta and Inferior Vena Cava and Illiac vessels | Multisection | Find | Pt | Chest>Aorta.thoracic & Abdomen>Aorta.abdominal+Vena cava.inferior & Abdomen+Pelvis>Iliac vessels | Doc | US.doppler | DOP T Ao+Abd Ao+IVC+Ves-Il | |
| 2020-04-13 | 94680-6 | US.doppler Thoracic and Abdominal Aorta and Inferior Vena Cava and Illiac vessels limited | Multisection limited | Find | Pt | Chest>Aorta.thoracic & Abdomen>Aorta.abdominal+Vena cava.inferior & Abdomen+Pelvis>Iliac vessels | Doc | US.doppler | DOP T Ao+Abd Ao+IVC+Ves-Il Ltd | |
| 2020-04-13 | 94684-8 | XR Spine Lumbar and Sacrum GE 6 Views W right bending and W left bending | Views GE 6^W R-bending + W L-bending | Find | Pt | Abdomen>Spine.lumbar & Pelvis>Sacrum | Doc | XR | XR L-spine+Sacrum GE 6V W R+L-bending | |
| 2020-04-13 | 94682-2 | XR Calcaneus GE 2 Views | Views GE 2 | Find | Pt | Lower extremity>Calcaneus | Doc | XR | XR Heel GE 2V | |
| 2020-04-13 | 94683-0 | XR Pelvis and Hip - unilateral GE 2 Views | Views GE 2 | Find | Pt | Pelvis & Lower extremity.unilateral>Hip | Doc | XR | XR Pelvis and Hip-Ul GE 2V | |
| 2020-04-13 | 94685-5 | XR Ribs - unilateral GE 3 Views and Chest PA | Views GE 3 && view PA | Find | Pt | Chest>Ribs.unilateral && Chest | Doc | XR | XR Ribs-Ul GE 3V + Chest PA | |
| 2020-04-13 | 94686-3 | MR Brain WO and W contrast IV and MRA Brain WO contrast | Multisection^WO & W contrast IV && Multisection^WO contrast | Find | Pt | Head>Brain && Head>Head vessels | Doc | MR && MR.angio | MR Brain WO+W contr IV+MRA WO contr | |
| 2020-04-13 | 94687-1 | CTA Abdominal vessels and Pelvis vessels WO contrast | Multisection^WO contrast | Find | Pt | Abdomen>Abdominal vessels & Pelvis>Pelvis vessels | Doc | CT.angio | CTA Abd ves+Pelvis ves WO contr | |
| 2020-04-13 | 94688-9 | CTA Neck vessels and Chest vessels WO and W contrast IV | Multisection^WO & W contrast IV | Find | Pt | Neck>Neck vessels & Chest>Chest vessels | Doc | CT.angio | CTA Neck+Chest Ves WO+W contr IV | |
| 2020-04-13 | 94689-7 | CD20 cells/100 CD19 cells in Blood | Cells.CD20/100 cells.CD19 | NFr | Pt | Bld | Qn | CD20 Cells/100 CD19 cells NFr Bld | ||
| 2020-04-07 | 94665-7 | Granulomatous prostatitis [Presence] in Specimen by Microscopy | Granulomatous prostatitis | PrThr | Pt | Specimen | Ord | Microscopy | Granulomatous prostatitis Spec Ql Micro | |
| 2020-04-07 | 94666-5 | High grade prostatic intraepithelial neoplasia [Presence] in Specimen by Microscopy | High grade prostatic intraepithelial neoplasia | PrThr | Pt | Specimen | Ord | Microscopy | HGPIN Spec Ql Micro | |
| 2020-04-07 | 94667-3 | Delayed hypersensitivity anergy intradermal panel | Delayed hypersensitivity anergy panel | - | Pt | Skin | - | DTH Anergy Pnl Skin | ||
| 2020-04-07 | 94668-1 | Reaction wheal [Diameter] --1 day post dose control intradermal | Reaction wheal^1D post control ID | Diam | Pt | Skin | Qn | Rx wheal 1D p control ID Diam | ||
| 2020-04-07 | 94669-9 | Reaction wheal [Diameter] --2 day post dose control intradermal | Reaction wheal^2D post control ID | Diam | Pt | Skin | Qn | Rx wheal 2D p control ID Diam | ||
| 2020-04-07 | 94670-7 | Tetanus reaction wheal [Diameter] --1 day post tetanus toxoid intradermal | Tetanus reaction wheal^1D post tetanus toxoid ID | Diam | Pt | Skin | Qn | Tetanus Rx 1D p tet tox ID Diam | ||
| 2020-04-07 | 94671-5 | Tetanus reaction wheal [Diameter] --2 day post tetanus toxoid intradermal | Tetanus reaction wheal^2D post tetanus toxoid ID | Diam | Pt | Skin | Qn | Tetanus Rx 2D p tet tox ID Diam | ||
| 2020-04-07 | 94672-3 | 24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol | MCnc | Pt | Ser/Plas | Qn | 24,25(OH)2 VitD SerPl-mCnc | ||
| 2020-04-07 | 94673-1 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2/24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 [Mass Ratio] in Serum or Plasma | Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol | MRto | Pt | Ser/Plas | Qn | 25(OH)D3+25(OH)D2/24,25(OH)2 VitD SerPl | ||
| 2020-04-07 | 94674-9 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2/24,25-dihydroxyvitamin D3+24,25-dihydroxyvitamin D2 ratio panel in Serum or Plasma | Calcidiol+ercalcidiol/24r-Hydroxycalcidiol+24r-Hydroxyercalcidiol ratio panel | - | Pt | Ser/Plas | - | 25D3+25D2/24,25D3+24,25D2 Pnl SerPl | ||
| 2020-04-07 | 94675-6 | Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Titer] in Serum by Immunofluorescence | Dipeptidyl aminopeptidase-like protein 6 Ab.IgG | Titr | Pt | Ser | Qn | IF | DPPX IgG Titr Ser IF | |
| 2020-04-07 | 94676-4 | Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Serum by Cell binding assay immunofluorescent assay | Dipeptidyl aminopeptidase-like protein 6 Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | DPPX IgG Ser Ql CBA IFA | |
| 2020-04-07 | 94677-2 | Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine and Cystatin C-based formula (CKD-EPI) | Glomerular filtration rate/1.73 sq M.predicted | ArVRat | Pt | Ser/Plas/Bld | Qn | Creatinine and Cystatin C-based formula (CKD-EPI) | GFR/BSA.pred SerPlBld Creat+Cyst CKD-EPI | |
| 2020-04-06 | 94662-4 | Coccidioides immitis IgG Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID) | Coccidioides immitis Ab.IgG | PrThr | Pt | CSF | Ord | Immune diffusion | C immitis IgG CSF Ql ID | |
| 2020-04-06 | 94663-2 | Coccidioides immitis IgM Ab [Presence] in Cerebral spinal fluid by Immune diffusion (ID) | Coccidioides immitis Ab.IgM | PrThr | Pt | CSF | Ord | Immune diffusion | C immitis IgM CSF Ql ID | |
| 2020-04-06 | 94664-0 | Anticipated discharge date | Anticipated discharge date | Date | Pt | ^Patient | Qn | Anticipated discharge date | ||
| 2020-04-03 | 94655-8 | Identifier and Assigning authority panel | Identifier & Assigning authority panel | - | Pt | ^Patient | - | ID & Authority panel | ||
| 2020-04-01 | 94594-9 | Neurological surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Neurological surgery | Neuro surgery Telehealth Note | |
| 2020-04-01 | 94595-6 | Pharmacology Telehealth Medication management note | Medication management note | Find | Pt | Telehealth | Doc | Pharmacology | Pharmacology Telehealth Med mgmt note | |
| 2020-04-01 | 94596-4 | Equine infectious anemia virus Ab [Units/volume] in Serum by Immunoassay | Equine infectious anemia virus Ab | ACnc | Pt | Ser | Qn | IA | EIAV Ab Ser IA-aCnc | |
| 2020-04-01 | 94597-2 | Equine adenovirus 1 RNA [Presence] in Unspecified specimen by NAA with probe detection | Equine adenovirus 1 RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | EAdV1 RNA XXX Ql NAA+probe | |
| 2020-04-01 | 94598-0 | Equine herpesvirus 2 RNA [Presence] in Unspecified specimen by NAA with probe detection | Equine herpesvirus 2 RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | EHV2 RNA XXX Ql NAA+probe | |
| 2020-04-01 | 94599-8 | Equine herpesvirus 3 RNA [Presence] in Unspecified specimen by NAA with probe detection | Equine herpesvirus 3 RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | EHV3 RNA XXX Ql NAA+probe | |
| 2020-04-01 | 94600-4 | Equine influenza virus [Presence] in Unspecified specimen by Organism specific culture | Equine influenza virus | PrThr | Pt | XXX | Ord | Organism specific culture | EIV XXX Ql Cult | |
| 2020-04-01 | 94601-2 | Listeria monocytogenes Ag [Presence] in Tissue by Immune stain | Listeria monocytogenes Ag | PrThr | Pt | Tiss | Ord | Immune stain | L monocytog Ag Tiss Ql ImStn | |
| 2020-04-01 | 94602-0 | West Nile virus IgM Ab/Positive control in Serum by Immunoassay | West Nile virus Ab.IgM/Positive control | RelRto | Pt | Ser | Qn | IA | WNV IgM/Pos cntrl Ser IA | |
| 2020-04-01 | 94603-8 | Bacterial 16S rRNA gene [Nucleotide sequence] in Isolate by Sequencing | Bacterial 16S rRNA gene | Seq | Pt | Isolate | Nom | Sequencing | Bact 16S rRNA gene Islt-Seq | |
| 2020-04-01 | 94604-6 | Equine arteritis virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Equine arteritis virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | EAV RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94607-9 | Equine rhinitis A virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Equine rhinitis A virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | ERAV RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94606-1 | Equine herpesvirus 4 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Equine herpesvirus 4 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | EHV4 RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94605-3 | Equine herpesvirus 1 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Equine herpesvirus 1 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | EHV1 RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94608-7 | Erbovirus A RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Erbovirus A RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | Erbovirus A RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94609-5 | Bovine leukemia virus Ab [Units/volume] in Serum by Immunoassay | Bovine leukemia virus Ab | ACnc | Pt | Ser | Qn | IA | BLV Ab Ser IA-aCnc | |
| 2020-04-01 | 94610-3 | Bovine diarrhea virus subtype [Identifier] in Unspecified specimen by NAA with probe detection | Bovine diarrhea virus subtype | Prid | Pt | XXX | Nom | Probe.amp.tar | BVDV subtype XXX NAA+probe | |
| 2020-04-01 | 94611-1 | Pasteurella multocida toxin toxA gene [Presence] in Unspecified specimen by NAA with probe detection | Pasteurella multocida toxin toxA gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | P multoc Tox toxA XXX Ql NAA+probe | |
| 2020-04-01 | 94612-9 | Mycoplasma bovis Ag [Presence] in Tissue by Immune stain | Mycoplasma bovis Ag | PrThr | Pt | Tiss | Ord | Immune stain | Mp bovis Ag Tiss Ql ImStn | |
| 2020-04-01 | 94613-7 | Bovine respiratory syncytial virus Ag [Presence] in Tissue by Immune stain | Bovine respiratory syncytial virus Ag | PrThr | Pt | Tiss | Ord | Immune stain | BRSV Ag Tiss Ql ImStn | |
| 2020-04-01 | 94614-5 | Bovine parainfluenza virus 3 RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Bovine parainfluenza virus 3 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | BPIV3 RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94615-2 | Bovine herpesvirus 1 DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Bovine herpesvirus 1 DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | BoHV1 DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94616-0 | Bovine coronavirus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Bovine coronavirus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | BCV RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94617-8 | Anaplasma marginale DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Anaplasma marginale DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | A marginale DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94618-6 | Bovine respiratory syncytial virus [Presence] in Unspecified specimen by Organism specific culture | Bovine respiratory syncytial virus | PrThr | Pt | XXX | Ord | Organism specific culture | BRSV XXX Ql Cult | |
| 2020-04-01 | 94619-4 | Bovine herpesvirus 1 [Presence] in Unspecified specimen by Organism specific culture | Bovine herpesvirus 1 | PrThr | Pt | XXX | Ord | Organism specific culture | BoHV1 XXX Ql Cult | |
| 2020-04-01 | 94620-2 | Bovine diarrhea virus [Presence] in Unspecified specimen by Organism specific culture | Bovine diarrhea virus | PrThr | Pt | XXX | Ord | Organism specific culture | BVDV XXX Ql Cult | |
| 2020-04-01 | 94621-0 | Mycobacterium avium ss paratuberculosis Ab/Positive control in Unspecified specimen by Immunoassay | Mycobacterium avium subspecies paratuberculosis Ab/Positive control | RelRto | Pt | XXX | Qn | IA | M avium paraTB Ab/Pos cntrl XXX IA | |
| 2020-04-01 | 94622-8 | Bovine diarrhea virus Ag/Positive control in Unspecified specimen by Immunoassay | Bovine diarrhea virus Ag/Positive control | RelRto | Pt | XXX | Qn | IA | BVDV Ag/Pos cntrl XXX IA | |
| 2020-04-01 | 94623-6 | Ureaplasma diversum DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Ureaplasma diversum DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | U diversum DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94624-4 | Tritrichomonas foetus DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Tritrichomonas foetus DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | T foet DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94626-9 | Ovine herpesvirus 2 DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Ovine herpesvirus 2 DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | OvHV2 DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94627-7 | Neospora caninum DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Neospora caninum DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | N caninum DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94625-1 | Pasteurella multocida DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Pasteurella multocida DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | P multoc DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94628-5 | Mycoplasma bovis DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycoplasma bovis DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | Mp bovis DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94629-3 | Mycobacterium avium ss paratuberculosis DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mycobacterium avium subspecies paratuberculosis DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M avium paraTB DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94631-9 | Haemophilus somnus DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Haemophilus somnus DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | H somnus DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94630-1 | Mannheimia haemolytica DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Mannheimia haemolytica DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | M haemolytica DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94634-3 | Coxiella burnetii DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Coxiella burnetii DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | C burnet DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94632-7 | Escherichia coli K99 DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Escherichia coli K99 DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | E coli K99 DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94633-5 | Cryptosporidium parvum DNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Cryptosporidium parvum DNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | C parvum DNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94635-0 | Bovine diarrhea virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Bovine diarrhea virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | BVDV RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94636-8 | Bovine respiratory syncytial virus RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection | Bovine respiratory syncytial virus RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | BRSV RNA Ct XXX Qn NAA+probe | |
| 2020-04-01 | 94637-6 | Mycobacterium avium ss paratuberculosis Ab [Titer] in Serum by Complement fixation | Mycobacterium avium subspecies paratuberculosis Ab | Titr | Pt | Ser | Qn | Comp fix | M avium paraTB Ab Titr Ser CF | |
| 2020-04-01 | 94638-4 | Bovine respiratory syncytial virus Ab [Titer] in Serum by Neutralization test | Bovine respiratory syncytial virus Ab | Titr | Pt | Ser | Qn | Neut | BRSV Ab Titr Ser Nt | |
| 2020-03-31 | 94586-5 | Dermatan sulfate and heparan sulfate and keratan sulfate panel - DBS | Dermatan sulfate & heparan sulfate & keratan sulfate panel | - | Pt | Bld.dot | - | MPS panel DBS | ||
| 2020-03-31 | 94587-3 | Germline disorder chromosome analysis in Amniotic fluid or Chorionic villus sample by Mate pair sequencing | Germline disorder chromosome analysis | Find | Pt | Amnio fld/CVS | Doc | Mate pair sequencing | Germline chromo analy Amn/CVS MPSeq | |
| 2020-03-31 | 94588-1 | Myeloid neoplasm chromosome analysis in Blood or Marrow by Mate pair sequencing | Myeloid neoplasm chromosome analysis | Find | Pt | Bld/Bone mar | Doc | Mate pair sequencing | Myeloid neoplasm chr analy Bld/Mar MPSeq | |
| 2020-03-31 | 94589-9 | Hematologic neoplasm chromosome analysis in Blood or Marrow by Mate pair sequencing | Hematologic neoplasm chromosome analysis | Find | Pt | Bld/Bone mar | Doc | Mate pair sequencing | Hematologic chrom analy Bld/Mar MPSeq | |
| 2020-03-31 | 94591-5 | Chromosome rearrangement [Identifier] in Blood or Tissue by Molecular genetics method Narrative | Chromosome rearrangement | Prid | Pt | Bld/Tiss | Nar | Molgen | Chromosome rearrangement Bld/T | |
| 2020-03-31 | 94590-7 | Oncologic chromosome analysis in Tissue by Mate pair sequencing | Oncologic chromosome analysis | Find | Pt | Tiss | Doc | Mate pair sequencing | Oncologic chrom analy Tiss MPSeq | |
| 2020-03-31 | 94592-3 | Chromosome rearrangement [Identifier] in Blood or Tissue by Mate pair sequencing Nominal | Chromosome rearrangement | Prid | Pt | Bld/Tiss | Nom | Mate pair sequencing | AML chromo analys Bld/Mar MPSeq | |
| 2020-03-31 | 94593-1 | Multiplex allergen panel - Serum or Plasma | Multiplex allergen panel | - | Pt | Ser/Plas | - | Multiplex Allergy Pnl SerPl | ||
| 2020-03-28 | 94566-7 | Maple syrup urine disease therapy monitoring panel - Serum or Plasma | Maple syrup urine disease therapy monitoring panel | - | Pt | Ser/Plas | Qn | MSUD therapy monitor Pnl SerPl | ||
| 2020-03-28 | 94567-5 | Valine [Moles/volume] in Serum or Plasma --post therapeutic diet | Valine^post therapeutic diet | SCnc | Pt | Ser/Plas | Qn | Valine p diet SerPl-sCnc | ||
| 2020-03-28 | 94568-3 | Isoleucine [Moles/volume] in Serum or Plasma --post therapeutic diet | Isoleucine^post therapeutic diet | SCnc | Pt | Ser/Plas | Qn | Isoleucine p diet SerPl-sCnc | ||
| 2020-03-28 | 94569-1 | Leucine [Moles/volume] in Serum or Plasma --post therapeutic diet | Leucine^post therapeutic diet | SCnc | Pt | Ser/Plas | Qn | Leucine p diet SerPl-sCnc | ||
| 2020-03-28 | 94570-9 | Alloisoleucine [Moles/volume] in Serum or Plasma --post therapeutic diet | Alloisoleucine^post therapeutic diet | SCnc | Pt | Ser/Plas | Qn | Alloisoleucine p diet SerPl-sCnc | ||
| 2020-03-28 | 94572-5 | Alloisoleucine [Moles/volume] in DBS | Alloisoleucine | SCnc | Pt | Bld.dot | Qn | Alloisoleucine DBS-sCnc | ||
| 2020-03-28 | 94571-7 | Branched chain amino acid panel - DBS | Branched chain amino acid panel | - | Pt | Bld.dot | Qn | Branched chain aa Pnl DBS | ||
| 2020-03-28 | 94573-3 | Tyrosinemia newborn screening follow-up and therapeutic monitoring panel - DBS | Tyrosinemia newborn screening follow-up & therapeutic monitoring panel | - | Pt | Bld.dot | Qn | TYR NBS f/u + monitor Pnl DBS | ||
| 2020-03-28 | 94574-1 | Heavy metals panel - Nail | Heavy metals panel | - | Pt | Nail | - | Heavy Met Pnl Nail | ||
| 2020-03-28 | 94575-8 | Heavy metals panel - 24 hour Urine | Heavy metals panel | - | 24H | Urine | - | Heavy Met Pnl 24h Ur | ||
| 2020-03-28 | 94576-6 | Mycobacterium tuberculosis complex species identified in Isolate by NAA with probe detection | Mycobacterium tuberculosis complex species identified | Prid | Pt | Isolate | Nom | Probe.amp.tar | MTB complex sp Islt NAA+probe | |
| 2020-03-28 | 94577-4 | Maximum amplitude AA induced [Length] in Blood by Resonance TEG | Maximum clot strength amplitude.arachidonic acid induced | Len | Pt | Bld | Qn | Thromboelastography.resonance | MA AA Bld Res TEG | |
| 2020-03-28 | 94578-2 | Clot strength TXA2 receptor inhibited [Length fraction] in Blood by calculation | Clot strength.platelet thromboxane A2 receptor inhibited | LenFr | Pt | Bld | Qn | Calculated | Clot strength TXA2-R inhib LenFr Bld Cal | |
| 2020-03-28 | 94579-0 | Clot strength AA induced [Length fraction] in Blood by calculation | Clot strength.arachidonic acid induced | LenFr | Pt | Bld | Qn | Calculated | Clot strength AA induced LenFr Bld Calc | |
| 2020-03-28 | 94580-8 | Herpes simplex virus 1 and 2 DNA panel - Unspecified specimen by NAA with non-probe detection | Herpes simplex virus 1 & 2 DNA panel | - | Pt | XXX | - | Non-probe.amp.tar | HSV 1+2 DNA Pnl XXX NAA+non-probe | |
| 2020-03-28 | 94581-6 | Herpes simplex virus 1 DNA [Presence] in Unspecified specimen by NAA with non-probe detection | Herpes simplex virus 1 DNA | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | HSV1 DNA XXX Ql NAA+non-probe | |
| 2020-03-28 | 94582-4 | Herpes simplex virus 2 DNA [Presence] in Unspecified specimen by NAA with non-probe detection | Herpes simplex virus 2 DNA | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | HSV2 DNA XXX Ql NAA+non-probe | |
| 2020-03-28 | 94584-0 | Varicella zoster virus DNA [Presence] in Unspecified specimen by NAA with non-probe detection | Varicella zoster virus DNA | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | VZV DNA XXX Ql NAA+non-probe | |
| 2020-03-28 | 94585-7 | Herpes simplex virus 1 and 2 and Varicella zoster virus DNA panel - Unspecified specimen by NAA with non-probe detection | Herpes simplex virus 1 & 2 & Varicella zoster virus DNA panel | - | Pt | XXX | - | Non-probe.amp.tar | HSV 1 + 2 + VZV DNA Pnl XXX NAA+non-prob | |
| 2020-03-28 | 94583-2 | Herpes simplex virus 1 and 2 DNA panel - Cerebral spinal fluid by NAA with non-probe detection | Herpes simplex virus 1 & 2 DNA panel | - | Pt | CSF | - | Non-probe.amp.tar | HSV 1+2 DNA Pnl CSF NAA+non-probe | |
| 2020-03-25 | 94560-0 | Diabetes risk [Score] Calculated | Diabetes risk | Score | Pt | ^Patient | Qn | Calculated | Diabetes risk Score Calc | |
| 2020-03-25 | 94561-8 | Risk calculation method used | Risk calculation method used | Type | Pt | ^Patient | Nom | * | Risk calc method | |
| 2020-03-19 | 94554-3 | Soluble CD14 subtype [Mass/volume] in Serum, Plasma or Blood by Immunoassay | Soluble CD14 subtype | MCnc | Pt | Ser/Plas/Bld | Qn | IA | sCD14-ST SerPlBld IA-mCnc | |
| 2020-03-19 | 94556-8 | dRVVT excess phospholipid in Platelet poor plasma by Coagulation assay --post DOAC neutralization | Coagulation dilute Russell viper venom induced.excess phospholipid^post DOAC neutralization | Time | Pt | PPP | Qn | Coag | dRVVT confirm p DOAC neut PPP | |
| 2020-03-19 | 94555-0 | dRVVT/dRVVT.excess phospholipid [Ratio] in Platelet poor plasma by Coagulation assay --post DOAC neutralization | Coagulation dilute Russell viper venom induced/Coagulation dilute Russell viper venom induced.excess phospholipid^post DOAC neutralization | Ratio | Pt | PPP | Qn | Coag | dRVVT/dRVVT cfm p DOAC neut PPP-Rto | |
| 2020-03-19 | 94557-6 | dRVVT in Platelet poor plasma by Coagulation assay --post DOAC neutralization | Coagulation dilute Russell viper venom induced^post DOAC neutralization | Time | Pt | PPP | Qn | Coag | dRVVT p DOAC neut PPP | |
| 2020-03-16 | 94548-5 | Porphyrin fractions panel [Mass/time] - 24 hour Stool | Porphyrin fractions panel | MRat | 24H | Stool | Qn | Porphyrin Fract Pnl 24h Stl-mRate | ||
| 2020-03-16 | 94550-1 | Hexacarboxylporphyrin I [Mass/time] in 24 hour Stool | Hexacarboxylporphyrin I | MRat | 24H | Stool | Qn | Hexa-CP I 24h Stl-mRate | ||
| 2020-03-16 | 94551-9 | Hexacarboxylporphyrin III [Mass/time] in 24 hour Stool | Hexacarboxylporphyrin III | MRat | 24H | Stool | Qn | Hexa-CPr3 24h Stl-mRate | ||
| 2020-03-16 | 94549-3 | Isoheptacarboxylporphyrin [Mass/time] in 24 hour Stool | Isoheptacarboxylporphyrin | MRat | 24H | Stool | Qn | Isohepta-CP 24h Stl-mRate | ||
| 2020-03-16 | 94552-7 | Isohexacarboxylporphyrin [Mass/time] in 24 hour Stool | Isohexacarboxylporphyrin | MRat | 24H | Stool | Qn | Isohexa-CP 24h Stl-mRate | ||
| 2020-03-16 | 94553-5 | Isopentacarboxylporphyrin [Mass/time] in 24 hour Stool | Isopentacarboxylporphyrin | MRat | 24H | Stool | Qn | Isopenta-CP 24h Stl-mRate | ||
| 2020-03-11 | 94542-8 | Leprosy [Type] | Leprosy | Type | Pt | ^Patient | Nom | Leprosy Patient | ||
| 2020-03-11 | 94543-6 | Microscopic observation [Identifier] in Skin by Acid fast stain | Microscopic observation | Prid | Pt | Skin | Nom | Acid fast stain | Acid fast Stn Skin | |
| 2020-03-11 | 94545-1 | Household contacts [#] | Household contacts | Num | Pt | ^Patient | Qn | Household contacts | ||
| 2020-03-11 | 94544-4 | Exposure source in 30 days prior to onset of illness | Exposure source in 30D prior to onset of illness | Type | Pt | ^Patient | Nom | Exp source 30D prior onset | ||
| 2020-03-11 | 94546-9 | Relationship to individual with confirmed or suspected illness | Relationship to individual with confirmed or suspected illness | Type | Pt | ^Patient | Nom | Rel to ind w conf/susp ill | ||
| 2020-03-10 | 94535-2 | Skin tone | Skin tone | Type | Pt | Skin | Nom | Skin tone | ||
| 2020-03-10 | 94536-0 | Natural color of Hair | Natural color | Type | Pt | Hair | Nom | Hair Color | ||
| 2020-03-10 | 94537-8 | Hemoglobin panel - Blood by HPLC | Hemoglobin panel | - | Pt | Bld | - | HPLC | Hgb Pnl Bld HPLC | |
| 2020-03-10 | 94538-6 | Hemoglobin HPLC and electrophoresis panel - Blood | Hemoglobin HPLC & electrophoresis panel | - | Pt | Bld | - | Hgb HPLC + electrophoresis Pnl Bld | ||
| 2020-03-10 | 94539-4 | Hepatitis A virus IgM and total panel - Serum or Plasma Qualitative | Hepatitis A virus Ab.IgM & total panel | - | Pt | Ser/Plas | Ord | HAV IgM + total Pnl SerPl | ||
| 2020-03-10 | 94541-0 | Mycobacterial identification panel - Unspecified specimen by Molecular genetics method | Mycobacterial identification panel | - | Pt | XXX | - | Molgen | Mycobacterial ID Pnl XXX | |
| 2020-03-10 | 94540-2 | Mycobacterial stain and culture panel - Unspecified specimen | Mycobacterial stain & culture panel | - | Pt | XXX | - | Mycobacterial stain + cx Pnl XXX | ||
| 2020-03-09 | 94512-1 | Staphylococcus aureus and Methicillin Resistant Staphylococcus aureus identified in Isolate or Specimen by NAA with probe detection | Staphylococcus aureus & Staphylococcus aureus.methicillin resistant identified | Prid | Pt | Isolate/Specimen | Nom | Probe.amp.tar | SA + MRSA Islt/Spm NAA+probe | |
| 2020-03-09 | 94515-4 | Anesthesiology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Anesthesiology | Anesthesiology Discharge sum | |
| 2020-03-09 | 94516-2 | Audiology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Audiology | Audiology Discharge sum | |
| 2020-03-09 | 94517-0 | Clinical cardiac electrophysiology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Clinical cardiac electrophysiology | Electrophysiology Discharge sum | |
| 2020-03-09 | 94518-8 | Clinical cardiac electrophysiology Progress note | Progress note | Find | Pt | {Setting} | Doc | Clinical cardiac electrophysiology | Electrophysiology Progress note | |
| 2020-03-09 | 94519-6 | Dermatology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Dermatology | Dermatology Discharge sum | |
| 2020-03-09 | 94520-4 | Gastroenterology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Gastroenterology | Gastroenterology Discharge sum | |
| 2020-03-09 | 94521-2 | Endocrinology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Endocrinology | Endocrinology Discharge sum | |
| 2020-03-09 | 94522-0 | Immunology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Immunology | Immunology Discharge sum | |
| 2020-03-09 | 94523-8 | Orthotics prosthetics Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Orthotics prosthetics | Orthotics prosthetics Discharge sum | |
| 2020-03-09 | 94524-6 | Interventional radiology Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Interventional radiology | IR Discharge sum | |
| 2020-03-09 | 94525-3 | Infectious disease Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Infectious disease | Infectious disease Discharge sum | |
| 2020-03-09 | 94526-1 | Pulmonary Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Pulmonary disease | Pulmonary disease Discharge sum | |
| 2020-03-09 | 94527-9 | Trauma Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Trauma | Trauma Discharge sum | |
| 2020-03-09 | 94528-7 | Thromboembolism Consult note | Consultation note | Find | Pt | {Setting} | Doc | Thromboembolism | Thromboemb Consult note | |
| 2020-03-09 | 94529-5 | Wound, Ostomy, and Continence Care Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Wound, ostomy, and continence care | WOC Discharge sum | |
| 2020-03-09 | 94530-3 | Thromboembolism Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Thromboembolism | Thromboemb Discharge sum | |
| 2020-03-08 | 94487-6 | Galactosylceramidase [Enzymatic activity/mass] in Leukocytes by Confirmatory method | Galactosylceramidase | CCnt | Pt | WBC | Qn | Confirm | GALC WBC Cfm-cCnt | |
| 2020-03-08 | 94488-4 | Acid alpha glucosidase [Enzymatic activity/mass] in Leukocytes by Confirmatory method | Acid alpha glucosidase | CCnt | Pt | WBC | Qn | Confirm | Acid A-Glucosidase WBC Cfm-cCnt | |
| 2020-03-08 | 94489-2 | Lysosomal storage disorders panel - Leukocytes | Lysosomal storage disorders panel | - | Pt | WBC | Qn | LSD pnl WBC | ||
| 2020-03-08 | 94490-0 | Protoporphyrin fractions panel - Red Blood Cells | Protoporphyrin fractions panel | - | Pt | RBC | Qn | Protoporphyrin fract Pnl RBC | ||
| 2020-03-08 | 94491-8 | Protoporphyrin Free [Mass/volume] in Red Blood Cells | Protoporphyrin.free | MCnc | Pt | RBC | Qn | FEP RBC-mCnc | ||
| 2020-03-08 | 94492-6 | HLA-DQA1 and HLA-DQB1 typing panel - Blood or Tissue by Molecular genetics method | HLA-DQA1 & HLA-DQB1 typing panel | - | Pt | Bld/Tiss | - | Molgen | HLA-DQA1 + HLA-DQB1 typing Pnl Bld/T | |
| 2020-03-08 | 94493-4 | Celiac disease IgA and HLA typing and serology panel - Blood or Tissue | Celiac disease IgA & HLA typing & serology panel | - | Pt | Bld/Tiss | - | Celiac IgA + HLA + Sero Bld/T | ||
| 2020-03-08 | 94495-9 | HLA-DQA1 [Type] | HLA-DQA1 | Type | Pt | Bld/Tiss | Nom | HLA-DQA1 | ||
| 2020-03-08 | 94494-2 | Celiac disease serology panel - Serum | Celiac disease serology panel | - | Pt | Ser | - | Celiac disease serology panel Ser | ||
| 2020-03-08 | 94496-7 | Cell suspension [Volume] of Specimen | Cell suspension | Vol | Pt | Specimen | Qn | Cell susp Vol Spec | ||
| 2020-03-08 | 94497-5 | Packed erythrocytes [Volume] of Specimen | Packed erythrocytes | Vol | Pt | Specimen | Qn | Packed RBC Vol Spec | ||
| 2020-03-05 | 94470-2 | VEGFA gene targeted mutation analysis in Blood or Tissue by Molecular genetics method | VEGFA gene targeted mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | VEGFA Mut Anl Bld/T | |
| 2020-03-05 | 94471-0 | VEGFA gene c.-1154A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal | VEGFA gene.c.-1154A>G | Geno | Pt | Bld/Tiss | Nom | Molgen | VEGFA c.-1154A>G Geno Bld/T | |
| 2020-03-05 | 94472-8 | VEGFA gene c.-1498C>G and c.-1498C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal | VEGFA gene.c.-1498C>G & c.-1498C>T | Geno | Pt | Bld/Tiss | Nom | Molgen | VEGFA c.-1498C>G + C>T Geno Bld/T | |
| 2020-03-05 | 94473-6 | VEGFA gene c.-2578A>C and c.-2578A>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal | VEGFA gene.c.-2578A>C & c.-2578A>T | Geno | Pt | Bld/Tiss | Nom | Molgen | VEGFA c.-2578A>C + A>T Geno Bld/T | |
| 2020-03-05 | 94474-4 | VEGFA gene c.-634C>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal | VEGFA gene.c.-634C>G | Geno | Pt | Bld/Tiss | Nom | Molgen | VEGFA c.-634C>G Geno Bld/T | |
| 2020-03-05 | 94475-1 | Borrelia burgdorferi IgA and IgG and IgM [Interpretation] in Cerebral spinal fluid | Borrelia burgdorferi Ab.IgA & IgG & IgM | Imp | Pt | CSF | Nom | B burgdor IgA+IgG+IgM CSF-Imp | ||
| 2020-03-05 | 94476-9 | Borrelia burgdorferi G39/40 IgG bands [#] in Blood by Immunoblot | Borrelia burgdorferi G39_40 Ab.IgG bands | Num | Pt | Bld | Qn | IB | B burgdor G39/40 IgG bands Bld IB | |
| 2020-03-05 | 94477-7 | Borrelia burgdorferi 49736 IgG bands [#] in Blood by Immunoblot | Borrelia burgdorferi 49736 Ab.IgG bands | Num | Pt | Bld | Qn | IB | B burgdor 49736 IgG bands Bld IB | |
| 2020-03-05 | 94478-5 | Bordetella pertussis.pertussis toxin promoter region [Presence] in Lower respiratory specimen by NAA with non-probe detection | Bordetella pertussis.pertussis toxin promoter region | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | B pert.PT prom reg Lower Resp Ql NAA+non | |
| 2020-03-05 | 94479-3 | Human coronavirus 229E RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Human coronavirus 229E RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HCoV 229E RNA Lower Resp Ql NAA+non-prob | |
| 2020-03-05 | 94480-1 | Human coronavirus HKU1 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Human coronavirus HKU1 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HCoV HKU1 RNA Lower Resp Ql NAA+non-prob | |
| 2020-03-05 | 94481-9 | Human coronavirus NL63 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Human coronavirus NL63 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HCoV NL63 RNA Lower Resp Ql NAA+non-prob | |
| 2020-03-05 | 94482-7 | Human coronavirus OC43 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Human coronavirus OC43 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HCoV OC43 RNA Lower Resp Ql NAA+non-prob | |
| 2020-03-05 | 94483-5 | Parainfluenza virus 1 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Parainfluenza virus 1 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HPIV1 RNA Lower Resp Ql NAA+non-probe | |
| 2020-03-05 | 94486-8 | Parainfluenza virus 4 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Parainfluenza virus 4 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HPIV4 RNA Lower Resp Ql NAA+non-probe | |
| 2020-03-05 | 94484-3 | Parainfluenza virus 2 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Parainfluenza virus 2 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HPIV2 RNA Lower Resp Ql NAA+non-probe | |
| 2020-03-05 | 94485-0 | Parainfluenza virus 3 RNA [Presence] in Lower respiratory specimen by NAA with non-probe detection | Parainfluenza virus 3 RNA | PrThr | Pt | Respiratory.lower | Ord | Non-probe.amp.tar | HPIV3 RNA Lower Resp Ql NAA+non-probe | |
| 2020-03-04 | 94469-4 | F2 gene.c.20210G>A and c.1691G>A panel - Blood or Tissue by Molecular genetics method | F2 gene.c.20210G>A & F5 gene.c.1691G>A panel | - | Pt | Bld/Tiss | - | Molgen | F2 20210G>A + F5 1691G>A Pnl Bld/T | |
| 2020-03-02 | 94460-3 | Healthcare navigator Conference note | Conference note | Find | Pt | {Setting} | Doc | Healthcare navigator | Navigator Conf eval note | |
| 2020-03-02 | 94461-1 | Solid Organ Transplant Consult note | Consultation note | Find | Pt | {Setting} | Doc | Solid organ transplant | Solid Org Transplant Consult note | |
| 2020-03-02 | 94462-9 | Cardiology Intensive care unit Consult note | Consultation note | Find | Pt | Intensive care unit | Doc | Cardiovascular disease | Cardiology ICU Consult note | |
| 2020-03-02 | 94463-7 | Bone Marrow Transplant Consult note | Consultation note | Find | Pt | {Setting} | Doc | Bone marrow transplant | BM Transplant Consult note | |
| 2020-03-02 | 94464-5 | Solid Organ Transplant Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Solid organ transplant | Solid Org Transplant Discharge sum | |
| 2020-03-02 | 94465-2 | Bone Marrow Transplant Discharge summary | Discharge summary note | Find | Pt | {Setting} | Doc | Bone marrow transplant | BM Transplant Discharge sum | |
| 2020-03-02 | 94466-0 | Solid Organ Transplant Progress note | Progress note | Find | Pt | {Setting} | Doc | Solid organ transplant | Solid Org Transplant Progress note | |
| 2020-03-02 | 94467-8 | Cardiology Intensive care unit Progress note | Progress note | Find | Pt | Intensive care unit | Doc | Cardiovascular disease | Cardiology ICU Progress note | |
| 2020-03-02 | 94468-6 | Bone Marrow Transplant Progress note | Progress note | Find | Pt | {Setting} | Doc | Bone marrow transplant | BM Transplant Progress note | |
| 2020-02-25 | 94459-5 | Date treatment prescribed | Date treatment prescribed | Date | Pt | ^Patient | Qn | Date treatment prescribed | ||
| 2020-02-24 | 94454-6 | Arsenite [Mass/volume] in Urine | Arsenite | MCnc | Pt | Urine | Qn | Arsenite Ur-mCnc | ||
| 2020-02-24 | 94455-3 | Arsenobetaine [Mass/volume] in Urine | Arsenobetaine | MCnc | Pt | Urine | Qn | Arsenobetaine Ur-mCnc | ||
| 2020-02-24 | 94456-1 | Arsenocholine [Mass/volume] in Urine | Arsenocholine | MCnc | Pt | Urine | Qn | Arsenocholine Ur-mCnc | ||
| 2020-02-24 | 94457-9 | Dimethylarsinate [Mass/volume] in Urine | Dimethylarsinate | MCnc | Pt | Urine | Qn | Dimethylarsinate Ur-mCnc | ||
| 2020-02-24 | 94458-7 | Monomethylarsonate [Mass/volume] in Urine | Monomethylarsonate | MCnc | Pt | Urine | Qn | MMA Ur-mCnc | ||
| 2020-02-22 | 94451-2 | PhenX - Use of Creatine Growth Hormone and Steroids Protocol 230801 | PhenX - Use of creatine growth hormone and steroids protocol 230801 | - | Pt | ^Patient | - | PhenX | PhenX - Creatine GH+steroids use proto | |
| 2020-02-21 | 94428-0 | HLA class I and II IgG panel - Serum or Plasma by Flow cytometry (FC) | HLA class I & II Ab.IgG panel | - | Pt | Ser/Plas | - | Flow cytometry | HLA class I + II IgG Pnl SerPl FC | |
| 2020-02-21 | 94429-8 | HLA-DP and DQ and DR (class II) IgG low risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG low risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class II Ab.IgG low risk SerPl FC | |
| 2020-02-21 | 94430-6 | HLA-A and B and C (class I) IgG low risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG low risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class I Ab.IgG low risk SerPl FC | |
| 2020-02-21 | 94432-2 | HLA-DP and DQ and DR (class II) IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DP+DQ+DR (class II) IgG SerPl FC | |
| 2020-02-21 | 94431-4 | Dilution factor [Titer] in Serum or Plasma | Dilution factor | Titr | Pt | Ser/Plas | Qn | Dilution factor Titr SerPl | ||
| 2020-02-21 | 94434-8 | HLA-DPB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DPB1 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DPB1 IgG SerPl FC | |
| 2020-02-21 | 94433-0 | HLA-DP and DQ and DR (class II) IgG with prozone effect [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG with prozone effect | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA classII Ab.IgG prozone SerPl FC | |
| 2020-02-21 | 94437-1 | HLA-DQA1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DQA1 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DQA1 IgG SerPl FC | |
| 2020-02-21 | 94436-3 | HLA-DQB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DQB1 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DQB1 IgG SerPl FC | |
| 2020-02-21 | 94435-5 | HLA-DPA1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DPA1 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DPA1 IgG SerPl FC | |
| 2020-02-21 | 94438-9 | HLA-DRB3 and HLA-DRB4 and HLA DRB5 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DRB3 & HLA-DRB4 & HLA DRB5 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DRB3 + 4 + 5 IgG SerPl FC | |
| 2020-02-21 | 94439-7 | HLA-DRB1 IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DRB1 Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-DRB1 IgG SerPl FC | |
| 2020-02-21 | 94440-5 | HLA-DP and DQ and DR (class II) IgG panel - Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG panel | - | Pt | Ser/Plas | - | Flow cytometry | HLA-DP + DQ + DR (class II) IgG Pnl SerP | |
| 2020-02-21 | 94441-3 | HLA-A and B and C (class I) IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-A+B+C (class I) IgG SerPl FC | |
| 2020-02-21 | 94442-1 | HLA-A and B and C (class I) IgG with prozone effect [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG with prozone effect | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class I Ab.IgG prozone SerPl FC | |
| 2020-02-21 | 94443-9 | HLA-C IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-C Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-C IgG SerPl FC | |
| 2020-02-21 | 94444-7 | HLA-B IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-B Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-B IgG SerPl FC | |
| 2020-02-21 | 94445-4 | HLA-A IgG Ab [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A Ab.IgG | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA-A IgG SerPl FC | |
| 2020-02-21 | 94446-2 | HLA-A and B and C (class I) IgG panel - Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG panel | - | Pt | Ser/Plas | - | Flow cytometry | HLA-A + B + C (class I) IgG Pnl SerPl FC | |
| 2020-02-21 | 94447-0 | HLA-DP and DQ and DR (class II) IgG high risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG high risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class II Ab.IgG high risk SerPl FC | |
| 2020-02-21 | 94448-8 | HLA-DP and DQ and DR (class II) IgG intermediate risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-DP & DQ & DR (class II) Ab.IgG intermediate risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class II Ab.IgG med risk SerPl FC | |
| 2020-02-21 | 94449-6 | HLA-A and B and C (class I) IgG high risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG high risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class I Ab.IgG high risk SerPl FC | |
| 2020-02-21 | 94450-4 | HLA-A and B and C (class I) IgG intermediate risk [Identifier] in Serum or Plasma by Flow cytometry (FC) | HLA-A & B & C (class I) Ab.IgG intermediate risk | Prid | Pt | Ser/Plas | Nom | Flow cytometry | HLA class I Ab.IgG med risk SerPl FC | |
| 2020-02-20 | 94426-4 | Dengue virus 1+2+3+4 3' UTR RNA [Presence] in Cerebral spinal fluid by NAA with probe detection | Dengue virus 1+2+3+4 3' UTR RNA | PrThr | Pt | CSF | Ord | Probe.amp.tar | DENV 1+2+3+4 3' UTR RNA CSF Ql NAA+probe | |
| 2020-02-20 | 94427-2 | Dengue virus 1+2+3+4 3' UTR RNA [Presence] in Serum by NAA with probe detection | Dengue virus 1+2+3+4 3' UTR RNA | PrThr | Pt | Ser | Ord | Probe.amp.tar | DENV 1+2+3+4 3' UTR RNA Ser Ql NAA+probe | |
| 2020-02-19 | 94332-4 | Microsporidia sp 18S rRNA gene panel - Unspecified specimen by NAA with non-probe detection | Microsporidia sp 18S rRNA gene panel | - | Pt | XXX | - | Non-probe.amp.tar | Microsporidia 18S rRNA Pnl NAA+non-prb | |
| 2020-02-19 | 94333-2 | Encephalitozoon sp 18S rRNA gene [Presence] in Unspecified specimen by NAA with non-probe detection | Encephalitozoon sp 18S rRNA gene | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | Encephalitozoon 18S rRNA XXX Ql NAA+prb | |
| 2020-02-19 | 94334-0 | Enterocytozoon bieneusi 18S rRNA gene [Presence] in Unspecified specimen by NAA with non-probe detection | Enterocytozoon bieneusi 18S rRNA gene | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | E bieneusi 18S rRNA XXX Ql NAA+non-probe | |
| 2020-02-19 | 94335-7 | Desmoglein 1 and Desmoglein 3 IgG panel - Serum by Immunoassay | Desmoglein 1 & Desmoglein 3 Ab.IgG panel | - | Pt | Ser | Qn | IA | Desmoglein 1+3 IgG Pnl Ser IA | |
| 2020-02-19 | 94336-5 | Desmoglein 1 IgG Ab [Units/volume] in Serum by Immunoassay | Desmoglein 1 Ab.IgG | ACnc | Pt | Ser | Qn | IA | Desmoglein 1 IgG Ser IA-aCnc | |
| 2020-02-19 | 94337-3 | Desmoglein 3 IgG Ab [Units/volume] in Serum by Immunoassay | Desmoglein 3 Ab.IgG | ACnc | Pt | Ser | Qn | IA | Desmoglein 3 IgG Ser IA-aCnc | |
| 2020-02-19 | 94338-1 | Chromosome 13+15+16+18+21+22+X+Y aneuploidy in Products of Conception by FISH | Chromosome 13+15+16+18+21+22+X+Y aneuploidy | Find | Pt | POC | Doc | FISH | Chr 13+15+16+18+21+22+X+Y aneup POC FISH | |
| 2020-02-19 | 94339-9 | Autoimmune myelopathy evaluation panel - Serum | Autoimmune myelopathy evaluation panel | - | Pt | Ser | - | Autoimmune myelopathy eval pnl Ser | ||
| 2020-02-19 | 94340-7 | Amphiphysin IgG Ab [Titer] in Serum by Immunofluorescence | Amphiphysin Ab.IgG | Titr | Pt | Ser | Qn | IF | Amphiphysin IgG Titr Ser IF | |
| 2020-02-19 | 94341-5 | Glial nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence | Glial nuclear type 1 Ab.IgG | Titr | Pt | Ser | Qn | IF | Glial nuc type 1 IgG Titr Ser IF | |
| 2020-02-19 | 94342-3 | Neuronal nuclear type 1 IgG Ab [Titer] in Serum by Immunofluorescence | Neuronal nuclear type 1 Ab.IgG | Titr | Pt | Ser | Qn | IF | Hu1 IgG Titr Ser IF | |
| 2020-02-19 | 94343-1 | Neuronal nuclear type 2 IgG Ab [Titer] in Serum by Immunofluorescence | Neuronal nuclear type 2 Ab.IgG | Titr | Pt | Ser | Qn | IF | Hu2 IgG Titr Ser IF | |
| 2020-02-19 | 94344-9 | Neuronal nuclear type 3 IgG Ab [Titer] in Serum by Immunofluorescence | Neuronal nuclear type 3 Ab.IgG | Titr | Pt | Ser | Qn | IF | Hu3 IgG Titr Ser IF | |
| 2020-02-19 | 94346-4 | Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Serum by Immunofluorescence | Glial fibrillary acidic protein.alpha subunit Ab.IgG | PrThr | Pt | Ser | Ord | IF | GFAP alpha IgG Ser Ql IF | |
| 2020-02-19 | 94345-6 | Glutamate decarboxylase 65 IgG+IgM Ab [Moles/volume] in Serum by Immunoassay | Glutamate decarboxylase 65 Ab.IgG+IgM | SCnc | Pt | Ser | Qn | IA | GAD65 IgG+IgM Ser IA-sCnc | |
| 2020-02-19 | 94347-2 | Metabotropic glutamate receptor 1 IgG Ab [Presence] in Serum by Immunofluorescence | Metabotropic glutamate receptor 1 Ab.IgG | PrThr | Pt | Ser | Ord | IF | mGluR1 IgG Ser Ql IF | |
| 2020-02-19 | 94348-0 | Voltage-gated calcium channel N type binding IgG+IgM Ab [Moles/volume] in Serum by Immunoassay | Voltage-gated calcium channel N type binding Ab.IgG+IgM | SCnc | Pt | Ser | Qn | IA | VGCC-N Bind IgG+IgM Ser IA-sCnc | |
| 2020-02-19 | 94349-8 | Voltage-gated calcium channel P/Q type binding IgG+IgM Ab [Moles/volume] in Serum by Immunoassay | Voltage-gated calcium channel PQ type binding Ab.IgG+IgM | SCnc | Pt | Ser | Qn | IA | VGCC-P/Q Bind IgG+IgM Ser IA-sCnc | |
| 2020-02-19 | 94352-2 | PCA-Tr IgG Ab [Titer] in Serum by Immunofluorescence | Purkinje cell cytoplasmic type Tr Ab.IgG | Titr | Pt | Ser | Qn | IF | PCA-Tr IgG Titr Ser IF | |
| 2020-02-19 | 94350-6 | PCA-1 IgG Ab [Titer] in Serum by Immunofluorescence | Purkinje cell cytoplasmic type 1 Ab.IgG | Titr | Pt | Ser | Qn | IF | PCA-1 IgG Titr Ser IF | |
| 2020-02-19 | 94351-4 | PCA-2 IgG Ab [Titer] in Serum by Immunofluorescence | Purkinje cell cytoplasmic type 2 Ab.IgG | Titr | Pt | Ser | Qn | IF | PCA-2 IgG Titr Ser IF | |
| 2020-02-19 | 94353-0 | Autoimmune myelopathy evaluation panel - Cerebral spinal fluid | Autoimmune myelopathy evaluation panel | - | Pt | CSF | - | Autoimmune myelopathy eval pnl CSF | ||
| 2020-02-19 | 94354-8 | Amphiphysin IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Amphiphysin Ab.IgG | Titr | Pt | CSF | Qn | IF | Amphiphysin IgG Titr CSF IF | |
| 2020-02-19 | 94355-5 | Glial nuclear type 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Glial nuclear type 1 Ab.IgG | Titr | Pt | CSF | Qn | IF | Glial nuc type 1 IgG Titr CSF IF | |
| 2020-02-19 | 94356-3 | Neuronal nuclear type 1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Neuronal nuclear type 1 Ab.IgG | Titr | Pt | CSF | Qn | IF | Hu1 IgG Titr CSF IF | |
| 2020-02-19 | 94357-1 | Neuronal nuclear type 2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Neuronal nuclear type 2 Ab.IgG | Titr | Pt | CSF | Qn | IF | Hu2 IgG Titr CSF IF | |
| 2020-02-19 | 94360-5 | Glial fibrillary acidic protein alpha subunit IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence | Glial fibrillary acidic protein.alpha subunit Ab.IgG | PrThr | Pt | CSF | Ord | IF | GFAP alpha IgG CSF Ql IF | |
| 2020-02-19 | 94358-9 | Neuronal nuclear type 3 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Neuronal nuclear type 3 Ab.IgG | Titr | Pt | CSF | Qn | IF | Hu3 IgG Titr CSF IF | |
| 2020-02-19 | 94359-7 | Glutamate decarboxylase 65 IgG+IgM Ab [Moles/volume] in Cerebral spinal fluid by Immunoassay | Glutamate decarboxylase 65 Ab.IgG+IgM | SCnc | Pt | CSF | Qn | IA | GAD65 IgG+IgM CSF IA-sCnc | |
| 2020-02-19 | 94363-9 | PCA-1 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Purkinje cell cytoplasmic type 1 Ab.IgG | Titr | Pt | CSF | Qn | IF | PCA-1 IgG Titr CSF IF | |
| 2020-02-19 | 94362-1 | PCA-Tr IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Purkinje cell cytoplasmic type Tr Ab.IgG | Titr | Pt | CSF | Qn | IF | PCA-Tr IgG Titr CSF IF | |
| 2020-02-19 | 94361-3 | Metabotropic glutamate receptor 1 IgG Ab [Presence] in Cerebral spinal fluid by Immunofluorescence | Metabotropic glutamate receptor 1 Ab.IgG | PrThr | Pt | CSF | Ord | IF | mGluR1 IgG CSF Ql IF | |
| 2020-02-19 | 94364-7 | PCA-2 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Purkinje cell cytoplasmic type 2 Ab.IgG | Titr | Pt | CSF | Qn | IF | PCA-2 IgG Titr CSF IF | |
| 2020-02-19 | 94365-4 | Bordetella pertussis DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Bordetella pertussis DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | B pert DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94366-2 | Streptococcus pyogenes DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Streptococcus pyogenes DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | S pyo DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94369-6 | Staphylococcus aureus DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Staphylococcus aureus DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | S aureus DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94367-0 | Streptococcus pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Streptococcus pneumoniae DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | S pneum DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94368-8 | Streptococcus agalactiae DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Streptococcus agalactiae DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | Gp B Strep DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94372-0 | Proteus sp DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Proteus sp DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | Proteus sp DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94370-4 | Serratia marcescens DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Serratia marcescens DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | S marcescens DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94371-2 | Pseudomonas aeruginosa DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Pseudomonas aeruginosa DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | P aeruginosa DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94373-8 | Moraxella catarrhalis DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Moraxella catarrhalis DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | M catarrhalis DNA Lower Resp Ql NAA+prb | |
| 2020-02-19 | 94374-6 | Klebsiella pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Klebsiella pneumoniae DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | K pneumon DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94375-3 | Klebsiella oxytoca DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Klebsiella oxytoca DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | K oxytoca DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94378-7 | Escherichia coli DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Escherichia coli DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | E coli DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94377-9 | Haemophilus influenzae DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Haemophilus influenzae DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | Haem influ DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94376-1 | Klebsiella aerogenes DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Klebsiella aerogenes DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | K. aerogenes DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94380-3 | Acinetobacter baumannii DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Acinetobacter baumannii DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | A baumannii DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94379-5 | Enterobacter cloacae complex DNA [Presence] in Lower respiratory specimen by NAA with probe detection | Enterobacter cloacae complex DNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | E cloac comp DNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94381-1 | 2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine [Mass Ratio] in 24 hour Urine | 2,3-dinor 11 beta-Prostaglandin F2 alpha/Creatinine | MRto | 24H | Urine | Qn | 2,3-dinor 11B-PG F2a/Creat 24h Ur | ||
| 2020-02-19 | 94382-9 | Glial nuclear type 1 IgG Ab [Presence] in Serum by Line blot | Glial nuclear type 1 Ab.IgG | PrThr | Pt | Ser | Ord | Line blot | Glial nuc type 1 IgG Ser Ql Line blot | |
| 2020-02-19 | 94383-7 | Glial nuclear type 1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Glial nuclear type 1 Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | Glial nuc type 1 IgG CSF Ql Line blot | |
| 2020-02-19 | 94385-2 | Amphiphysin IgG Ab [Presence] in Serum by Line blot | Amphiphysin Ab.IgG | PrThr | Pt | Ser | Ord | Line blot | Amphiphysin IgG Ser Ql Line blot | |
| 2020-02-19 | 94386-0 | PCA-Tr IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Purkinje cell cytoplasmic type Tr Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | PCA-Tr IgG CSF Ql Line blot | |
| 2020-02-19 | 94384-5 | Amphiphysin IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Amphiphysin Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | Amphiphysin IgG CSF Ql Line blot | |
| 2020-02-19 | 94388-6 | Neuronal nuclear type 2 IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Neuronal nuclear type 2 Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | Hu2 IgG CSF Ql Line blot | |
| 2020-02-19 | 94389-4 | Neuronal nuclear type 1 IgG Ab [Presence] in Serum by Line blot | Neuronal nuclear type 1 Ab.IgG | PrThr | Pt | Ser | Ord | Line blot | Hu1 IgG Ser Ql Line blot | |
| 2020-02-19 | 94387-8 | Neuronal nuclear type 2 IgG Ab [Presence] in Serum by Line blot | Neuronal nuclear type 2 Ab.IgG | PrThr | Pt | Ser | Ord | Line blot | Hu2 IgG Ser Ql Line blot | |
| 2020-02-19 | 94390-2 | Neuronal nuclear type 1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Neuronal nuclear type 1 Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | Hu1 IgG CSF Ql Line blot | |
| 2020-02-19 | 94391-0 | Respiratory viral pathogens DNA and RNA panel - Lower respiratory specimen by NAA with probe detection | Respiratory viral pathogens DNA & RNA panel | - | Pt | Respiratory.lower | - | Probe.amp.tar | Resp viral DNA+RNA Pnl Low Resp NAA+prb | |
| 2020-02-19 | 94394-4 | Influenza virus A H3 RNA [Presence] in Lower respiratory specimen by NAA with probe detection | Influenza virus A H3 RNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | FLUAV H3 RNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94392-8 | Bordetella pertussis+parapertussis+bronchiseptica gidA gene [Presence] in Lower respiratory specimen by NAA with probe detection | Bordetella pertussis+parapertussis+bronchiseptica gidA gene | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | B per+par+bron gidA Lo Resp Ql NAA+probe | |
| 2020-02-19 | 94393-6 | Respiratory pathogens DNA and RNA panel - Lower respiratory specimen by NAA with probe detection | Respiratory pathogens DNA & RNA panel | - | Pt | Respiratory.lower | - | Probe.amp.tar | Resp path DNA+RNA Pnl Lower Resp NAA+prb | |
| 2020-02-19 | 94396-9 | Influenza virus A H1 RNA [Presence] in Lower respiratory specimen by NAA with probe detection | Influenza virus A H1 RNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | FLUAV H1 RNA Lower Resp Ql NAA+probe | |
| 2020-02-19 | 94395-1 | Influenza virus A H1 2009 pandemic RNA [Presence] in Lower respiratory specimen by NAA with probe detection | Influenza virus A H1 2009 pandemic RNA | PrThr | Pt | Respiratory.lower | Ord | Probe.amp.tar | FLUAV H1 09 pan RNA Lo Rsp Ql NAA+probe | |
| 2020-02-19 | 94397-7 | Sulfocysteine, Hypoxanthine, Xanthine, Urate and Creatinine panel - Urine | Sulfocysteine, Hypoxanthine, Xanthine, Urate & Creatinine panel | - | Pt | Urine | Qn | SSC HypoXan Xan Urate Pnl Ur | ||
| 2020-02-19 | 94398-5 | Ethyl sulfate [Mass/mass] in Meconium by Confirmatory method | Ethyl sulfate | MCnt | Pt | Meconium | Qn | Confirm | Ethyl sulfate Mec Cfm-mCnt | |
| 2020-02-19 | 94399-3 | Ethyl glucuronide [Mass/mass] in Meconium by Confirmatory method | Ethyl glucuronide | MCnt | Pt | Meconium | Qn | Confirm | Ethyl glucuronide Mec Cfm-mCnt | |
| 2020-02-19 | 94400-9 | Protein.monoclonal [Presence] in Serum or Plasma | Protein.monoclonal | PrThr | Pt | Ser/Plas | Ord | M Protein SerPl Ql | ||
| 2020-02-19 | 94401-7 | ADRA2A gene c.-1252G>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal | ADRA2A gene.c.-1252G>C | Geno | Pt | Bld/Tiss | Nom | Molgen | ADRA2A c.-1252G>C Geno Bld/T | |
| 2020-02-19 | 94402-5 | ANKK1 gene c.2137G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal | ANKK1 gene.c.2137G>A | Geno | Pt | Bld/Tiss | Nom | Molgen | ANKK1 c.2137G>A Geno Bld/T | |
| 2020-02-19 | 94403-3 | CHRNA3 gene c.645C>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal | CHRNA3 gene.c.645C>T | Geno | Pt | Bld/Tiss | Nom | Molgen | CHRNA3 c.645C>T Geno Bld/T | |
| 2020-02-19 | 94411-6 | DRD2 gene c.-585A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal | DRD2 gene.c.-585A>G | Geno | Pt | Bld/Tiss | Nom | Molgen | DRD2 c.-585A>G Geno Bld/T | |
| 2020-02-19 | 94412-4 | EPHX1 gene.c.416A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal | EPHX1 gene.c.416A>G | Geno | Pt | Bld/Tiss | Nom | Molgen | EPHX1 c.416A>G Geno Bld/T | |
| 2020-02-19 | 94413-2 | GRIK4 gene c.83-10039T>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal | GRIK4 gene.c.83-10039T>C | Geno | Pt | Bld/Tiss | Nom | Molgen | GRIK4 c.83-10039T>C Geno Bld/T | |
| 2020-02-19 | 94414-0 | MTHFR gene c.677C>T and c.1298A>C [Genotype] in Blood or Tissue by Molecular genetics method Nominal | MTHFR gene.c.677C>T & c.1298A>C | Geno | Pt | Bld/Tiss | Nom | Molgen | MTHFR c.677C>T + 1298A>C Geno Bld/T | |
| 2020-02-19 | 94415-7 | OPRM1 gene c.118A>G [Genotype] in Blood or Tissue by Molecular genetics method Nominal | OPRM1 gene.c.118A>G | Geno | Pt | Bld/Tiss | Nom | Molgen | OPRM1 c.118A>G Geno Bld/T | |
| 2020-02-19 | 94416-5 | SCN1A gene.c.603-91G>A [Genotype] in Blood or Tissue by Molecular genetics method Nominal | SCN1A gene.c.603-91G>A | Geno | Pt | Bld/Tiss | Nom | Molgen | SCN1A c.603-91G>A Geno Bld/T | |
| 2020-02-19 | 94417-3 | SLC6A4 gene 5-HTTLPR variant [Genotype] in Blood or Tissue by Molecular genetics method Nominal | SLC6A4 gene 5-HTTLPR variant | Geno | Pt | Bld/Tiss | Nom | Molgen | SLC6A4 5-HTTLPR Geno Bld/T | |
| 2020-02-19 | 94418-1 | UGT2B15 gene c.253G>T [Genotype] in Blood or Tissue by Molecular genetics method Nominal | UGT2B15 gene.c.253G>T | Geno | Pt | Bld/Tiss | Nom | Molgen | UGT2B15 c.253G>T Geno Bld/T | |
| 2020-02-19 | 94419-9 | Candida auris [Presence] in Isolate by MS.MALDI-TOF | Candida auris | PrThr | Pt | Isolate | Ord | MS.MALDI-TOF | C auris Islt Ql MS.MALDI-TOF | |
| 2020-02-19 | 94420-7 | Lactobacillus crispatus+gasseri+jensenii + Gardnerella vaginalis + Atopobium vaginae rRNA [Presence] in Vaginal fluid by NAA with probe detection | Lactobacillus crispatus+gasseri+jensenii+Gardnerella vaginalis+Atopobium vaginae rRNA | PrThr | Pt | Vag | Ord | Probe.amp.tar | BV bacteria rRNA Vag Ql NAA+probe | |
| 2020-02-19 | 94421-5 | Candida glabrata RNA [Presence] in Vaginal fluid by NAA with probe detection | Candida glabrata RNA | PrThr | Pt | Vag | Ord | Probe.amp.tar | C glabrata RNA Vag Ql NAA+probe | |
| 2020-02-19 | 94422-3 | Candida albicans, C. dubliniensis, C. parapsilosis, and C. tropicalis RNA [Presence] in Vaginal fluid by NAA with probe detection | Candida albicans+dubliniensis+parapsilosis+tropicalis RNA | PrThr | Pt | Vag | Ord | Probe.amp.tar | Candida sp group RNA Vag Ql NAA+probe | |
| 2020-02-19 | 94423-1 | Lysosomal enzymes screen [Interpretation] in Urine Narrative | Lysosomal enzymes screen | Imp | Pt | Urine | Nar | Lysosomal Enzymes Scn Ur-Imp | ||
| 2020-02-19 | 94424-9 | Staphylococcus aureus methicillin resistance SCCmec+orfX junction [Presence] by Molecular method | Staphylococcus aureus methicillin resistance SCCmec+orfX junction | PrThr | Pt | Isolate/Specimen | Ord | Molgen | MRSA SCCmec+orfX Islt/Spm Ql | |
| 2020-02-19 | 94425-6 | Human papilloma virus E6+E7 mRNA [Presence] in Unspecified specimen by NAA with probe detection | Human papilloma virus 16+18+31+33+35+39+45+51+52+56+58+59+66+68 E6+E7 mRNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | HPV E6+E7 mRNA XXX Ql NAA+probe | |
| 2020-02-17 | 94330-8 | Specimen Processing comment | Processing comment | Find | Pt | Specimen | Nom | Specimen Processing comment | ||
| 2020-02-17 | 94331-6 | Specimen Collection procedure comment | Collection procedure comment | Find | Pt | Specimen | Nom | Spec Collect proc comment | ||
| 2020-02-11 | 94328-2 | Patient Health Questionnaire 8 item (PHQ-8) total score [Reported] | Patient health questionnaire 8 item total score | Score | Pt | ^Patient | Qn | Reported.PHQ | ||
| 2020-02-11 | 94329-0 | Patient Health Questionnaire 8 item (PHQ-8) [Reported] | Patient Health Questionnaire 8 item | - | Pt | ^Patient | - | Reported.PHQ | ||
| 2020-02-09 | 94327-4 | PhenX - human papillomavirus vaccine use protocol 100802 | PhenX - human papillomavirus vaccine use protocol 100802 | - | Pt | ^Patient | - | PhenX | PhenX - HPV vaccine use protocol | |
| 2020-02-06 | 94318-3 | Medical Aid in Dying Plan of care note | Plan of care note | Find | Pt | {Setting} | Doc | Medical aid in dying | MAiD Plan of care note | |
| 2020-02-06 | 94319-1 | Medical Aid in Dying Consult note | Consultation note | Find | Pt | {Setting} | Doc | Medical aid in dying | MAiD Consult note | |
| 2020-02-06 | 94320-9 | Medical Aid in Dying procedure note | Procedure note | Find | Pt | {Setting} | Doc | Medical aid in dying | MAiD Procedure note | |
| 2020-02-06 | 94321-7 | Medical Aid in Dying Team Note | Note | Find | Pt | {Setting} | Doc | Medical aid in dying.team | MAiD Team Note | |
| 2020-02-06 | 94322-5 | Medical Aid in Dying Telephone encounter Note | Note | Find | Pt | Telephone encounter | Doc | Medical aid in dying | MAiD Phone Note | |
| 2020-02-06 | 94323-3 | Wound, Ostomy, and Continence Care Team Conference note | Conference note | Find | Pt | {Setting} | Doc | Wound, ostomy, and continence care.team | WOC Team Conf eval note | |
| 2020-02-06 | 94324-1 | Orthopaedic surgery Care management note | Care management note | Find | Pt | {Setting} | Doc | Orthopaedic surgery | Orthopaedic surgery Care management note | |
| 2020-01-31 | 94303-5 | Pregnenolone and 17-Hydroxypregnenolone panel - Serum or Plasma | Pregnenolone & 17-Hydroxypregnenolone panel | - | Pt | Ser/Plas | Qn | Preg + 17-OH Preg pnl SerPl | ||
| 2020-01-31 | 94304-3 | OxyCODONE and metabolites panel - Urine by Confirmatory method | OxyCODONE & metabolites panel | - | Pt | Urine | - | Confirm | OxyCODONE+metabolites Pnl Ur Cfm | |
| 2020-01-31 | 94305-0 | OxyMORphone and Noroxymorphone panel - Urine by Confirmatory method | OxyMORphone & Noroxymorphone panel | - | Pt | Urine | - | Confirm | OxyMORphone+Noroxymorph Pnl Ur Cfm | |
| 2020-01-30 | 94269-8 | Platelet aggregation EPINEPHrine induced in Platelet rich plasma --50 umol/L | Platelet aggregation.EPINEPHrine induced^50 umol/L | RelACnc | Pt | PRP | Qn | PA Epineph 50 umol/L PRP | ||
| 2020-01-30 | 94270-6 | Coenzyme Q10 [Moles/mass] in Leukocytes | Ubiquinone 10 | SCnt | Pt | WBC | Qn | Ubiquinone10 WBC-sCnt | ||
| 2020-01-30 | 94271-4 | PCA-1 IgG Ab [Presence] in Serum by Line blot | Purkinje cell cytoplasmic type 1 Ab.IgG | PrThr | Pt | Ser | Ord | Line blot | PCA-1 IgG Ser Ql Line blot | |
| 2020-01-30 | 94272-2 | PCA-1 IgG Ab [Presence] in Cerebral spinal fluid by Line blot | Purkinje cell cytoplasmic type 1 Ab.IgG | PrThr | Pt | CSF | Ord | Line blot | PCA-1 IgG CSF Ql Line blot | |
| 2020-01-30 | 94273-0 | Muscle specific receptor tyrosine kinase IgG Ab [Moles/volume] in Serum by Immunoassay | Muscle specific receptor tyrosine kinase Ab.IgG | SCnc | Pt | Ser | Qn | IA | MuSK IgG Ser IA-sCnc | |
| 2020-01-30 | 94274-8 | Bedaquiline [Susceptibility] | Bedaquiline | Susc | Pt | Isolate | OrdQn | Bedaquiline Susc Islt | ||
| 2020-01-30 | 94275-5 | Honey bee acid phosphatase recombinant (rApi m) 3 IgE Ab [Units/volume] in Serum | Apis mellifera acid phosphatase recombinant (rApi m) 3 Ab.IgE | ACnc | Pt | Ser | Qn | Honey bee (rApi m) 3 IgE Qn | ||
| 2020-01-30 | 94276-3 | Honey bee dipeptidyl peptidase recombinant (rApi m) 5 IgE Ab [Units/volume] in Serum | Apis mellifera dipeptidyl peptidase recombinant (rApi m) 5 Ab.IgE | ACnc | Pt | Ser | Qn | Honey bee DPP (rApi m) 5 IgE Qn | ||
| 2020-01-30 | 94277-1 | Dog recombinant 6 IgE Ab [Units/volume] in Serum | Dog recombinant (rCan f) 6 Ab.IgE | ACnc | Pt | Ser | Qn | Dog (rCan f) 6 IgE Qn | ||
| 2020-01-30 | 94278-9 | Cat recombinant (rFel d) 7 IgE Ab [Units/volume] in Serum | Cat recombinant (rFel d) 7 Ab.IgE | ACnc | Pt | Ser | Qn | Cat (rFel d) 7 IgE Qn | ||
| 2020-01-30 | 94279-7 | Honey bee acid phosphatase recombinant (rApi m) 3 IgE Ab RAST class [Presence] in Serum | Apis mellifera acid phosphatase recombinant (rApi m) 3 Ab.IgE.RAST class | PrThr | Pt | Ser | Ord | Honey bee (rApi m) 3 IgE RAST Ql | ||
| 2020-01-30 | 94281-3 | Dog recombinant 6 IgE Ab RAST class [Presence] in Serum | Dog recombinant (rCan f) 6 Ab.IgE.RAST class | PrThr | Pt | Ser | Ord | Dog (rCan f) 6 IgE RAST Ql | ||
| 2020-01-30 | 94282-1 | Cat recombinant (rFel d) 7 IgE Ab RAST class [Presence] in Serum | Cat recombinant (rFel d) 7 Ab.IgE.RAST class | PrThr | Pt | Ser | Ord | Cat (rFel d) 7 IgE RAST Ql | ||
| 2020-01-30 | 94280-5 | Honey bee dipeptidyl peptidase recombinant (rApi m) 5 IgE Ab RAST class [Presence] in Serum | Apis mellifera dipeptidyl peptidase recombinant (rApi m) 5 Ab.IgE.RAST class | PrThr | Pt | Ser | Ord | Honey bee DPP (rApi m) 5 IgE RAST Ql | ||
| 2020-01-30 | 94284-7 | Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence | Dipeptidyl aminopeptidase-like protein 6 Ab.IgG | Titr | Pt | CSF | Qn | IF | DPPX IgG Titr CSF IF | |
| 2020-01-30 | 94283-9 | Dipeptidyl aminopeptidase-like protein 6 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding assay immunofluorescent assay | Dipeptidyl aminopeptidase-like protein 6 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | DPPX IgG CSF Ql CBA IFA | |
| 2020-01-30 | 94285-4 | Contactin-associated protein 2 IgG Ab [Presence] in Serum by Cell binding assay immunofluorescent assay | Contactin-associated protein 2 Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | CASPR2 IgG Ser Ql CBA IFA | |
| 2020-01-30 | 94286-2 | Contactin-associated protein 2 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding assay immunofluorescent assay | Contactin-associated protein 2 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | CASPR2 IgG CSF Ql CBA IFA | |
| 2020-01-30 | 94287-0 | Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Serum by Cell binding assay immunofluorescent assay | Leucine-rich glioma-inactivated protein 1 Ab.IgG | PrThr | Pt | Ser | Ord | CBA IFA | LGI1 IgG Ser Ql CBA IFA | |
| 2020-01-30 | 94288-8 | Leucine-rich glioma-inactivated protein 1 IgG Ab [Presence] in Cerebral spinal fluid by Cell binding assay immunofluorescent assay | Leucine-rich glioma-inactivated protein 1 Ab.IgG | PrThr | Pt | CSF | Ord | CBA IFA | LGI1 IgG CSF Ql CBA IFA | |
| 2020-01-30 | 94289-6 | West Nile virus Ab [Presence] in Unspecified specimen by Neutralization test | West Nile virus Ab | PrThr | Pt | XXX | Ord | Neut | WNV Ab XXX Ql Nt | |
| 2020-01-30 | 94290-4 | Saint Louis encephalitis virus Ab [Presence] in Unspecified specimen by Neutralization test | Saint Louis encephalitis virus Ab | PrThr | Pt | XXX | Ord | Neut | SLEV Ab XXX Ql Nt | |
| 2020-01-30 | 94291-2 | Hydroxybupropion [Presence] in Serum or Plasma by Screen method | Hydroxybupropion | PrThr | Pt | Ser/Plas | Ord | Screen | OH-buPROPion SerPl Ql Scn | |
| 2020-01-30 | 94293-8 | Citalopram+Escitalopram [Mass/volume] in Serum or Plasma by Confirmatory method | Citalopram+Escitalopram | MCnc | Pt | Ser/Plas | Qn | Confirm | Citalopram+Escitalopram SerPl Cfm-mCnc | |
| 2020-01-30 | 94294-6 | Norcitalopram [Presence] in Serum or Plasma by Screen method | Norcitalopram | PrThr | Pt | Ser/Plas | Ord | Screen | Norcitalopram SerPl Ql Scn | |
| 2020-01-30 | 94292-0 | Citalopram+Escitalopram [Presence] in Serum or Plasma by Screen method | Citalopram+Escitalopram | PrThr | Pt | Ser/Plas | Ord | Screen | Citalopram+Escitalopram SerPl Ql Scn | |
| 2020-01-30 | 94295-3 | DULoxetine [Presence] in Serum or Plasma by Screen method | Duloxetine | PrThr | Pt | Ser/Plas | Ord | Screen | DULoxetine SerPl Ql Scn | |
| 2020-01-30 | 94296-1 | Norfluvoxamine [Presence] in Serum or Plasma by Screen method | Norfluvoxamine | PrThr | Pt | Ser/Plas | Ord | Screen | Norfluvoxamine SerPl Ql Scn | |
| 2020-01-30 | 94297-9 | Norfluvoxamine [Mass/volume] in Serum or Plasma by Confirmatory method | Norfluvoxamine | MCnc | Pt | Ser/Plas | Qn | Confirm | Norfluvoxamine SerPl Cfm-mCnc | |
| 2020-01-30 | 94298-7 | Norvenlafaxine [Presence] in Serum or Plasma by Screen method | Norvenlafaxine | PrThr | Pt | Ser/Plas | Ord | Screen | ODV SerPl Ql Scn | |
| 2020-01-30 | 94299-5 | Vilazodone [Presence] in Serum or Plasma by Screen method | Vilazodone | PrThr | Pt | Ser/Plas | Ord | Screen | Vilaz SerPl Ql Scn | |
| 2020-01-30 | 94300-1 | Vilazodone [Mass/volume] in Serum or Plasma by Confirmatory method | Vilazodone | MCnc | Pt | Ser/Plas | Qn | Confirm | Vilaz SerPl Cfm-mCnc | |
| 2020-01-30 | 94301-9 | Vortioxetine [Presence] in Serum or Plasma by Screen method | Vortioxetine | PrThr | Pt | Ser/Plas | Ord | Screen | Vortioxetine SerPl Ql Scn | |
| 2020-01-30 | 94302-7 | Vortioxetine [Mass/volume] in Serum or Plasma by Confirmatory method | Vortioxetine | MCnc | Pt | Ser/Plas | Qn | Confirm | Vortioxetine SerPl Cfm-mCnc | |
| 2020-01-29 | 94265-6 | CD18 cells [Presence] in Blood | Cells.CD18 | PrThr | Pt | Bld | Ord | CD18 Cells Bld Ql | ||
| 2020-01-29 | 94266-4 | CD11a, CD11b, and CD18 phenotyping panel - Blood Qualitative | CD11a & CD11b & CD18 phenotyping panel | - | Pt | Bld | Ord | CD11a + CD11b + CD18 Pnl Bld | ||
| 2020-01-29 | 94267-2 | CD11b cells [Presence] in Blood | Cells.CD11b | PrThr | Pt | Bld | Ord | CD11b Cells Bld Ql | ||
| 2020-01-29 | 94268-0 | CD11a cells [Presence] in Blood | Cells.CD11a | PrThr | Pt | Bld | Ord | CD11a Cells Bld Ql | ||
| 2020-01-28 | 94264-9 | Brucella sp Ab [Titer] in Cerebral spinal fluid by Immunocapture agglutination | Brucella sp ab | Titr | Pt | CSF | Qn | Aggl.capture | Brucella Ab Titr CSF Capture aggl | |
| 2020-01-27 | 94247-4 | Borrelia burgdorferi oppA2 gene [Presence] in Blood by NAA with non-probe detection | Borrelia burgdorferi oppA2 gene | PrThr | Pt | Bld | Ord | Non-probe.amp.tar | B burgdorferi oppA2 Bld Ql NAA+non-probe | |
| 2020-01-27 | 94248-2 | Borrelia mayonii oppA2 gene [Presence] in Blood by NAA with non-probe detection | Borrelia mayonii oppA2 gene | PrThr | Pt | Bld | Ord | Non-probe.amp.tar | B mayonii oppA2 Bld Ql NAA+non-probe | |
| 2020-01-27 | 94249-0 | Borrelia garinii+afzelii oppA2 gene [Presence] in Blood by NAA with non-probe detection | Borrelia garinii+afzelii oppA2 gene | PrThr | Pt | Bld | Ord | Non-probe.amp.tar | B gar+afz oppA2 Bld Ql NAA+non-probe | |
| 2020-01-27 | 94250-8 | Borrelia burgdorferi oppA2 gene [Presence] in Unspecified specimen by NAA with non-probe detection | Borrelia burgdorferi oppA2 gene | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | B burgdorferi oppA2 XXX Ql NAA+non-probe | |
| 2020-01-27 | 94251-6 | Borrelia mayonii oppA2 gene [Presence] in Unspecified specimen by NAA with non-probe detection | Borrelia mayonii oppA2 gene | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | B mayonii oppA2 XXX Ql NAA+non-probe | |
| 2020-01-27 | 94252-4 | Borrelia garinii+afzelii oppA2 gene [Presence] in Unspecified specimen by NAA with non-probe detection | Borrelia garinii+afzelii oppA2 gene | PrThr | Pt | XXX | Ord | Non-probe.amp.tar | B gar+afz oppA2 XXX Ql NAA+non-probe | |
| 2020-01-27 | 94253-2 | Borrelia sp panel - Unspecified specimen by NAA with non-probe detection | Borrelia sp panel | - | Pt | XXX | - | Non-probe.amp.tar | B sp panel XXX NAA+non-probe | |
| 2020-01-27 | 94254-0 | CYP1A2 gene product metabolic activity interpretation in Blood or Tissue Qualitative by Molecular genetics method | CYP1A2 gene product metabolic activity interpretation | Imp | Pt | Bld/Tiss | Ord | Molgen | CYP1A2 gene prod met act Bld/T-Imp | |
| 2020-01-27 | 94255-7 | Calcium [Mass/volume] in Sweat | Calcium | MCnc | Pt | Sweat | Qn | Calcium Sweat-mCnc | ||
| 2020-01-27 | 94256-5 | Magnesium [Mass/volume] in Sweat | Magnesium | MCnc | Pt | Sweat | Qn | Magnesium Sweat-mCnc | ||
| 2020-01-27 | 94257-3 | PROMIS pediatric - global health 7 - version 1.0 | PROMIS pediatric - global health 7 - version 1.0 | - | Pt | ^Patient | - | PROMIS.PEDS | ||
| 2020-01-27 | 94258-1 | PROMIS pediatric - global health 7 - version 1.0 raw score | PROMIS pediatric - global health 7 - version 1.0 raw score | Score | Pt | ^Patient | Qn | PROMIS.PEDS | ||
| 2020-01-27 | 94263-1 | PROMIS pediatric - global health 7 - version 1.0 T-score | PROMIS pediatric - global health 7 - version 1.0 T-score | Tscore | Pt | ^Patient | Qn | PROMIS.PEDS | ||
| 2020-01-22 | 94182-3 | PROMIS parent proxy physical function - upper extremity - version 1.0 T-score | PROMIS parent proxy physical function - upper extremity - version 1.0 T-score | Tscore | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-22 | 94183-1 | Heartland banyangvirus RNA [Presence] in Unspecified specimen by NAA with probe detection | Heartland banyangvirus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | HRTV RNA XXX Ql NAA+probe | |
| 2020-01-22 | 94184-9 | Yellow fever virus RNA [Presence] in Unspecified specimen by NAA with probe detection | Yellow fever virus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | YFV RNA XXX Ql NAA+probe | |
| 2020-01-22 | 94185-6 | Borrelia miyamotoi glpQ gene [Presence] in Unspecified specimen by NAA with probe detection | Borrelia miyamotoi glpQ gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | B miyamotoi glpQ XXX Ql NAA+probe | |
| 2020-01-22 | 94186-4 | Origin of germline genetic variant [Type] | Origin of germline genetic variant | Type | Pt | ^Patient | Nom | Origin germline gen var | ||
| 2020-01-22 | 94187-2 | Platelet aggregation [Interpretation] in Platelet rich plasma | Platelet aggregation | Imp | Pt | PRP | Nom | PA PRP-Imp | ||
| 2020-01-22 | 94188-0 | APC gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | APC gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | APC gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94189-8 | APOA2 gene full mutation analysis in Blood or Tissue by Sequencing | APOA2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | APOA2 Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94190-6 | BPGM gene full mutation analysis in Blood or Tissue by Sequencing | BPGM gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | BPGM Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94191-4 | BRCA1+BRCA2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | BRCA1+BRCA2 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | BRCA1+BRCA2 Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94192-2 | SLC25A20 gene full mutation analysis in Blood or Tissue by Sequencing | SLC25A20 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | SLC25A20 Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94193-0 | CDKN1C gene full mutation analysis in Blood or Tissue by Sequencing | CDKN1C gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | CDKN1C Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94194-8 | CPOX gene full mutation analysis in Blood or Tissue by Sequencing | CPOX gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | CPOX Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94195-5 | CPT2 gene full mutation analysis in Blood or Tissue by Sequencing | CPT2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | CPT2 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94196-3 | CTRC gene full mutation analysis in Blood or Tissue by Sequencing | CTRC gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | CTRC Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94197-1 | CYP21A2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | CYP21A2 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | CYP21A2 Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94199-7 | FGA gene full mutation analysis in Blood or Tissue by Sequencing | FGA gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | FGA Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94198-9 | DPYD gene full mutation analysis in Blood or Tissue by Sequencing | DPYD gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | DPYD gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94200-3 | FTCD gene full mutation analysis in Blood or Tissue by Sequencing | FTCD gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | FTCD Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94201-1 | GNPTAB gene full mutation analysis in Blood or Tissue by Sequencing | GNPTAB gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GNPTAB Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94202-9 | GRHPR gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | GRHPR gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | GRHPR Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94203-7 | GSN gene full mutation analysis in Blood or Tissue by Sequencing | GSN gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GSN Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94204-5 | HMBS gene full mutation analysis in Blood or Tissue by Sequencing | HMBS gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | HMBS Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94205-2 | LYZ gene full mutation analysis in Blood or Tissue by Sequencing | LYZ gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | LYZ Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94206-0 | MMACHC gene full mutation analysis in Blood or Tissue by Sequencing | MMACHC gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | MMACHC Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94207-8 | MMADHC gene full mutation analysis in Blood or Tissue by Sequencing | MMADHC gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | MMADHC Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94208-6 | MLYCD gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | MLYCD gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | MLYCD Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94211-0 | NPC1 gene+NPC2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | NPC1 gene+NPC2 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | NPC1+NPC2 Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94209-4 | NAGLU gene full mutation analysis in Blood or Tissue by Sequencing | NAGLU gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | NAGLU Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94210-2 | ARSB gene full mutation analysis in Blood or Tissue by Sequencing | ARSB gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | ARSB Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94214-4 | PRKAR1A gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | PRKAR1A gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | PRKAR1A Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94212-8 | PKLR gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | PKLR gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | PKLR gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94213-6 | PPOX gene full mutation analysis in Blood or Tissue by Sequencing | PPOX gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | PPOX Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94215-1 | PRSS1 gene full mutation analysis in Blood or Tissue by Sequencing | PRSS1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | PRSS1 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94216-9 | STK11 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | STK11 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | STK11 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94217-7 | TP53 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | TP53 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | TP53 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94218-5 | UBE3A gene full mutation analysis in Blood or Tissue by Sequencing | UBE3A gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | UBE3A gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94219-3 | VWF gene full mutation analysis in Blood or Tissue by Sequencing | VWF gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | VWF gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94222-7 | SERPINA1 gene full mutation analysis in Blood or Tissue by Sequencing | SERPINA1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | SERPINA1 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94221-9 | SMN1 gene full mutation analysis in Blood or Tissue by Sequencing | SMN1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | SMN1 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94220-1 | SPINK1 gene full mutation analysis in Blood or Tissue by Sequencing | SPINK1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | SPINK1 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94223-5 | PTEN gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | PTEN gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | PTEN gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94224-3 | RET gene full mutation analysis in Blood or Tissue by Sequencing | RET gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | RET gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94225-0 | TTR gene full mutation analysis in Blood or Tissue by Sequencing | TTR gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | TTR gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94228-4 | MUTYH gene full mutation analysis in Blood or Tissue by Sequencing | MUTYH gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | MUTYH gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94226-8 | PKHD1 gene full mutation analysis in Blood or Tissue by Sequencing | PKHD1 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | PKHD1 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94227-6 | AGXT gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | AGXT gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | AGXT gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94231-8 | G6PD gene full mutation analysis in Blood or Tissue by Sequencing | G6PD gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | G6PD gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94229-2 | MECP2 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | MECP2 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | MECP2 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94230-0 | GBA gene full mutation analysis in Blood or Tissue by Sequencing | GBA gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | GBA gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94232-6 | FLCN gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | FLCN gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | FLCN gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94233-4 | FECH gene full mutation analysis in Blood or Tissue by Sequencing | FECH gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | FECH gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94234-2 | F8 gene full mutation analysis in Blood or Tissue by Sequencing | F8 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F8 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94237-5 | F2 gene full mutation analysis in Blood or Tissue by Sequencing | F2 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F2 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94236-7 | F5 gene full mutation analysis in Blood or Tissue by Sequencing | F5 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F5 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94235-9 | F7 gene full mutation analysis in Blood or Tissue by Sequencing | F7 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F7 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94239-1 | F11 gene full mutation analysis in Blood or Tissue by Sequencing | F11 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F11 Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94240-9 | CDH1 gene deletion+duplication and full mutation analysis in Blood or Tissue by Molecular genetics method | CDH1 gene deletion+duplication & full mutation analysis | Find | Pt | Bld/Tiss | Doc | Molgen | CDH1 gene Del+Dup + Full Mut Anl Bld/T | |
| 2020-01-22 | 94238-3 | F12 gene full mutation analysis in Blood or Tissue by Sequencing | F12 gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | F12 gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94241-7 | BTK gene full mutation analysis in Blood or Tissue by Sequencing | BTK gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | BTK gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94242-5 | BTD gene full mutation analysis in Blood or Tissue by Sequencing | BTD gene full mutation analysis | Find | Pt | Bld/Tiss | Doc | Sequencing | BTD gene Full Mut Anl Bld/T Seq | |
| 2020-01-22 | 94243-3 | Healthcare navigator Note | Note | Find | Pt | {Setting} | Doc | Healthcare navigator | Navigator Note | |
| 2020-01-22 | 94244-1 | Wound, Ostomy, and Continence Care Plan of care note | Plan of care note | Find | Pt | {Setting} | Doc | Wound, ostomy, and continence care | WOC Plan of care note | |
| 2020-01-22 | 94245-8 | Wound, Ostomy, and Continence Care Progress note | Progress note | Find | Pt | {Setting} | Doc | Wound, ostomy, and continence care | WOC Progress note | |
| 2020-01-22 | 94246-6 | Wound, Ostomy, and Continence Care Telephone encounter Note | Note | Find | Pt | Telephone encounter | Doc | Wound, ostomy, and continence care | WOC Phone Note | |
| 2020-01-21 | 94181-5 | PROMIS parent proxy global health - version 1.0 T-score | PROMIS parent proxy global health - version 1.0 T-score | Tscore | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94169-0 | PROMIS parent proxy short form - physical function - upper extremity 8 - version 1.0 | PROMIS parent proxy short form - physical function - upper extremity 8 - version 1.0 | - | 7D | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94170-8 | PROMIS parent proxy physical function - upper extremity - version 1.0 raw score | PROMIS parent proxy physical function - upper extremity - version 1.0 raw score | Score | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94171-6 | My child could pour a drink from a full pitcher in past 7D [PROMIS.PARENTPROXY] | My child could pour a drink from a full pitcher in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94172-4 | My child could open a jar by himself or herself in past 7D [PROMIS.PARENTPROXY] | My child could open a jar by himself or herself in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94173-2 | My child could pull open heavy doors in past 7D [PROMIS.PARENTPROXY] | My child could pull open heavy doors in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94174-0 | My child could use a key to unlock a door in past 7D [PROMIS.PARENTPROXY] | My child could use a key to unlock a door in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94175-7 | My child could pull a shirt on over his or her head without help in past 7D [PROMIS.PARENTPROXY] | My child could pull a shirt on over his or her head without help in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94176-5 | My child could open the rings in school binders in past 7D [PROMIS.PARENTPROXY] | My child could open the rings in school binders in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94177-3 | My child could button his or her shirt or pants in past 7D [PROMIS.PARENTPROXY] | My child could button his or her shirt or pants in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94178-1 | My child could put on his or her shoes without help in past 7D [PROMIS.PARENTPROXY] | My child could put on his or her shoes without help in past 7D | Find | 7D | ^Patient | Ord | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94179-9 | PROMIS parent proxy short form - pain interference 8 - version 1.0 raw score | PROMIS parent proxy short form - pain interference 8 - version 1.0 raw score | Score | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-17 | 94180-7 | PROMIS parent proxy short form - pain interference 8 - version 1.0 | PROMIS parent proxy short form - pain interference 8 - version 1.0 | - | 7D | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94161-7 | PROMIS parent proxy item bank - mobility - version 1.0 | PROMIS parent proxy item bank - mobility - version 1.0 | - | 7D | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94162-5 | PROMIS parent proxy item bank - pain interference - version 1.0 | PROMIS parent proxy item bank - pain interference - version 1.0 | - | 7D | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94163-3 | PROMIS parent proxy pain interference - version 1.0 T-score | PROMIS parent proxy pain interference - version 1.0 T-score | Tscore | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94164-1 | PROMIS parent proxy - global health 7 - version 1.0 raw score | PROMIS parent proxy - global health 7 - version 1.0 raw score | Score | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94165-8 | PROMIS parent proxy - global health 7 - version 1.0 | PROMIS parent proxy - global health 7 - version 1.0 | - | Pt | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94166-6 | PROMIS parent proxy short form - mobility 8 - version 1.0 | PROMIS parent proxy short form - mobility 8 - version 1.0 | - | 7D | ^Patient | - | PROMIS.PARENTPROXY | ||
| 2020-01-16 | 94167-4 | PROMIS parent proxy short form mobility 8 - version 1.0 raw score | PROMIS parent proxy short form mobility 8 - version 1.0 raw score | Score | Pt | ^Patient | Qn | PROMIS.PARENTPROXY | ||
| 2020-01-08 | 94157-5 | PhenX - age of initiation of first cigarette use - adult protocol 030703 | PhenX - age of initiation of first cigarette use - adult protocol 030703 | - | Pt | ^Patient | - | PhenX | Age init cig use adult proto | |
| 2020-01-08 | 94158-3 | PhenX - ethnicity protocol 010502 | PhenX - ethnicity protocol 010502 | - | Pt | ^Patient | - | PhenX | PhenX - ethnicity protocol | |
| 2020-01-06 | 94151-8 | Bacteria.carbapenem resistant identified in Unspecified specimen by Organism specific culture | Bacteria.carbapenem resistant identified | Prid | Pt | XXX | Nom | Organism specific culture | Bacteria.carbpm resist XXX Cult | |
| 2019-12-27 | 94149-2 | Heterophile Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | Heterophile Ab | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | Heteroph Ab SerPlBld Ql IA.rapid | |
| 2019-12-26 | 94147-6 | Mitral valve B-bump by US.M-mode | B-bump | Find | Pt | Mitral valve | Ord | US.M-mode | MV B-bump M-mode | |
| 2019-12-26 | 94148-4 | Descending thoracic aorta Holodiastolic flow reversal by US.doppler | Blood flow reversal.holodiastolic | Find | Pt | Aorta.thoracic.descending | Ord | US.doppler | DTA Holodias flow reversal DOP | |
| 2019-12-17 | 94145-0 | Crotonylglycine/Creatinine [Molar ratio] in Urine | Crotonylglycine/Creatinine | SRto | Pt | Urine | Qn | Crotonylglycine/Creat Ur-sRto | ||
| 2019-12-17 | 94146-8 | 2-Decenedioate/Creatinine [Molar ratio] in Urine | 2-Decenedioate/Creatinine | SRto | Pt | Urine | Qn | 2-Decenedioate/Creat Ur-sRto | ||
| 2019-09-11 | 93414-1 | Altered level of consciousness in last 3 day [CAM.CMS] | Altered level of consciousness in last 3D | Find | 3D | ^Patient | Ord | CAM.CMS |
TIP Click on headings to sort table by that column. Hold down Shift and click additional headings to add to sorting.
TIP In your web browser, use ControlF (or ⌘F on Mac) to find text on this page.
Receive notices of new and revised Special Use prerelease codes
Sign up to receive an email notification when new prerelease Special Use LOINC terms are created or revised.
For timely updates, follow @LOINC on Twitter. An RSS feed of new Special Use terms is also available.